{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 32,
   "id": "1d8ba90f",
   "metadata": {},
   "outputs": [],
   "source": [
    "import torch "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "id": "b10cd8c5",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "File HyperTension.pdf exists\n"
     ]
    }
   ],
   "source": [
    "import os \n",
    "import requests\n",
    "\n",
    "pdf_path = \"HyperTension.pdf\"\n",
    "\n",
    "if not os.path.exists(pdf_path):\n",
    "    print(f\"[INFO] failed to download the file.\")\n",
    "else:\n",
    "    print(f\"File {pdf_path} exists\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "id": "16aa952d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "64bc267e0213446196bccfee4e66e7d8",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "0it [00:00, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/plain": [
       "[{'Page_number': -41,\n",
       "  'page_char_count': 73,\n",
       "  'page_word_count': 13,\n",
       "  'page_sentence_count_raw': 1,\n",
       "  'page_token_count': 18.25,\n",
       "  'text': 'Guideline  for the pharmacological  treatment of  hypertension  in adults'},\n",
       " {'Page_number': -40,\n",
       "  'page_char_count': 0,\n",
       "  'page_word_count': 1,\n",
       "  'page_sentence_count_raw': 1,\n",
       "  'page_token_count': 0.0,\n",
       "  'text': ''}]"
      ]
     },
     "execution_count": 34,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import fitz\n",
    "from tqdm.auto import tqdm\n",
    "\n",
    "def text_formatter(text:str) -> str:\n",
    "    cleaned_text = text.replace(\"\\n\" , \" \"). strip()\n",
    "\n",
    "    return cleaned_text\n",
    "\n",
    "def open_and_read_pdf(pdf_path: str) -> list[dict]:\n",
    "    doc = fitz.open(pdf_path)\n",
    "    pages_and_texts = []\n",
    "    for page_number, page in tqdm(enumerate(doc)):\n",
    "        text = page.get_text()\n",
    "        text= text_formatter(text=text)\n",
    "        pages_and_texts.append({\"Page_number\": page_number - 41, \"page_char_count\": len(text), \n",
    "                                \"page_word_count\": len(text.split(\" \")),\n",
    "                                 \"page_sentence_count_raw\": len(text.split(\". \")),\n",
    "                                  \"page_token_count\": len(text) /4,\n",
    "                                   \"text\": text })\n",
    "    return pages_and_texts\n",
    "\n",
    "pages_and_texts = open_and_read_pdf(pdf_path=pdf_path)\n",
    "pages_and_texts[:2]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "id": "3c4d82a6",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Page_number</th>\n",
       "      <th>page_char_count</th>\n",
       "      <th>page_word_count</th>\n",
       "      <th>page_sentence_count_raw</th>\n",
       "      <th>page_token_count</th>\n",
       "      <th>text</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>-41</td>\n",
       "      <td>73</td>\n",
       "      <td>13</td>\n",
       "      <td>1</td>\n",
       "      <td>18.25</td>\n",
       "      <td>Guideline  for the pharmacological  treatment ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>-40</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>0.00</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>-39</td>\n",
       "      <td>73</td>\n",
       "      <td>13</td>\n",
       "      <td>1</td>\n",
       "      <td>18.25</td>\n",
       "      <td>Guideline  for the pharmacological  treatment ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>-38</td>\n",
       "      <td>3407</td>\n",
       "      <td>525</td>\n",
       "      <td>31</td>\n",
       "      <td>851.75</td>\n",
       "      <td>Guideline for the pharmacological treatment of...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>-37</td>\n",
       "      <td>1666</td>\n",
       "      <td>317</td>\n",
       "      <td>2</td>\n",
       "      <td>416.50</td>\n",
       "      <td>Contents Acknowledgements  v Acronyms and abbr...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   Page_number  page_char_count  page_word_count  page_sentence_count_raw  \\\n",
       "0          -41               73               13                        1   \n",
       "1          -40                0                1                        1   \n",
       "2          -39               73               13                        1   \n",
       "3          -38             3407              525                       31   \n",
       "4          -37             1666              317                        2   \n",
       "\n",
       "   page_token_count                                               text  \n",
       "0             18.25  Guideline  for the pharmacological  treatment ...  \n",
       "1              0.00                                                     \n",
       "2             18.25  Guideline  for the pharmacological  treatment ...  \n",
       "3            851.75  Guideline for the pharmacological treatment of...  \n",
       "4            416.50  Contents Acknowledgements  v Acronyms and abbr...  "
      ]
     },
     "execution_count": 35,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import pandas as pd \n",
    "df = pd.DataFrame(pages_and_texts)\n",
    "df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "id": "25d5819f",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<spacy.pipeline.sentencizer.Sentencizer at 0x2057fc82d90>"
      ]
     },
     "execution_count": 36,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from spacy.lang.en import English\n",
    "\n",
    "nlp = English()\n",
    "\n",
    "#Add a sentencizer\n",
    "\n",
    "nlp.add_pipe(\"sentencizer\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "id": "9bae832e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "61d7ce7e6f6e406b9136450f1d65ef91",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "  0%|          | 0/61 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "for item in tqdm(pages_and_texts):\n",
    "    item[\"sentences\"] = list(nlp(item['text']).sents)\n",
    "\n",
    "    item[\"sentences\"] = [str(sentence) for sentence in item[\"sentences\"]]\n",
    "\n",
    "    item[\"page_sentence_count_spacy\"] = len(item[\"sentences\"])\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "id": "86f488b0",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Page_number</th>\n",
       "      <th>page_char_count</th>\n",
       "      <th>page_word_count</th>\n",
       "      <th>page_sentence_count_raw</th>\n",
       "      <th>page_token_count</th>\n",
       "      <th>page_sentence_count_spacy</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>count</th>\n",
       "      <td>61.00</td>\n",
       "      <td>61.00</td>\n",
       "      <td>61.00</td>\n",
       "      <td>61.00</td>\n",
       "      <td>61.00</td>\n",
       "      <td>61.00</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>mean</th>\n",
       "      <td>-11.00</td>\n",
       "      <td>2611.20</td>\n",
       "      <td>398.13</td>\n",
       "      <td>20.79</td>\n",
       "      <td>652.80</td>\n",
       "      <td>20.15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>std</th>\n",
       "      <td>17.75</td>\n",
       "      <td>1280.78</td>\n",
       "      <td>195.22</td>\n",
       "      <td>21.11</td>\n",
       "      <td>320.19</td>\n",
       "      <td>19.30</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>min</th>\n",
       "      <td>-41.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>1.00</td>\n",
       "      <td>1.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25%</th>\n",
       "      <td>-26.00</td>\n",
       "      <td>1895.00</td>\n",
       "      <td>293.00</td>\n",
       "      <td>4.00</td>\n",
       "      <td>473.75</td>\n",
       "      <td>5.00</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>50%</th>\n",
       "      <td>-11.00</td>\n",
       "      <td>2716.00</td>\n",
       "      <td>420.00</td>\n",
       "      <td>18.00</td>\n",
       "      <td>679.00</td>\n",
       "      <td>19.00</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>75%</th>\n",
       "      <td>4.00</td>\n",
       "      <td>3714.00</td>\n",
       "      <td>540.00</td>\n",
       "      <td>24.00</td>\n",
       "      <td>928.50</td>\n",
       "      <td>24.00</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>max</th>\n",
       "      <td>19.00</td>\n",
       "      <td>4571.00</td>\n",
       "      <td>702.00</td>\n",
       "      <td>77.00</td>\n",
       "      <td>1142.75</td>\n",
       "      <td>74.00</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "       Page_number  page_char_count  page_word_count  page_sentence_count_raw  \\\n",
       "count        61.00            61.00            61.00                    61.00   \n",
       "mean        -11.00          2611.20           398.13                    20.79   \n",
       "std          17.75          1280.78           195.22                    21.11   \n",
       "min         -41.00             0.00             1.00                     1.00   \n",
       "25%         -26.00          1895.00           293.00                     4.00   \n",
       "50%         -11.00          2716.00           420.00                    18.00   \n",
       "75%           4.00          3714.00           540.00                    24.00   \n",
       "max          19.00          4571.00           702.00                    77.00   \n",
       "\n",
       "       page_token_count  page_sentence_count_spacy  \n",
       "count             61.00                      61.00  \n",
       "mean             652.80                      20.15  \n",
       "std              320.19                      19.30  \n",
       "min                0.00                       0.00  \n",
       "25%              473.75                       5.00  \n",
       "50%              679.00                      19.00  \n",
       "75%              928.50                      24.00  \n",
       "max             1142.75                      74.00  "
      ]
     },
     "execution_count": 38,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df = pd.DataFrame(pages_and_texts)\n",
    "df.describe().round(2)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "id": "8e556003",
   "metadata": {},
   "outputs": [],
   "source": [
    "#chunking \n",
    "num_sentence_chunk_size = 10\n",
    "\n",
    "def split_list(input_list: list, \n",
    "               slice_size: int) -> list[list[str]]:\n",
    "    return [input_list[i:i+slice_size] for i in range(0, len(input_list), slice_size)]\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "id": "baae90eb",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "7104bf1be81d4d17b06d27bcaa3723ef",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "  0%|          | 0/61 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "for item in tqdm(pages_and_texts):\n",
    "    item[\"sentence_chunks\"] = split_list(input_list=item[\"sentences\"], slice_size=num_sentence_chunk_size)\n",
    "\n",
    "    item[\"num_chunks\"] = len(item[\"sentence_chunks\"])\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "id": "c0d1df14",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Page_number</th>\n",
       "      <th>page_char_count</th>\n",
       "      <th>page_word_count</th>\n",
       "      <th>page_sentence_count_raw</th>\n",
       "      <th>page_token_count</th>\n",
       "      <th>page_sentence_count_spacy</th>\n",
       "      <th>num_chunks</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>count</th>\n",
       "      <td>61.00</td>\n",
       "      <td>61.00</td>\n",
       "      <td>61.00</td>\n",
       "      <td>61.00</td>\n",
       "      <td>61.00</td>\n",
       "      <td>61.00</td>\n",
       "      <td>61.00</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>mean</th>\n",
       "      <td>-11.00</td>\n",
       "      <td>2611.20</td>\n",
       "      <td>398.13</td>\n",
       "      <td>20.79</td>\n",
       "      <td>652.80</td>\n",
       "      <td>20.15</td>\n",
       "      <td>2.49</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>std</th>\n",
       "      <td>17.75</td>\n",
       "      <td>1280.78</td>\n",
       "      <td>195.22</td>\n",
       "      <td>21.11</td>\n",
       "      <td>320.19</td>\n",
       "      <td>19.30</td>\n",
       "      <td>1.89</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>min</th>\n",
       "      <td>-41.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>1.00</td>\n",
       "      <td>1.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25%</th>\n",
       "      <td>-26.00</td>\n",
       "      <td>1895.00</td>\n",
       "      <td>293.00</td>\n",
       "      <td>4.00</td>\n",
       "      <td>473.75</td>\n",
       "      <td>5.00</td>\n",
       "      <td>1.00</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>50%</th>\n",
       "      <td>-11.00</td>\n",
       "      <td>2716.00</td>\n",
       "      <td>420.00</td>\n",
       "      <td>18.00</td>\n",
       "      <td>679.00</td>\n",
       "      <td>19.00</td>\n",
       "      <td>2.00</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>75%</th>\n",
       "      <td>4.00</td>\n",
       "      <td>3714.00</td>\n",
       "      <td>540.00</td>\n",
       "      <td>24.00</td>\n",
       "      <td>928.50</td>\n",
       "      <td>24.00</td>\n",
       "      <td>3.00</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>max</th>\n",
       "      <td>19.00</td>\n",
       "      <td>4571.00</td>\n",
       "      <td>702.00</td>\n",
       "      <td>77.00</td>\n",
       "      <td>1142.75</td>\n",
       "      <td>74.00</td>\n",
       "      <td>8.00</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "       Page_number  page_char_count  page_word_count  page_sentence_count_raw  \\\n",
       "count        61.00            61.00            61.00                    61.00   \n",
       "mean        -11.00          2611.20           398.13                    20.79   \n",
       "std          17.75          1280.78           195.22                    21.11   \n",
       "min         -41.00             0.00             1.00                     1.00   \n",
       "25%         -26.00          1895.00           293.00                     4.00   \n",
       "50%         -11.00          2716.00           420.00                    18.00   \n",
       "75%           4.00          3714.00           540.00                    24.00   \n",
       "max          19.00          4571.00           702.00                    77.00   \n",
       "\n",
       "       page_token_count  page_sentence_count_spacy  num_chunks  \n",
       "count             61.00                      61.00       61.00  \n",
       "mean             652.80                      20.15        2.49  \n",
       "std              320.19                      19.30        1.89  \n",
       "min                0.00                       0.00        0.00  \n",
       "25%              473.75                       5.00        1.00  \n",
       "50%              679.00                      19.00        2.00  \n",
       "75%              928.50                      24.00        3.00  \n",
       "max             1142.75                      74.00        8.00  "
      ]
     },
     "execution_count": 41,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df = pd.DataFrame(pages_and_texts)\n",
    "df.describe().round(2)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "id": "fd0904f2",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "ad4030a47df74736a9253212d94899e4",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "  0%|          | 0/61 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/plain": [
       "152"
      ]
     },
     "execution_count": 42,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import re\n",
    "\n",
    "pages_and_chunks = []\n",
    "for item in tqdm(pages_and_texts):\n",
    "    for sentence_chunk in item[\"sentence_chunks\"]:\n",
    "        chunk_dict = {}\n",
    "        chunk_dict[\"page_number\"] = item[\"Page_number\"]\n",
    "\n",
    "        joined_sentence_chunk = \"\".join(sentence_chunk).replace(\" \", \" \").strip()\n",
    "        joined_sentence_chunk = re.sub(r'\\.([A-Z])',r'. \\1', joined_sentence_chunk)\n",
    "\n",
    "        chunk_dict[\"sentence_chunk\"] = joined_sentence_chunk\n",
    "\n",
    "        chunk_dict[\"chunk_char_count\"] = len(joined_sentence_chunk)\n",
    "        chunk_dict[\"chunk_word_count\"] = len([word for word in joined_sentence_chunk.split(\" \")])\n",
    "        chunk_dict[\"chunk_token_count\"] = len(joined_sentence_chunk) /4 \n",
    "\n",
    "        pages_and_chunks.append(chunk_dict)\n",
    "\n",
    "len(pages_and_chunks)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "id": "3315e141",
   "metadata": {},
   "outputs": [],
   "source": [
    "df = pd.DataFrame(pages_and_chunks)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "id": "c80ef713",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Chunk token count : 21.75| Text: J Clin Endocrinol Metab.2019;104(5):1575-1584.doi: 10.1210/jc.2019-00197. REFERENCES 33\n",
      "Chunk token count : 16.25| Text: In no event shall WHO be liable for damages arising from its use.\n",
      "Chunk token count : 15.25| Text: Hypertens Res.2005;28(7):585-91.doi: 10.1291/hypres.28.585.32\n",
      "Chunk token count : 18.25| Text: Guideline  for the pharmacological  treatment of  hypertension  in adults\n",
      "Chunk token count : 4.25| Text: RECOMMENDATIONS 9\n"
     ]
    }
   ],
   "source": [
    "min_token_length = 30\n",
    "\n",
    "for row in df[df[\"chunk_token_count\"] <= min_token_length].sample(5).iterrows():\n",
    "    print(f'Chunk token count : {row[1][\"chunk_token_count\"]}| Text: {row[1][\"sentence_chunk\"]}')\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "id": "bb6add0c",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'page_number': -38,\n",
       "  'sentence_chunk': 'Guideline for the pharmacological treatment of hypertension in adults ISBN 978-92-4-003398-6 (electronic version)  ISBN 978-92-4-003397-9 (print version) © World Health Organization 2021 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial- ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO;   https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial  purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there  should be no suggestion that WHO endorses any specific organization, products or services. The use of  the WHO logo is not permitted. If you adapt the work, then you must license your work under the same  or equivalent Creative Commons licence. If you create a translation of this work, you should add the  following disclaimer along with the suggested citation: “This translation was not created by the World  Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The  original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the  mediation rules of the World Intellectual Property Organization   (http://www.wipo.int/amc/en/mediation/rules/).',\n",
       "  'chunk_char_count': 1397,\n",
       "  'chunk_word_count': 208,\n",
       "  'chunk_token_count': 349.25},\n",
       " {'page_number': -38,\n",
       "  'sentence_chunk': 'Suggested citation. Guideline for the pharmacological treatment of hypertension in adults.  Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris. Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To  submit requests for commercial use and queries on rights and licensing, see   http://www.who.int/about/licensing. Third-party materials.',\n",
       "  'chunk_char_count': 489,\n",
       "  'chunk_word_count': 60,\n",
       "  'chunk_token_count': 122.25},\n",
       " {'page_number': -38,\n",
       "  'sentence_chunk': 'If you wish to reuse material from this work that is attributed to a third party,  such as tables, figures or images, it is your responsibility to determine whether permission is needed  for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from  infringement of any third-party-owned component in the work rests solely with the user. General disclaimers. The designations employed and the presentation of the material in this publication  do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status  of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or  boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may  not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are  endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital  letters. All reasonable precautions have been taken by WHO to verify the information contained in this  publication. However, the published material is being distributed without warranty of any kind, either  expressed or implied. The responsibility for the interpretation and use of the material lies with the reader.',\n",
       "  'chunk_char_count': 1447,\n",
       "  'chunk_word_count': 238,\n",
       "  'chunk_token_count': 361.75},\n",
       " {'page_number': -37,\n",
       "  'sentence_chunk': 'Contents Acknowledgements  v Acronyms and abbreviations  vi Executive summary  vii 1 Introduction  1 2 Method for developing the guideline   3 2.1  Guideline contributors   3 2.2  Analytical framework and PICOs  3 2.3  Outcome importance rating   4 2.4  Reviews of evidence   4 2.5  Certainty of evidence and strength of recommendations   5 2.6  Deciding upon recommendations  6 2.7  Funding   6 3 Recommendations  7 3.1  Blood pressure threshold for initiation of pharmacological treatment  7 3.2  Laboratory testing before and during pharmacological treatment  8 3.3  Cardiovascular disease risk assessment as guide to initiation of       antihypertensive medications  10 3.4  Drug classes to be used as first-line agents  11 3.5  Combination therapy  13 3.6  Target blood pressure  16 3.7  Frequency of re-assessment  17 3.8  Administration of treatment by nonphysician professionals  19 4 Special settings  21 4.1  Hypertension in disaster, humanitarian and emergency settings  21 4.2  COVID-19 and hypertension  22 4.3  Pregnancy and hypertension  22 5 Publication, implementation, evaluation and research gaps  24 5.1  Publication   24 5.2  Implementation and dissemination   24 5.3  Evaluation   24 5.4  Future updating of the guideline   24 5.5  Research gaps  24 6 Implementation tools  26 6.1  Guideline recommendations  26 6.2  Drug- and dose-specific protocols  28 References  30 Annex 1: List of contributors  37 Annex 2. Managing declarations of interest and conflicts of interest   42 Annex 3: Treatment outcomes relevant to hypertension  43 Annex 4: PICO questions   44 Web Annex A: Summary of evidence Web Annex B: Evidence-to-decision framework iii',\n",
       "  'chunk_char_count': 1666,\n",
       "  'chunk_word_count': 317,\n",
       "  'chunk_token_count': 416.5},\n",
       " {'page_number': -36,\n",
       "  'sentence_chunk': 'GUIDELINE FOR THE PHARMACOLOGICAL TREATMENT OF HYPERTENSION IN ADULTS Figures Fig.1  Analytic framework for antihypertensive medication treatment  3 Fig.2  Framework for analysis  9 Fig.3  An approach for starting treatment with a single-pill combination   26 Fig.4  An approach for starting treatment not using a single-pill combination   (i.e. with monotherapy or free combination therapy)  27 Fig.5  Algorithm 1  28 Fig.6  Algorithm 2  29 Fig. A3.1 Rating of outcomes  43 iv',\n",
       "  'chunk_char_count': 477,\n",
       "  'chunk_word_count': 84,\n",
       "  'chunk_token_count': 119.25},\n",
       " {'page_number': -35,\n",
       "  'sentence_chunk': 'Acknowledgements The Guideline for the pharmacological treatment of hypertension in adults was prepared by the  World Health Organization (WHO) Department of Noncommunicable Diseases. The departments of  HIV, Hepatitis and Sexually Transmitted Infections (HHS), Mental and Substance use Disorders (MSD),  Medicines and health products (MHP), the regional offices for Africa (AFRO), South East Asia (SEARO),  Europe (EURO) and Eastern Mediterranean (EMRO), and the Pan American Health Organization/Regional  Office of the Americas (PAHO/AMRO) also contributed. These departments were represented on the  WHO Steering Group for this guideline. Responsible technical officer: Taskeen Khan WHO Steering Group members: Bernadette Cappello (MHP), Neerja Chowdhury (MSD), Gampo Dorji  (SEARO), Jill Farrington (EURO), Taskeen Khan (NCD), Pedro Ordunez (PAHO/AMRO), Steven Shongwe  (AFRO), Slim Slama (EMRO), Cherian Varghese (NCD), Marco Vitoria (HHS), Temo Waqanivalu (NCD). Guideline Development Group: WHO would like to thank the members of the Guideline  Development Group (GDG) for their commitment, enthusiasm and expertise. GDG members were: Shrish Acharya (WPRO), Akram Al-Makki (AMRO), Hind Mamoun Beheiry (EMRO), Beatriz Champagne  (AMRO), Ugyen Choden (SEARO), Kenneth Connell (AMRO), Marie Therese Cooney (EURO), Donald  DiPette (AMRO), Nnenna Ezeigwe (AFRO), Tom Gaziano (AMRO), Agaba Gidio (AFRO), Vilma Irazola  (AMRO), Patricio Lopez Jaramillo (AMRO), Unab Khan (EMRO), Vindya Kumarapeli (SEARO), Andrew  Moran (AMRO), Margaret Mswema Silwimba (AFRO), Brian Rayner (AFRO), K. Srinath Reddy (SEARO),  Nizal Sarrafzadegan (EMRO), Apichard Sukonthasan (SEARO), Paul Whelton (AMRO), Jing Yu (WPRO). Methodologist: M Hassan Murad (Professor of Medicine at the Mayo Clinic, Rochester, USA) Systematic Review Team: Reem Mustapha, Abdallah Al Alayli, Romina Brignardello, Sara Jdiaa, Veena  Manja (University of Kansas Medical Center, Kansas, USA) External Review Group: WHO is grateful for the contributions of the following individuals who peer- reviewed the draft guideline: Mabel Aoun, Antoinette Péchère Bertschi, Jennifer Cohn, Prabhdeep Kaur, Daniel T Lackland, Venus  Mushininga, Marcelo Orias, and Xin Hua Zhang. Rebekah Thomas from the WHO Guidelines Review Committee Secretariat, and Nathan Ford, Chair of  the Guidelines Review Committee are gratefully acknowledged for their technical support throughout  the process. Thanks are also due to Alma Alic from the Department of Compliance, Risk Management  and Ethics for her support in the assessment of declarations of interests. Sheila Nakpil from the  Department of NCDs provided logistical support.',\n",
       "  'chunk_char_count': 2663,\n",
       "  'chunk_word_count': 383,\n",
       "  'chunk_token_count': 665.75},\n",
       " {'page_number': -35,\n",
       "  'sentence_chunk': 'WHO would like to recognize the voices of persons with lived experiences with hypertension whom we  heard from through consultation during development of this guideline. ACKNOWLEDGEMENTS v',\n",
       "  'chunk_char_count': 188,\n",
       "  'chunk_word_count': 28,\n",
       "  'chunk_token_count': 47.0},\n",
       " {'page_number': -34,\n",
       "  'sentence_chunk': 'GUIDELINE FOR THE PHARMACOLOGICAL TREATMENT OF HYPERTENSION IN ADULTS Acronyms and abbreviations ACE1 angiotensin-converting enzyme 1 ACE2 angiotensin-converting enzyme 2 ACEi angiotensin-converting enzyme inhibitor ARB angiotensin-II-receptor blocker BB beta-blocker BP blood pressure CAD coronary artery disease CCB calcium channel blocker CKD chronic kidney disease CRE WHO Office of Compliance, Risk Management and Ethics CV cardiovascular CVD cardiovascular disease DBP diastolic blood pressure DM diabetes mellitus DOI declaration of interest ECG electrocardiogram EML Essential Medicines List ERG External Review Group ESRD end-stage renal disease GDG Guideline Development Group GRADE Grading of Recommendations Assessment, Development and Evaluation HCW health care worker (nonphysician) HIC high-income country HTN hypertension LIC low-income country LMIC low- and middle-income country LVH left ventricular hypertrophy MACE major adverse cardiovascular event MI myocardial infarction MIC middle-income country NCD noncommunicable disease PEN WHO package of essential NCD interventions PICO  population intervention comparator outcome  QALY quality-adjusted life year RAAS renin-angiotensin-aldosterone system SBP systolic blood pressure ACRONYMS AND ABBREVIATIONS vi',\n",
       "  'chunk_char_count': 1277,\n",
       "  'chunk_word_count': 160,\n",
       "  'chunk_token_count': 319.25},\n",
       " {'page_number': -33,\n",
       "  'sentence_chunk': 'Executive summary More people die each year from cardiovascular diseases than from any other cause. Over three  quarters of heart disease and stroke-related deaths occur in low-income and middle-income countries. Hypertension – or elevated blood pressure – is a serious medical condition that significantly increases the  risk of heart, brain, kidney and other diseases. Hypertension can be defined using specific systolic and  diastolic blood pressure levels or reported use of antihypertensive medications. An estimated 1.4 billion  people worldwide have high blood pressure, but just 14% have it under control. However, cost-effective  treatment options do exist. In this guideline, the World Health Organization (WHO) provides the most current and relevant  evidence-based global public health guidance on the initiation of treatment with pharmacological  agents for hypertension in adults. The recommendations target adult, non-pregnant patients who were  appropriately diagnosed with hypertension and counselled about life-style modifications. The guideline provides new recommendations on the threshold for the initiation of pharmacological  treatment for hypertension, as well as recommendations on intervals for follow up, target blood  pressure to be achieved for control, and the cadre of health care workers who may initiate treatment. The guideline provides the basis for deciding whether to initiate treatment with monotherapy, dual  therapy or single-pill combinations, as well as guidance for countries selecting medicines and algorithms  for hypertension control for their national guidelines for hypertension management.',\n",
       "  'chunk_char_count': 1638,\n",
       "  'chunk_word_count': 237,\n",
       "  'chunk_token_count': 409.5},\n",
       " {'page_number': -33,\n",
       "  'sentence_chunk': 'The guideline was developed in accordance with the WHO Handbook for Guideline Development. In  brief, the WHO Steering Group, in collaboration with the Guideline Development Group, developed  key questions and rated outcomes to identify those critical for the development of the guideline. Conflicts of interest were handled in line with the current Compliance, Risk Management and Ethics  (CRE) policy and all members of the GDG were asked to fill in the standard WHO Declaration of Interest  (DOI) forms, which were reviewed. An overview of systematic reviews of the evidence was used to build  summary of findings tables according to the Grading of Recommendations, Assessment, Development  and Evaluations (GRADE) approach. The Guideline Development Group developed recommendations,  considering the certainty of the evidence; the balance between desirable and undesirable effects;  resource requirements and cost-effectiveness; health equity; acceptability, patient values and  preferences, and feasibility. Recommendations  1. RECOMMENDATION ON BLOOD PRESSURE THRESHOLD FOR INITIATION OF  PHARMACOLOGICAL TREATMENT WHO recommends initiation of pharmacological antihypertensive treatment of individuals  with a confirmed diagnosis of hypertension and systolic blood pressure of ≥140 mmHg or  diastolic blood pressure of ≥90 mmHg. Strong recommendation, moderate- to high-certainty evidence WHO recommends pharmacological antihypertensive treatment of individuals with existing  cardiovascular disease and systolic blood pressure of 130–139 mmHg. Strong recommendation, moderate- to high-certainty evidence EXECUTIVE SUMMARY vii',\n",
       "  'chunk_char_count': 1632,\n",
       "  'chunk_word_count': 229,\n",
       "  'chunk_token_count': 408.0},\n",
       " {'page_number': -32,\n",
       "  'sentence_chunk': 'GUIDELINE FOR THE PHARMACOLOGICAL TREATMENT OF HYPERTENSION IN ADULTS WHO suggests pharmacological antihypertensive treatment of individuals without  cardiovascular disease but with high cardiovascular risk, diabetes mellitus, or chronic kidney  disease, and systolic blood pressure of 130–139 mmHg. Conditional recommendation, moderate- to high-certainty evidence  2. RECOMMENDATION ON LABORATORY TESTING When starting pharmacological therapy for hypertension, WHO suggests obtaining tests to  screen for comorbidities and secondary hypertension, but only when testing does not delay  or impede starting treatment. Conditional recommendation, low-certainty evidence 3. RECOMMENDATION ON CARDIOVASCULAR DISEASE RISK ASSESSMENT  WHO suggests cardiovascular disease risk assessment at or after the initiation of  pharmacological treatment for hypertension, but only where this is feasible and does not  delay treatment. Conditional recommendation, low-certainty evidence 4. RECOMMENDATION ON DRUG CLASSES TO BE USED AS FIRST-LINE AGENTS For adults with hypertension requiring pharmacological treatment, WHO recommends the  use of drugs from any of the following three classes of pharmacological antihypertensive  medications as an initial treatment:  1.thiazide and thiazide-like agents 2.angiotensin-converting enzyme inhibitors (ACEis)/angiotensin-receptor blockers (ARBs) 3.long-acting dihydropyridine calcium channel blockers (CCBs).',\n",
       "  'chunk_char_count': 1435,\n",
       "  'chunk_word_count': 184,\n",
       "  'chunk_token_count': 358.75},\n",
       " {'page_number': -32,\n",
       "  'sentence_chunk': 'Strong recommendation, high-certainty evidence 5. RECOMMENDATION ON COMBINATION THERAPY For adults with hypertension requiring pharmacological treatment, WHO suggests  combination therapy, preferably with a single-pill combination (to improve adherence and  persistence), as an initial treatment. Antihypertensive medications used in combination  therapy should be chosen from the following three drug classes: diuretics (thiazide or  thiazide-like), angiotensin-converting enzyme inhibitors (ACEis)/angiotensin-receptor  blockers (ARBs), and long-acting dihydropyridine calcium channel blockers (CCBs). Conditional recommendation, moderate-certainty evidence 6. RECOMMENDATIONS ON TARGET BLOOD PRESSURE WHO recommends a target blood pressure treatment goal of <140/90 mmHg in all patients  with hypertension without comorbidities. Strong recommendation, moderate-certainty evidence viii',\n",
       "  'chunk_char_count': 887,\n",
       "  'chunk_word_count': 105,\n",
       "  'chunk_token_count': 221.75},\n",
       " {'page_number': -31,\n",
       "  'sentence_chunk': 'WHO recommends a target systolic blood pressure treatment goal of <130 mmHg in patients  with hypertension and known cardiovascular disease (CVD). Strong recommendation, moderate-certainty evidence WHO suggests a target systolic blood pressure treatment goal of <130 mmHg in high-risk  patients with hypertension (those with high CVD risk, diabetes mellitus, chronic kidney  disease). Conditional recommendation, moderate-certainty evidence 7. RECOMMENDATIONS ON FREQUENCY OF ASSESSMENT WHO suggests a monthly follow up after initiation or a change in antihypertensive  medications until patients reach target. Conditional recommendation, low-certainty evidence WHO suggests a follow up every 3–6 months for patients whose blood pressure is under  control. Conditional recommendation, low-certainty evidence 8. RECOMMENDATION ON TREATMENT BY NONPHYSICIAN PROFESSIONALS WHO suggests that pharmacological treatment of hypertension can be provided by  nonphysician professionals such as pharmacists and nurses, as long as the following  conditions are met: proper training, prescribing authority, specific management protocols  and physician oversight. Conditional recommendation, low-certainty evidence ix',\n",
       "  'chunk_char_count': 1203,\n",
       "  'chunk_word_count': 160,\n",
       "  'chunk_token_count': 300.75},\n",
       " {'page_number': -29,\n",
       "  'sentence_chunk': '1 Introduction More people die each year from cardiovascular diseases than from any other cause. Over three quarters  of heart disease and stroke-related deaths occur in low-income and middle-income countries (1). Blood  pressure is the force exerted by circulating blood against the walls of the body’s arteries, the major blood  vessels in the body. Blood pressure is written as two numbers. The first number (systolic) represents the  pressure in blood vessels when the heart contracts or beats. The second number (diastolic) represents  the pressure in the vessels when the heart rests between beats. Hypertension – or elevated blood  pressure – is a serious medical condition that significantly increases the risk of diseases of the heart,  brain, kidneys and other organs (2). Hypertension can be defined using specific systolic and diastolic  blood pressure levels or reported use of antihypertensive medications. An estimated 1.4 billion people  worldwide have high blood pressure, but just 14% have it under control (2). However, cost-effective  treatment options do exist.',\n",
       "  'chunk_char_count': 1082,\n",
       "  'chunk_word_count': 173,\n",
       "  'chunk_token_count': 270.5},\n",
       " {'page_number': -29,\n",
       "  'sentence_chunk': 'A World Health Organization (WHO) guideline dealing specifically with raised blood pressure was last  published more than 20 years ago – in 1999 – and is now outdated. In 2007, a comprehensive guideline  on cardiovascular risk included some recommendations on hypertension but this also needs revision  and updating in the light of new evidence and practice (3). Guidance is particularly needed on some  controversial issues, such as when to start treatment and whether laboratory testing and cardiovascular  risk assessment are needed prior to starting treatment. In the past decade, WHO has included diagnosis  and management of hypertension in a total cardiovascular risk approach as part of the WHO package  of essential noncommunicable disease (NCD) Interventions (WHO PEN) 2007, 2010 and 2013. However,  this approach has not included the most recent advances in pharmacological treatment. The WHO Essential Medicines List (EML) identifies all classes of antihypertensive drugs – angiotensin- converting enzyme inhibitors (ACEi), calcium channel blockers (CCB), angiotensin receptor blockers  (ARB) and thiazide diuretics – as essential. In June 2019, the EML included single-pill combination  medications for hypertension. This further supports the evaluation of all classes of antihypertensive  drugs as well as single-pill combinations in this current guideline. Scope and objectives of the hypertension guideline The 2021 WHO hypertension guideline aims to provide the most current and relevant evidence- based global public health guidance on the initiation of treatment (with pharmacological agents) for  hypertension in adults. The recommendations target the general adult, non-pregnant, hypertensive  population.',\n",
       "  'chunk_char_count': 1726,\n",
       "  'chunk_word_count': 257,\n",
       "  'chunk_token_count': 431.5},\n",
       " {'page_number': -29,\n",
       "  'sentence_chunk': 'Although several countries and professional societies have guidelines on the topic of hypertension,  these are specific to the population of that particular country or the specific setting or constituency of  the professional society. Recent shifts in hypertension management, such as moving away from using  beta-blockers as a first-line agent or the increased research and adoption of combination therapies  and single-pill combinations, are all additional reasons for new guidance. The Guideline for the  pharmacological treatment of hypertension in adults will be the first global guideline in the past two  decades on the topic and will have specific relevance to low- and middle-income countries (LMICs). The guideline provides new recommendations on the threshold for the initiation of pharmacological  treatment for hypertension, recommendations on intervals for follow up, target blood pressure to be  achieved for control, and the cadre of health care workers who may initiate treatment. It provides  the basis for deciding whether to initiate treatment with monotherapy, dual therapy, or single-pill  combination, as well as guidance for countries on selecting medicines for hypertension control in their  national guidelines for hypertension management. INTRODUCTION 1',\n",
       "  'chunk_char_count': 1280,\n",
       "  'chunk_word_count': 193,\n",
       "  'chunk_token_count': 320.0},\n",
       " {'page_number': -28,\n",
       "  'sentence_chunk': 'GUIDELINE FOR THE PHARMACOLOGICAL TREATMENT OF HYPERTENSION IN ADULTS This guideline will replace the guidance in the modules Evidence-based protocols and Risk-based CVD  management of the HEARTS technical package, as well as the guidance in the WHO PEN package  regarding the threshold for initiation of treatment, and for the preferred pharmacological treatment for  hypertension. The guideline does not address measurement of blood pressure or diagnosis of hypertension. It  addresses pharmacotherapy in individuals with a “confirmed” diagnosis of hypertension, such as  hypertension diagnosed when blood pressure is found to be elevated on two different days. Although this guideline does not address modifiable risk factors for hypertension such as unhealthy  diet, physical inactivity, consumption of tobacco and alcohol, and being overweight or obese, a  comprehensive treatment plan for hypertension must include addressing these risk factors through life- style modifications and other interventions (2). Nonpharmacological approaches to treatment or prevention of hypertension include:   [ reducing salt intake (to less than 5g daily)   [ eating more fruit and vegetables   [ being physically active on a regular basis   [ avoiding use of tobacco   [ reducing alcohol consumption   [ limiting the intake of foods high in saturated fats   [ eliminating/reducing trans fats in diet (2). The guideline does not address hypertensive crisis as it is focused on chronic blood pressure  management in regular care settings. The objectives of the hypertension guideline are to:   [ provide a blood pressure threshold for the initiation of treatment for hypertension;   [ determine if laboratory tests or cardiovascular risk assessment are required prior to initiation of  treatment for hypertension;   [ determine the pharmacological agents with which to initiate treatment;    [ determine the need to initiate treatment with monotherapy, dual therapy, or single-pill  combinations;    [ provide targets for blood pressure control in hypertension;   [ provide intervals for follow up for patients with hypertension; and   [ determine how nonphysician health care workers can participate in the management of  hypertension. Target audience Primary audience Clinicians/health care providers at all levels of health care. Secondary audience  National NCD/CVD programme managers, health care academics, policy-makers setting practice  recommendations, students, and hypertension medicine manufacturers. 2',\n",
       "  'chunk_char_count': 2502,\n",
       "  'chunk_word_count': 391,\n",
       "  'chunk_token_count': 625.5},\n",
       " {'page_number': -27,\n",
       "  'sentence_chunk': '2 Method for developing the  guideline  2.1 Guideline contributors  In order to develop the hypertension guideline, WHO established three groups:  1. An internal WHO Steering Group to coordinate the guideline development process. 2. A Guideline Development Group (GDG), composed of hypertension (HTN) physicians,  nephrologists, cardiologists, pharmacists, nurses, researchers, academics, policy-makers and  representatives of patient groups, to review the evidence and develop recommendations. WHO  selected the members of the GDG based on relevant expertise but it also considered appropriate  representation by region and sex. 3. An External Review Group (ERG), composed of technical experts, representatives of HTN patient  groups and ministries of health from low-resource countries, to provide peer review of the  guideline and ensure recommendations are aligned with current global needs. Annex 1 lists the contributors in each group. Annex 2 describes the process for declaring and managing  conflicts of interest. 2.2 Analytical framework and PICOs An initial GDG meeting was held in Geneva in July 2019 to determine the scope and PICO (population,  intervention, comparison, outcome) questions of the guideline.',\n",
       "  'chunk_char_count': 1221,\n",
       "  'chunk_word_count': 183,\n",
       "  'chunk_token_count': 305.25},\n",
       " {'page_number': -27,\n",
       "  'sentence_chunk': 'The GDG first developed an analytical  framework (Fig.1) that demonstrates the impact of interventions on intermediate and final outcomes  and displays the order of the key questions to better visualize and place them along the patient-flow  pathway. Following this, and a preliminary scoping review and discussion between the steering group  and methodologist, PICO questions were developed. These were considered, deliberated on, further  refined and voted on during the meeting. Fig.1 Analytic framework for antihypertensive medication treatment Q1: At what BP level should pharmacological  therapy be initiated?Q2: Are lab tests needed to start therapy?Q3: Is risk assessment needed to start therapy Q4: Monotherapy vs no therapy?Q5: Monotherapy vs other monotherapy?Q6: Monotherapy vs combination therapy?',\n",
       "  'chunk_char_count': 810,\n",
       "  'chunk_word_count': 119,\n",
       "  'chunk_token_count': 202.5},\n",
       " {'page_number': -27,\n",
       "  'sentence_chunk': 'Q7: What choice of combination therapy?Q8: Single-pill combination vs free combination?Q9: Post-treatment target BP level?Q10: When should BP be re-assessed after  treatment initiation?Q11: Management by physician vs non-physician  provider?Adults with  adequately  diagnosed HTN  who have initiated  life-style  modification Intermediate  outcomes [BP reduction [HTN control % Final health  outcomes [all-cause mortality [CV mortality [MI [CAD [stroke [ESRD [heart failure Pharmacological  therapy Serious adverse effects METHOD FOR DEVELOPING THE GUIDELINE 3',\n",
       "  'chunk_char_count': 560,\n",
       "  'chunk_word_count': 79,\n",
       "  'chunk_token_count': 140.0},\n",
       " {'page_number': -26,\n",
       "  'sentence_chunk': 'GUIDELINE FOR THE PHARMACOLOGICAL TREATMENT OF HYPERTENSION IN ADULTS 2.3 Outcome importance rating  Members of the WHO Steering Group, in consultation with the GDG and methodologist, developed a  list of treatment outcomes most relevant to the care of individuals with HTN. The GDG then rated each  outcome on a scale from 1 to 9 and indicated whether it considered each outcome critical (rated 7–9),  important (rated 4–6) or not important (rated 1–3) for decision-making. The mean scores are provided in  Annex 3. 2.4 Reviews of evidence  The WHO Steering Group, with the participation of the GDG, determined the scope of the guideline  and identified eleven questions in the format of population, intervention, comparison, and outcomes  (PICO) to guide the search for systematic reviews (Annex 4). Eleven overviews of reviews informed the  guideline development process. A systematic search was carried out in PubMed, Embase, The Cochrane  Library, and Epistemonikos to identify existing systematic reviews that answered the PICO questions  published in 2015 or after. Suitable systematic reviews were then evaluated based on the following  criteria:    [ their methodology as appraised by the AMSTAR (Assessing the Methodological Quality of  Systematic Reviews) tool;   [ how directly they matched the PICO questions;   [ whether they reported sufficient information to allow for an assessment of the certainty of the  evidence (e.g. tables with characteristics of included studies, risk of bias assessments at the study  level, results of meta analyses in forest plots);   [ whether they reported evidence in subgroups of interest (e.g. patients with diabetes mellitus  (DM), cardiovascular disease (CVD), chronic kidney disease (CKD) etc); and    [ the date of the most recent review to ensure the most updated evidence was used. The Systematic Review Team prioritized the most useful reviews for each question, comparison,  outcome and subpopulation within questions, and included as many reviews as necessary to address  each question comprehensively. (Web Annex A provides details of the search terms and strategy used.) No reviews were updated.',\n",
       "  'chunk_char_count': 2155,\n",
       "  'chunk_word_count': 353,\n",
       "  'chunk_token_count': 538.75},\n",
       " {'page_number': -26,\n",
       "  'sentence_chunk': 'Two questions (PICO 2 and 10, see Annex 4) were not addressed in an existing systematic review, and  evidence from primary studies was therefore used. In this case, the Systematic Review Team reviewed  the list of studies used in existing guidelines, queried the GDG and content experts, and searched for  primary studies. A total of 159 systematic reviews and 17 additional primary studies were included. Most of these were  traditional systematic reviews in which the authors conducted pairwise meta-analysis, whereas nine  analysed individual patient data. The Systematic Review Team also identified several published network  meta-analyses. (See Web Annex A for full details.) Most of the included reviews were found to be of high certainty when assessed using the AMSTAR  tool. Details of the selection process, and the reviews and studies included for each PICO question, are  presented in Web Annex A. Another overview of reviews was conducted to identify systematic reviews to inform other decision  criteria in the evidence-to-decision framework, including people’s values, resources, acceptability,  feasibility and equity, presented in Web Annex A. This review was enriched by primary studies identified  by GDG members. This review focused on evidence informing HTN management in low- and middle- income settings.4',\n",
       "  'chunk_char_count': 1326,\n",
       "  'chunk_word_count': 209,\n",
       "  'chunk_token_count': 331.5},\n",
       " {'page_number': -25,\n",
       "  'sentence_chunk': '2.5 Certainty of evidence and strength of recommendations  The GDG rated the certainty of evidence and developed the recommendations using the GRADE  (Grading of Recommendations Assessment, Development and Evaluation) approach (4). When making  recommendations, GRADE defines the certainty of a body of evidence as “the extent of our confidence  that the estimates of an effect are adequate to support a particular decision or recommendation” (5). Members of the GDG, with the help of the methodologist, developed evidence profiles to summarize  relative and absolute estimates of effects, and an assessment of the certainty of the evidence. One  evidence profile for each comparison within a PICO question was constructed, using the online  Guideline Development Tool GRADEpro (https://gradepro.org). When there were systematic reviews  addressing the relative effects in specific subpopulations, separate evidence profiles were constructed  for each subpopulation. According to the GRADE approach, the certainty of the evidence can be high, moderate, low, or very  low. Bodies of evidence from randomized controlled trials – which comprised almost the totality of those  included in this guideline – start the assessment as high-certainty evidence but can be down-rated due  to considerations of risk of bias, inconsistency, imprecision, indirectness, and publication bias.  Table 1 presents an explanation of the different levels of certainty of the evidence (5). Table 1 Certainty of evidence and its implications Certainty level Definition High We are very confident that the true effect lies close to that of the estimate   of effect. Moderate We are moderately confident in the effect estimate. (',\n",
       "  'chunk_char_count': 1703,\n",
       "  'chunk_word_count': 265,\n",
       "  'chunk_token_count': 425.75},\n",
       " {'page_number': -25,\n",
       "  'sentence_chunk': 'The true effect is likely to  be close to the estimate of effect, but there is a possibility that it is substantially  different.)Low Our confidence in the effect estimate is limited. (The true effect may be  substantially different from the estimate of the effect.)Very low We have very little confidence in the effect estimate. (The true effect is likely to be  substantially different from the estimate of effect.)The strength of the recommendations reflects the degree of confidence of the GDG that the desirable  effects (e.g. beneficial health outcomes) of the recommendations outweigh the undesirable effects  (e.g. adverse effects). The strength of recommendations in this guideline was graded into two  categories:  A strong recommendation is one for which the GDG was confident that the desirable effects of  adhering to the recommendation outweigh the undesirable effects. A weak or conditional recommendation is one for which the GDG concluded that the desirable  effects of adhering to the recommendation probably outweigh the undesirable effects, but was not  confident about these trade-offs. METHOD FOR DEVELOPING THE GUIDELINE 5',\n",
       "  'chunk_char_count': 1145,\n",
       "  'chunk_word_count': 184,\n",
       "  'chunk_token_count': 286.25},\n",
       " {'page_number': -24,\n",
       "  'sentence_chunk': 'GUIDELINE FOR THE PHARMACOLOGICAL TREATMENT OF HYPERTENSION IN ADULTS 2.6 Deciding upon recommendations The GDG met virtually for four sessions in February 2021. Systematic reviews and GRADE tables were  presented at the meeting. Formulation of recommendations and their strength were facilitated by the  chair and supported by the methodologist, with the aim of achieving unanimous consensus. While the  plan was to use a simple majority vote, full consensus was reached on all recommendations. The GDG used evidence-to-decision tables to guide the process of developing recommendations. These  tables addressed the certainty of evidence, the balance between desirable and undesirable effects,  values, resource use and cost-effectiveness, equity, acceptability and feasibility. These tables are available  in Web Annex B, and the full evidence profiles in Web Annex A. The WHO Steering Group noted  remarks made by members of the External Review Group and considered incorporating these into the  final guideline. Some evidence-to-decision frameworks were consolidated to provide recommendations  that are more practical and implementable from an end-user perspective; hence, the 11 questions led to  eight recommendations.2.7 Funding  The development of this guideline was financially supported by the US Centers for Disease Control and  Prevention and the World Health Organization.6',\n",
       "  'chunk_char_count': 1387,\n",
       "  'chunk_word_count': 208,\n",
       "  'chunk_token_count': 346.75},\n",
       " {'page_number': -23,\n",
       "  'sentence_chunk': '3 Recommendations 3.1 Blood pressure threshold for initiation of pharmacological treatment 1. RECOMMENDATION ON BLOOD PRESSURE THRESHOLD FOR INITIATION OF  PHARMACOLOGICAL TREATMENT WHO recommends initiation of pharmacological antihypertensive treatment of individuals  with a confirmed diagnosis of hypertension and systolic blood pressure of ≥140 mmHg or  diastolic blood pressure of ≥90 mmHg. Strong recommendation, moderate- to high-certainty evidence WHO recommends pharmacological antihypertensive treatment of individuals with existing  cardiovascular disease and systolic blood pressure of 130–139 mmHg. Strong recommendation, moderate- to high-certainty evidence WHO suggests pharmacological antihypertensive treatment of individuals without  cardiovascular disease but with high cardiovascular risk, diabetes mellitus, or chronic kidney  disease, and systolic blood pressure of 130–139 mmHg. Conditional recommendation, moderate- to high-certainty evidence Implementation remarks:   [ Initiation of pharmacological hypertension (HTN) treatment should start no later than four  weeks following diagnosis of HTN. If blood pressure level is high (e.g. systolic ≥160 mmHg or  diastolic ≥100 mmHg) or there is accompanying evidence of end organ damage, initiation of  treatment should be started without delay. Evidence and rationale The GDG reviewed evidence from 14 relevant systematic reviews that summarized data from a large  number of randomized trials involving over 120 000 adult participants (Web Annex A). Evidence  summaries are presented for the general population and for higher-risk populations (with diabetes (DM),  coronary artery disease (CAD), prior stroke) and were presented for various systolic blood pressure (SBP)  thresholds (Web Annex A). The anticipated benefits of a lower blood pressure (BP) target (140 SBP in the general population  and 130 SBP in a high-risk population) were reduction in mortality, cardiovascular mortality, stroke,  myocardial infarction (MI) and heart failure events. The anticipated harms were mostly not serious  side-effects, and some were a surrogate outcome, such as rise in creatinine that may not be clinically  relevant.',\n",
       "  'chunk_char_count': 2184,\n",
       "  'chunk_word_count': 312,\n",
       "  'chunk_token_count': 546.0},\n",
       " {'page_number': -23,\n",
       "  'sentence_chunk': 'On average, treatment was associated with a reduction in deaths and cardiovascular events  that ranged from 5 to 10/1000 and harms that ranged from 20 to 30/1000. The benefits were a  reduction in severe events with significant morbidity and mortality whereas the harms were mostly not  clinically significant. In summary, the anticipated benefits were large and clearly outweighed the harms. The overall certainty  varied from moderate to high, depending on the BP level and agent used. RECOMMENDATIONS 7',\n",
       "  'chunk_char_count': 505,\n",
       "  'chunk_word_count': 82,\n",
       "  'chunk_token_count': 126.25},\n",
       " {'page_number': -22,\n",
       "  'sentence_chunk': 'GUIDELINE FOR THE PHARMACOLOGICAL TREATMENT OF HYPERTENSION IN ADULTS Evidence-to-decision considerations The value of antihypertensive therapy is well accepted by most patients, health care providers, health  systems, professional societies and government agencies. From a patient’s perspective, preventing  cardiovascular events is highly valued. However, some individuals who are eligible for antihypertensive  treatment may not present to care, may be lost to follow up, or are prescribed a treatment but fail to  take/adhere to the treatment. Treatment may be perceived as low value from the perspective of an  asymptomatic patient unless the person is convinced of a trade-off between immediate inconvenience/ side-effects and potential long-term health gains (6). The patient perception of an unfavourable cost- benefit may be further exacerbated by the requirement for out-of-pocket payment for appointments or  medications. Therefore, the GDG considered that although there is important variability in stakeholder  values, overall initiation of hypertension (HTN) medications is likely to be feasible and acceptable overall. Given that the barriers to accessing HTN care in low-income settings include low patient health literacy,  lack of financial protections, and limited resources (7), the GDG felt that health inequalities would  probably be reduced by HTN treatment. In terms of costs and resource requirements, the GDG acknowledged variability, based on the structure  of a country’s public health system and its economic status. Other costs, including human resources  and medications, were considered moderate, given the benefits. Multiple sources of cost effectiveness  are available from various countries, such as Argentina, Nigeria, the USA and UK (8, 9, 10, 11, 12, 13),  and for lower thresholds and higher-risk individuals (14, 15, 16).',\n",
       "  'chunk_char_count': 1861,\n",
       "  'chunk_word_count': 277,\n",
       "  'chunk_token_count': 465.25},\n",
       " {'page_number': -22,\n",
       "  'sentence_chunk': 'Most cost-effectiveness estimates were  clustered below USD 1000 per averted disability-adjusted life year (DALY) – well below the average 2017  GDP per capita for lower-middle income countries of USD 2188 (17), suggesting that pharmacological  treatment could be very cost-effective for this group of countries. HTN treatment (treating all with BP  ≥140/90 mmHg) has been shown to be cost-effective and a “best buy” intervention by the Kostova  study (8). Treating high-risk/CVD patients with baseline 130–139 mmHg has been shown to be cost  effective, but not cost saving (SPRINT cost-effective analyses) (15); value depends on maintaining the  intervention effect for more than five years.3.2 Laboratory testing before and during pharmacological treatment 2. RECOMMENDATION ON LABORATORY TESTING When starting pharmacological therapy for hypertension, WHO suggests obtaining tests to  screen for comorbidities and secondary hypertension, but only when testing does not delay  or impede starting treatment. Conditional recommendation, low-certainty evidence Implementation remarks:   [ Suggested tests include serum electrolytes and creatinine, lipid panel, HbA1C or fasting glucose,  urine dipstick, and electrocardiogram (ECG).   [ In low-resourced areas or non-clinical settings, where testing may not be possible because of  additional costs, and lack of access to laboratories and ECG, treatment should not be delayed,  and testing can be done subsequently.   [ Some medicines, such as long-acting dihydropyridine calcium-channel blockers (CCBs) are more  suitable for initiation without testing, compared to diuretics or angiotensin-converting enzyme  inhibitors (ACEi)/angiotensin-II receptor blockers (ARBs).8',\n",
       "  'chunk_char_count': 1719,\n",
       "  'chunk_word_count': 251,\n",
       "  'chunk_token_count': 429.75},\n",
       " {'page_number': -21,\n",
       "  'sentence_chunk': 'Evidence and rationale Comparative studies that evaluate various testing strategies prior to the initiation of antihypertensive  treatment were not identified, despite a search of the literature. Therefore, indirect evidence was  sought to evaluate this question. An analytic framework was developed to conceptualize the rationale  for obtaining diagnostic testing, such as laboratory tests and electrocardiogram (ECG), in this context  (see Fig.2). This framework identified the four most important reasons for obtaining testing, which are  to diagnose secondary HTN, identify comorbidities (e.g. DM), identify end organ damage (e.g. chronic  kidney disease (CKD) or left ventricular hypertrophy (LVH)), and for cardiac risk stratification. Fig.2  Framework for analysis People with  high BP Laboratory tests ECG Treatment Patient-important  outcomes Follow-up tests PICO 2: No comparative studies  Desirable effects of testing Identification of: • secondary HTN • comorbidities (e.g. DM) • end organ damage (e.g.   CKD, LVH) Opportunity to: • develop cardiac risk  stratification • choose certain medications  over others  direct evidence Color legend: indirect evidence Undesirable effects of  testing • incidental findings • cost • delay in starting treatment In terms of secondary HTN, various studies suggest a prevalence of 5–10% among patients with a  diagnosis of HTN and a higher prevalence of 10–30% among patients with particularly high BP (e.g.  over 175/115 mmHg) or BP that is resistant to treatment (18, 19, 20). Morbidities and end organ  damage that could be identified by testing patients with HTN are also common. One estimation  indicates that 23%, 24% and 39% of patients with a diagnosis of HTN have one, two, three or more  comorbidities respectively. Common comorbidities among patients with HTN that can be discovered  via laboratory testing are hyperlipidaemia and diabetes, which have a prevalence of 56% and 27%  respectively (21).',\n",
       "  'chunk_char_count': 1960,\n",
       "  'chunk_word_count': 309,\n",
       "  'chunk_token_count': 490.0},\n",
       " {'page_number': -21,\n",
       "  'sentence_chunk': 'Testing at the point of starting HTN medications or for subsequent monitoring can  also identify patients who develop certain adverse events after treatment (e.g. hyperkalaemia and  acute kidney injury), thus providing a rationale for testing. Testing also had the additional advantage of  identifying compelling indications for choosing certain medications over others. For example, identifying  diabetes would favour the use of ACEis/ARBs, and identifying hyponatraemia would lead to not starting  diuretics. Overall, the desirable effects of testing were judged to be at least moderate. The framework also identified the most undesirable effects of obtaining testing, which were delay  of starting treatment, cost and incidental findings. Delay of treatment was judged to be the most  important concern since it can lead to losing the patient for follow up and the potential for adverse  cardiovascular (CV) outcomes. Incidental findings on testing were thought to be less important. The  undesirable effects of testing were judged to have smaller magnitude. On balance, desirable effects are  likely to outweigh undesirable effects. The certainty of evidence across outcome was judged to be very  low due to serious concerns about the indirectness of evidence.',\n",
       "  'chunk_char_count': 1264,\n",
       "  'chunk_word_count': 197,\n",
       "  'chunk_token_count': 316.0},\n",
       " {'page_number': -20,\n",
       "  'sentence_chunk': 'GUIDELINE FOR THE PHARMACOLOGICAL TREATMENT OF HYPERTENSION IN ADULTS Evidence-to-decision considerations There is uncertainty about patients’ values and preferences regarding the issue of testing before starting  treatment for HTN. The cost of tests such as electrolytes, creatinine, lipid panel, glucose, HbA1C,  urine dipstick, and ECG relative to overall costs of treatment and complications of HTN are small (22). However, in less well-resourced settings, this cost can have a large impact. Furthermore, if additional  tests like ECG or 24-hour ambulatory BP monitoring were added, the cost can become a barrier (23). It is unknown whether testing would lead to cost saving or be cost-effective. Testing was judged to be  acceptable to most stakeholders, particularly patients and health care providers, and to a lesser extent  to those governing health systems. Requiring testing before starting HTN medications can exacerbate  health inequities and may not be feasible in low-resource settings.3.3 Cardiovascular disease risk assessment as guide to initiation of        antihypertensive medications 3. RECOMMENDATION ON CARDIOVASCULAR DISEASE RISK ASSESSMENT WHO suggests cardiovascular risk assessment at or after the initiation of pharmacological  treatment for hypertension, but only where this is feasible and does not delay treatment. Conditional recommendation, low-certainty evidence Implementation remarks:   [ Most patients with SBP ≥140 or DBP ≥90 mmHg are high risk and indicated for pharmacological  treatment; they do not require cardiovascular (CVD) risk assessment prior to initiating treatment.',\n",
       "  'chunk_char_count': 1617,\n",
       "  'chunk_word_count': 243,\n",
       "  'chunk_token_count': 404.25},\n",
       " {'page_number': -20,\n",
       "  'sentence_chunk': 'CVD risk assessment is most important for guiding decisions about initiating pharmacological  treatment for hypertension (HTN) in those with lower SBP (130–139 mmHg). It is critical in  those with HTN that other risk factors must be identified and treated appropriately to lower  total cardiovascular risk.  [ Many CVD risk-assessment systems are available. In the absence of a calibrated equation for the  local population, the choice should depend on resources available, acceptability and feasibility  of application.   [ Whenever risk assessment may threaten timely initiation of HTN treatment and/or patient follow  up, it should be postponed and included in the follow-up strategy, rather than taken as a first  step to indicate treatment. Evidence and rationale The most direct evidence is derived from an individual patient data meta-analysis by Karmali that  compared the number of major adverse cardiovascular events (MACE) at five years when using a CVD  risk assessment strategy (based on age, sex, body mass index, blood pressure, previous antihypertensive  treatment, smoking, diabetes mellitus (DM), and history of CVD) vs BP levels alone for determining  which patients receive treatment (24). This analysis suggested that risk assessment can potentially  prevent 310 MACE events in 1000 people over five years, which the GDG considered to be a moderate- to-large benefit. However, this evidence was indirect for many reasons, including the effect being  dependent on the BP at presentation (graphs diverge at higher level of BP, compared with starting  medications without risk assessment) and the fact that these trials did not actually randomize patients  to the two strategies sought in PICO question 3 (see Annex 4). Furthermore this evidence should not  suggest that people with intermediate risk would not have important treatment benefit. There was no evidence of the undesirable anticipated effects of starting treatment based on  cardiovascular risk assessment.',\n",
       "  'chunk_char_count': 1987,\n",
       "  'chunk_word_count': 315,\n",
       "  'chunk_token_count': 496.75},\n",
       " {'page_number': -20,\n",
       "  'sentence_chunk': 'However, delay in initiating care for HTN management and loss to follow  up are important considerations, especially in low-resource settings.10',\n",
       "  'chunk_char_count': 144,\n",
       "  'chunk_word_count': 21,\n",
       "  'chunk_token_count': 36.0},\n",
       " {'page_number': -19,\n",
       "  'sentence_chunk': 'The GDG deduced that benefits of risk assessment may not all be attributable to risk assessment per  se, but rather to the various treatments provided for risk factors identified during risk assessment. The certainty of evidence across outcome was judged to be very low due to serious concerns about  the indirectness of evidence. Overall, the desirable effects of risk assessment at or after initiating HTN  medications outweighed the plausible undesirable effects, particularly when risk assessment was  deemed not to delay the initiation of treatment. Evidence-to-decision considerations There is important uncertainty over the value stakeholders place on conducting a CVD risk assessment  prior to starting pharmacological treatment, and it was noted that patient perspectives may vary,  depending on the setting. In low-resource settings, patients may focus more on immediate treatment  without having to bear additional costs for screening for other risk factors and treating them. Studies  have also shown that in high-income countries (HICs) such as the United States, people of a lower  socioeconomic status have lower control of blood pressure and higher CVD risk over the years (25). Thus, in low-resource settings, adding one more step before initiating treatment may increase inequities,  as those patients who have limited access to health care services may suffer delays in treatment or even  end up not receiving HTN treatment at all. In terms of costs, there is no direct evidence of whether treatment of HTN with or without risk  stratification is more cost effective. The cost of implementation of CVD risk assessment should also  account for capacity building of health care providers and the time taken to do so for each patient. Cost of testing and delay in initiating care can be significant following a CVD risk stratification strategy  in low-resource settings.',\n",
       "  'chunk_char_count': 1886,\n",
       "  'chunk_word_count': 303,\n",
       "  'chunk_token_count': 471.5},\n",
       " {'page_number': -19,\n",
       "  'sentence_chunk': 'Modelling by Gaziano et al.showed significant cost reduction using CVD risk- stratification before initiation of treatment in low-resource settings. However, screening costs, including  the cost of obtaining risk-factor information, productivity costs due to work loss, care costs and travel  time were not included in the analysis (26). A meta-analysis showed that proportional relative risk reduction in major CVD events from BP lowering  did not differ substantially with the presence or absence of previous CVD events, coronary heart disease,  or cerebrovascular disease. Hence, the absolute benefit of blood pressure lowering would be greatest in  those with the highest absolute risk of CVD (27). 3.4 Drug classes to be used as first-line agents To develop a recommendation that is practical and implementable by end-users, the evidence-to-decision  frameworks of PICO questions 4 and 5 (see Annex 4) were used to develop one recommendation. 4. RECOMMENDATION ON DRUG CLASSES TO BE USED AS FIRST-LINE AGENTS For adults with hypertension requiring pharmacological treatment, WHO recommends the  use of drugs from any of the following three classes of pharmacological antihypertensive  medications as an initial treatment:  1.thiazide and thiazide-like agents 2.angiotensin-converting enzyme inhibitors (ACEis)/angiotensin-receptor blockers (ARBs) 3.',\n",
       "  'chunk_char_count': 1354,\n",
       "  'chunk_word_count': 199,\n",
       "  'chunk_token_count': 338.5},\n",
       " {'page_number': -19,\n",
       "  'sentence_chunk': 'long-acting dihydropyridine calcium channel blockers (CCBs). Strong recommendation, high-certainty evidence Implementation remarks:   [ Long-acting antihypertensives are preferred.  [ Examples of indications to consider specific agents include diuretics or CCBs in patients over  65 years or those of African descent, beta-blockers in ischaemic heart disease, ACEis/ARBs in  patients with severe proteinuria, diabetes mellitus, heart failure or kidney disease. RECOMMENDATIONS 11',\n",
       "  'chunk_char_count': 479,\n",
       "  'chunk_word_count': 64,\n",
       "  'chunk_token_count': 119.75},\n",
       " {'page_number': -18,\n",
       "  'sentence_chunk': 'GUIDELINE FOR THE PHARMACOLOGICAL TREATMENT OF HYPERTENSION IN ADULTS Evidence and rationale Data from 32 systematic reviews were used to derive evidence on benefits and harms of various  medication classes (19 for comparisons against placebo and 13 for head-to-head comparisons). These  reviews summarized the results of a many large randomized trials (Web Annex A). The anticipated  benefits were considered to be large. Mortality and major adverse cardiac events (MACE) reduction per  1000 treated people for the various classes were 3 and 14 (low-dose thiazide), 12 and 39 (high-dose  thiazide), 23 and 48 (ACEi), 8 and 23 (CCB), 2 and 8 (beta-blockers) and 14 and no data for MACE  (ARBs) respectively. The anticipated adverse events were judged to be moderate. Compared to placebo,  60 and 100 additional adverse events per 1000 treated people were observed for thiazides and beta- blockers respectively. Withdrawal from ACEi treatment and cough per 1000 treated people were 12  and 26 respectively. A systematic review of studies of pharmacotherapy for HTN in sub-Saharan Africa  showed a rate of side-effects of CCB of 6% (headache), 2% (dizziness) 2% (ankle oedema) (28). In terms of the head-to-head comparisons among various classes, there was a smaller body of evidence,  with less data available on hard endpoints and patient-important outcomes. Comparisons showed  overall minimal differences in SBP or DBP.',\n",
       "  'chunk_char_count': 1421,\n",
       "  'chunk_word_count': 229,\n",
       "  'chunk_token_count': 355.25},\n",
       " {'page_number': -18,\n",
       "  'sentence_chunk': 'For example, ACEis/ARBs vs CCBs differed by less than  2 mmHg, and so did comparisons between ACEis/ARBs vs thiazide or ACEis vs ARB. There were more  stroke events with beta-blockers than CCBs or ACEis/ARBs. The anticipated benefits clearly outweighed the potential harms for three classes of medications:  thiazide and thiazide-like agents, ACEis/ARBs, and long-acting dihydropyridine CCBs. The adverse  events of these three classes were infrequent, usually mild, and can be managed or another agent can  be substituted. The amount of BP reduction appeared to be a more major determinant of reduction in  CV events than the choice between these three classes of antihypertensive medications, as was shown  in several landmark trials (ALLHAT, VALUE, CAMELOT trials) (29, 30, 31). This balance of benefits and  harms was not as clear for beta-blockers as a first choice for HTN management. In terms of potential subgroups of patients that may benefit more from specific medication classes,  ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) suggested greater  BP reduction in individuals of African descent with chlorthalidone than lisinopril, and that stroke was  significantly less likely with the diuretic than with the lisinopril in this group of patients than in those of  Caucasian ethnicity (32). Other studies suggested benefit of diuretics or CCBs in patients over 65 years of  age or of African descent, beta-blockers in patients with HTN who are post-myocardial infarction, ACEis/ ARBs in diabetes mellitus, heart failure or kidney disease (33, 34). Diuretics were likely to be the most  efficacious medications, and CCBs the least efficacious medications for the prevention of heart failure. The overall certainty of evidence varied from high to moderate for these three classes of medications  when compared against placebo.',\n",
       "  'chunk_char_count': 1873,\n",
       "  'chunk_word_count': 297,\n",
       "  'chunk_token_count': 468.25},\n",
       " {'page_number': -18,\n",
       "  'sentence_chunk': 'It was noted that diuretic trials were older and practice patterns may  have changed over time, and that the severity and stage spectrum of diabetes mellitus and chronic kidney  disease varied in the available trials. In addition, evidence supporting the efficacy of antihypertensive  drug therapy is derived from trials conducted in adults at high risk for CVD/atherosclerotic CVD. Since  CVD risk increases with higher levels of BP, and given that risk factors for CVD tend to track together, the  assumption of greater benefits using CVD risk could be attributed to this.12',\n",
       "  'chunk_char_count': 576,\n",
       "  'chunk_word_count': 96,\n",
       "  'chunk_token_count': 144.0},\n",
       " {'page_number': -17,\n",
       "  'sentence_chunk': 'Evidence-to-decision considerations The value of antihypertensive therapy is well accepted by most patients, health care providers, health  systems, professional societies and government agencies. From a patient’s perspective, preventing  cardiovascular events is highly valued. However, some individuals who are eligible for antihypertensive  treatment may evade efforts aimed at treatment or are prescribed a treatment but fail to take/adhere  to the treatment. The asymptomatic nature of the disease and concern about adverse events are the  likely driver for this perspective. Interviews of patients in England suggested greater acceptance of  antihypertensive drug therapy with higher socioeconomic status. In one study, as many as 35% of the Caucasians and 20% of the South Asians in the two lowest  socioeconomic categories told their interviewer that they would not accept antihypertensive drug  therapy (35). Shahaj et al. (6) synthesized six qualitative and 29 quantitative reviews and identified a  range of individual and social factors that affect treatment adherence, including familial (lack of support,  need for separate meals), and environmental (sense of security, local amenities, healthy food availability). A review by Fragasso et al. (36) suggested that quality of life on antihypertensive therapy is an important  issue because clinicians are asked to initiate drug therapy in mostly asymptomatic patients who are  never happy to become, instead, symptomatic because of side-effects.',\n",
       "  'chunk_char_count': 1507,\n",
       "  'chunk_word_count': 225,\n",
       "  'chunk_token_count': 376.75},\n",
       " {'page_number': -17,\n",
       "  'sentence_chunk': 'Therefore, the GDG considered  that there is important variability in stakeholder values, but overall initiation of HTN medications is likely  to be feasible and acceptable overall. Considering the ample literature on disparities in adherence to BP  medication regimes and cardiovascular outcomes based on race or socioeconomic status, treatment was  judged to reduce health inequities. In terms of costs and resource requirements, thiazide-like agents, ACEis/ARBs and long-acting  dihydropyridine CCBs are available as generic drugs, are simple to manufacture, and should be  available at low cost globally. Other costs related to workforce requirements, provision of infrastructure,  laboratory testing, lost work time etc.are real but modest. Numerous modelling studies demonstrate  cost effectiveness of antihypertensive therapy, which is especially beneficial in LMICs where large  numbers of adults have untreated HTN, as long as medications are available at low cost. Models were  available from many countries, including Bangladesh, Ghana and Nigeria (37, 38, 39, 40). 3.5 Combination therapy To develop a recommendation that is practical and implementable by end-users, the evidence- to-decision frameworks of PICO questions 6, 7 and 8 (see Annex 4) were used to develop one  recommendation. 5. RECOMMENDATION ON COMBINATION THERAPY For adults with hypertension requiring pharmacological treatment, WHO suggests  combination therapy, preferably with a single-pill combination (to improve adherence and  persistence), as an initial treatment.',\n",
       "  'chunk_char_count': 1550,\n",
       "  'chunk_word_count': 227,\n",
       "  'chunk_token_count': 387.5},\n",
       " {'page_number': -17,\n",
       "  'sentence_chunk': 'Antihypertensive medications used in combination  therapy should be chosen from the following three drug classes: diuretics (thiazide or  thiazide-like), angiotensin-converting enzyme inhibitors (ACEis)/angiotensin-receptor  blockers (ARBs), and long-acting dihydropyridine calcium channel blockers (CCBs). Conditional recommendation, moderate-certainty evidence Implementation remarks:   [ Combination medication therapy may be especially valuable when the baseline BP is  ≥20/10 mmHg higher than the target blood pressure.  [ Single-pill combination therapy improves medication-taking adherence and persistence and BP  control. RECOMMENDATIONS 13',\n",
       "  'chunk_char_count': 648,\n",
       "  'chunk_word_count': 81,\n",
       "  'chunk_token_count': 162.0},\n",
       " {'page_number': -16,\n",
       "  'sentence_chunk': 'GUIDELINE FOR THE PHARMACOLOGICAL TREATMENT OF HYPERTENSION IN ADULTS Evidence and rationale The GDG developed three PICO questions to address: monotherapy vs combination therapy as a first- line treatment for HTN, a comparison of the various combination therapies, and a comparison of single- pill combinations vs multiple-pill combinations. These three questions were addressed separately in the  evidence profiles and evidence-to-decision framework, but eventually led to one recommendation. The  evidence base consisted of six, seven and eight systematic reviews respectively (Web Annex A). Evidence summaries demonstrate several comparisons of combination therapy to monotherapy. Data  on mortality, MACE and other hard endpoints were imprecise. Combination therapy lowered SBP more  than monotherapy did (e.g. standard dose CCB combined with ARB vs high dose CCB; or ACEi and ARB  combination vs either drug class alone) and had fewer adverse events (standard dose CCB combined  with ARB vs high dose CCB). Data on cardiovascular outcomes are limited from randomized trials. A  large nonrandomized study from Italy (125 635 patients, age 40–85 years) evaluated those who started  antihypertensive treatment with one drug vs a two-drug single-pill or free combination. Propensity score  adjusted analysis suggests that an initial two-drug single-pill or free combination was associated with  significant reductions in the risk of death (20%, 11–28%) and hospitalization for cardiovascular events  (16%, 10–21%) compared with initial monotherapy (41). Combination antihypertensive therapy may be  associated with fewer side-effects due to use of lower doses of each drug.',\n",
       "  'chunk_char_count': 1675,\n",
       "  'chunk_word_count': 250,\n",
       "  'chunk_token_count': 418.75},\n",
       " {'page_number': -16,\n",
       "  'sentence_chunk': 'A comparison of the various combination therapies suggested overall effectiveness of combination  therapies that contained the three drug classes of diuretic, ACEi/ARB and CCB. Other desirable  effects of a combination therapy are improved treatment adherence and persistence. However, many  of these studies used a single-pill combination, thereby confounding the question of monotherapy  vs combination therapy. A meta-analysis compared adherence and persistence between groups of  patients taking antihypertensives as single-pill combinations vs free-equivalent components based  on 12 retrospective database studies. Adherence, measured as the mean difference in medication  possession ratio, was 8–14% higher with a single-pill combination. Persistence was also twice as likely  (42). A second systematic review demonstrated that simplifying dosing regimens results in significant  improvements in medication adherence, ranging from 6% to 20% (43). The desirable effects of greater adherence/persistence, improved BP control, and potentially improved  clinical outcomes of combinations of the three classes of antihypertensive therapy compared outweigh  the undesirable effects such as side-effects, particularly when provided as a single-pill combination. The  overall certainty in evidence was low across the outcomes of interest, noting that evidence was limited  in terms of hard endpoints. Evidence-to-decision considerations In terms of stakeholder values and preferences about monotherapy vs combination therapy or the  various combination therapies, data were minimal.',\n",
       "  'chunk_char_count': 1581,\n",
       "  'chunk_word_count': 221,\n",
       "  'chunk_token_count': 395.25},\n",
       " {'page_number': -16,\n",
       "  'sentence_chunk': 'No important variability in values was expected  with regard to the critical outcomes. A systematic review demonstrated that simplifying dosing  regimens results in significant improvements in medication adherence, ranging from 6% to 20% (43). Considering the comparative ease of using a single-pill combination over multiple-pill combinations, and  the anticipated impact on adherence and persistence, the GDG judged that from a patient perspective  the single-pill option will be favoured by most. Combination therapy is accompanied initially by a moderate increase in resource requirements, such as  procurement, supply chain, and direct medication costs. Some combinations may be expensive, or not  allow for exact dosing of both agents. However, the net benefit of improved BP control and reduction  of major events associated with the hypertensive process compared to the increase in cost is large. BP control is also likely to be achieved sooner with combination therapy. Many modelling studies that  evaluated combination vs monotherapy used a fixed dose (thereby not truly addressing the question). One model from Japan used data from randomized trials and compared low-dose combination therapy  of controlled-release nifedipine (20 mg/day) plus candesartan (8 mg/day) vs titrated monotherapy of  14',\n",
       "  'chunk_char_count': 1308,\n",
       "  'chunk_word_count': 199,\n",
       "  'chunk_token_count': 327.0},\n",
       " {'page_number': -15,\n",
       "  'sentence_chunk': 'candesartan. In the combination therapy group, higher efficacy and lower incremental treatment cost  (dominance) were observed when compared to the monotherapy group (44). A retrospective cohort  study that used the 2008–2012 BlueCross BlueShield of Texas claims suggests that mean annual drug  utilization costs were highest for a single-pill combination strategy. However, disease-related inpatient  services utilization costs were lower compared with the up-titration strategy, which may offset initial  costs (45). In one model from China, olmesartan/amlodipine as a single pill was dominant, compared  with olmesartan and amlodipine free combination and valsartan/amlodipine single-pill combination (46). In a second study, there was a reduction in the cost of therapy of 33%, with a saving of USD 19 per  patient/month after switching from free combination to the single-pill combination (47). Since single-pill combination therapy increases medication adherence and persistence, which could  improve HTN control rates and decrease major clinical events, the impact on health equities is expected  to be favourable. In terms of acceptability, combination therapy, including in a single-pill form, can  initially be met with scepticism among stakeholders, including health care providers. However, this initial  scepticism may improve once BP control improves. Despite effective, safe, affordable, and available  pharmacological antihypertensive agents, the control rates of HTN are dismal worldwide, and over  the last 5 to 10 years have been decreasing in some HICs, and in LMICS, in tandem with increasing  major cardiovascular events.',\n",
       "  'chunk_char_count': 1643,\n",
       "  'chunk_word_count': 244,\n",
       "  'chunk_token_count': 410.75},\n",
       " {'page_number': -15,\n",
       "  'sentence_chunk': 'Over 30% of the world population has HTN and only 13.8% of cases are  considered controlled (48). One major reason for this poor level of control (one in seven) is that most  patients only receive monotherapy, whereas empirical evidence demonstrates that most patients require  two drugs or more to achieve optimal and sustained control (44, 46, 49, 50, 51, 52). The rationale for  recommending a combination therapy, particularly in a single-pill approach, is based on the following  considerations:    [ most individuals with HTN will eventually require two or more antihypertensive agents to achieve  BP control;    [ the combination of two agents from complementary classes yields greater BP-reduction efficacy  (at least equal to the sum of the efficacy of each chosen agent);    [ lower doses of each agent are needed, which results in a reduction of side-effects and the fact  that use of complementary classes of antihypertensive agents may mitigate the side-effects of  each agent;    [ adherence and persistence are increased; and    [ simplified logistics can lead to fewer stock-outs and a reduced pharmacy inventory (53, 54). In terms of feasibility, a study from India compared prices of antihypertensive single-pill combinations  and equivalent single-agent pills in the private health care sector. The results suggested that  manufacturers have priced the combination higher than the price of its components. These data  demonstrate that the price of combination pills could be lowered to match the combined price of  the component, and that manufacturing costs and market forces do not present a barrier to the  implementation of antihypertensive combination pills (55). Thus, the intervention is likely feasible  to implement. The GDG acknowledged some challenges to single-pill combinations, such as limited  flexibility in modifying the doses of individual components, and difficulty in attributing side-effects to  one of its components (56). Although randomized trials addressing this issue are not abundant, and those available are not  sufficiently large or conducted for a long enough period to clearly address differences in major clinical  events, the initial combination treatment approach has been in place for over 15 years in large health  systems, such as the Kaiser Permanente system in the United States (57) and is a major component of  the WHO Global HEARTS Programme and the PAHO HEARTS in the Americas Initiative (53). Recently,  combination antihypertensive medications in a single pill have been added to the WHO Essential  Medicines List (49).',\n",
       "  'chunk_char_count': 2584,\n",
       "  'chunk_word_count': 429,\n",
       "  'chunk_token_count': 646.0},\n",
       " {'page_number': -15,\n",
       "  'sentence_chunk': 'This approach has demonstrated general acceptance by government, public, and  private stakeholders and is demonstrating success in increasing HTN control rates worldwide. RECOMMENDATIONS 15',\n",
       "  'chunk_char_count': 189,\n",
       "  'chunk_word_count': 25,\n",
       "  'chunk_token_count': 47.25},\n",
       " {'page_number': -14,\n",
       "  'sentence_chunk': 'GUIDELINE FOR THE PHARMACOLOGICAL TREATMENT OF HYPERTENSION IN ADULTS 3.6 Target blood pressure 6. RECOMMENDATION ON TARGET BLOOD PRESSURES WHO recommends a target blood pressure treatment goal of <140/90 mmHg in all patients  with hypertension without comorbidities. Strong recommendation, moderate-certainty evidence WHO recommends a target systolic blood pressure treatment goal of <130 mmHg in  patients with hypertension and known cardiovascular disease (CVD). Strong recommendation, moderate-certainty evidence WHO suggests a target systolic blood pressure treatment goal of <130 mmHg in high-risk  patients with hypertension (those with high CVD risk, diabetes mellitus, chronic kidney  disease). Conditional recommendation, moderate-certainty evidence Evidence and rationale The evidence base consisted of five systematic reviews as well as a review of the SPRINT trial (58). Evidence profiles were constructed for various BP treatment targets, based on age and comorbidities  (Web Annex A). The desirable effects of lower target BP (per 1000 treated patients) were: a reduction in mortality  of 27 (for SBP <120 vs <130–139) and of 7 (for SBP 140/90 vs 150–160/95–105); a reduction in  cardiovascular mortality of 40 (for SBP <130 vs <130–149) and 6 (for SBP 140/90 vs 150–160/95–105);  and a reduction in stroke of 17 (for SBP <130 vs <140). The increase in serious adverse events per 1000  treated patients was 20 (for SBP <130 vs <140) and 5 (for SBP 140/90 vs 150–160/95–105). Summary results from a systematic review focusing on adults 65 years and older by Murad et al (59). suggests that treatment to a lower BP target in individuals 65 years or older leads to a significant  reduction in all-cause and CVD mortality, chronic kidney disease, myocardial infarction, or stroke  outcomes.',\n",
       "  'chunk_char_count': 1801,\n",
       "  'chunk_word_count': 282,\n",
       "  'chunk_token_count': 450.25},\n",
       " {'page_number': -14,\n",
       "  'sentence_chunk': 'Similar conclusions were provided by another systematic review by Reboussin et al (60). Neither of these meta-analyses was able to account for the high risk of patients enrolled in the available  trials – at least in SPRINT and ACCORD (11, 61). Therefore, the GDG cautions against applying this  evidence to lower-risk patients with raised BP or HTN – specifically, those not meeting trial eligibility  criteria for SPRINT, ACCORD or SPS3 (62). Network meta-analyses found a similar direction of effect but  more optimistic beneficial effect sizes with intensive treatment (63, 64). In patients with comorbidity (CAD, DM, CKD) there is consistent benefit with lower targets (variable  thresholds); however, data in these subgroups were imprecise and the evidence was less certain. Adverse events such as dizziness in intensive control group and ischaemia in patients with coronary  artery disease can shift the balance of benefits and harms in those aged 65 years or older. Concern  about lower adherence due to the need for extra patient and provider effort to reach lower targets  should also be balanced against intensive control. The overall certainty of the evidence was judged to  be moderate, with large benefits and moderate harms. The GDG made a judgement that the desirable  effects outweigh the undesirable effects at a treatment goal of <140/90 mmHg in all patients with HTN  without comorbidities and of <130 mmHg in high-risk patients with HTN – those with high CVD risk,  diabetes, chronic kidney disease.16',\n",
       "  'chunk_char_count': 1522,\n",
       "  'chunk_word_count': 251,\n",
       "  'chunk_token_count': 380.5},\n",
       " {'page_number': -13,\n",
       "  'sentence_chunk': 'Evidence-to-decision considerations From a patient perspective, HTN is often a silent disease and patients may not take antihypertensive  medications as directed because the positive effects of these medications are not as obvious as potential  side-effects (61). Society and patients want to avoid premature mortality or disability. Serious adverse  events are also feared, but their duration and severity are often not well characterized in trials. Lower  targets are likely acceptable to other stakeholders, such as governments and providers, though there are  usually several competing priorities and interests – especially the more acute demands of, and a higher  priority placed on, acute conditions and health emergencies. Many well-known barriers to access to  HTN care in low-income settings exist (6). Investment in the primary health care platform required for  effective HTN management is often a challenge. Countries with low rates of HTN control using more  conservative BP thresholds may feel burdened by any request to set more ambitious BP treatment goals,  even if only in selected high-risk patients. Intensive treatment for selected patients adds complexity for health workers; emphasis on team-based  care in low-resource settings means that simple, protocolized care is needed. Intensive treatment for  some patients complicates treatment protocols and may lead to decisional overload, especially for health  workers with more limited training and/or autonomy. On the other hand, strict BP targets in the general population with HTN are likely to be less acceptable  to stakeholders.',\n",
       "  'chunk_char_count': 1605,\n",
       "  'chunk_word_count': 248,\n",
       "  'chunk_token_count': 401.25},\n",
       " {'page_number': -13,\n",
       "  'sentence_chunk': 'Most available evidence is derived from high-risk patients receiving intensive treatment  and not the general population living with HTN. Treating HTN will reduce health inequity because  preventing CV events reduces mortality across the population. Uncontrolled HTN might be over- represented in vulnerable populations. Therefore, improvement of HTN treatment and control through  better treatment and a lower BP target could reduce long-standing inequality. Regarding costs, intensive treatment in the SPRINT trial meant one additional medication, one additional  office visit, and one additional laboratory test evaluation on average, and additional titration visits per  participant over 3.25 years, compared with standard treatment. In the United States, this translates  to about USD 23 000 more per patient per year over their remaining lifetime (14, 15). Health care  costs are much less in countries other than the United States. Treating to lower BP targets will have  diminishing returns in progressively lower-risk patients as the magnitude of benefit becomes smaller. A  cost-effectiveness study of screening and optimal management of HTN, diabetes mellitus and chronic  kidney disease in an Australian setting found that an intensive management of previously uncontrolled  HTN compared with usual care resulted in an incremental cost-effectiveness ratio of AUD 2588. The  study does not specify the target BP for the comparisons (65).',\n",
       "  'chunk_char_count': 1448,\n",
       "  'chunk_word_count': 220,\n",
       "  'chunk_token_count': 362.0},\n",
       " {'page_number': -13,\n",
       "  'sentence_chunk': 'A SPRINT trial health economic analysis  provided similar inferences (48, 50). 3.7 Frequency of re-assessment 7. RECOMMENDATION ON FREQUENCY OF ASSESSMENT WHO suggests a monthly follow up after initiation or a change in antihypertensive  medications until patients reach target. Conditional recommendation, low-certainty evidence WHO suggests a follow up every 3–6 months for patients whose blood pressure is under  control. Conditional recommendation, low-certainty evidence RECOMMENDATIONS 17',\n",
       "  'chunk_char_count': 494,\n",
       "  'chunk_word_count': 68,\n",
       "  'chunk_token_count': 123.5},\n",
       " {'page_number': -12,\n",
       "  'sentence_chunk': 'GUIDELINE FOR THE PHARMACOLOGICAL TREATMENT OF HYPERTENSION IN ADULTS There was a minimal number of comparative studies that evaluated different follow-up lengths after  initiation of HTN medications. One randomized controlled trial compared a follow-up interval of three  months to an interval of six months in family practice clinics in Canada. Participants (age 30–74 years)  had essential HTN that was controlled for at least three months before entry into the study. Mean BP,  control of HTN, patient satisfaction and adherence to treatment were similar between the two groups  (66). A retrospective population-based cohort study of family-practice clinics in the UK (67) studied  88 756 adults with HTN (1986–2010). This study showed that in patients newly diagnosed with HTN,  those with >1.4 months prior to initiation of treatment had a hazard ratio of 1.12 (1.05–1.20) for a  major adverse cardiovascular event (MACE) compared to those who started treatment at <1.4 months. For patients who were initiated on treatment, those who waited >2.7 months before re-evaluation  had a hazard ratio of 1.18 (1.11–1.25) for MACE compared to those reassessed at <2.7 months. In  addition, when reviewing protocols of large HTN trials that demonstrated important improvement in  cardiovascular events with BP control, such as ACCORD and SPRINT, the initial length of time to follow  up was one month (68, 69). This evidence indirectly suggests the appropriateness of this initial follow up  in settings that conferred important benefit. The anticipated desirable consequences of shorter follow up are better BP control and monitoring of  side-effects, and perhaps improved adherence.',\n",
       "  'chunk_char_count': 1681,\n",
       "  'chunk_word_count': 267,\n",
       "  'chunk_token_count': 420.25},\n",
       " {'page_number': -12,\n",
       "  'sentence_chunk': 'Longer follow-up times are expected to lead to loss to  follow up. A systematic review of the impact of interventions to improve medication adherence in adults  prescribed antihypertensive medications suggested a decrease in adherence with an increase in time  between intervention and follow up (70). The undesirable consequences of shorter follow up are the  burden on patients and the health system. Certainty relating to these effects is very low. The GDG found no evidence related to the question of the optimal follow-up time after the point that  the treated HTN patient achieves stable blood pressure control. Evidence-to-decision considerations Data on what patients consider significant in terms of the length of follow up after initiation of HTN  medications are lacking. Many patients, particularly those aged 65 years or older, or who live alone,  are likely to be reassured by more frequent monitoring of BP, which can identify early signs of clinical  deterioration and provide a sense of security (71). However, younger asymptomatic patients may  have the opposite perspective and find that frequent monitoring interferes with work and family  responsibilities. Telemonitoring may reduce the need for follow up, especially for patients living in  areas remote from health care facilities. However, despite existing evidence on the effectiveness of  telemonitoring for patients with HTN, there is no empirical evidence of its long-term outcomes or  generalizability to patients with various backgrounds and educational levels (72).',\n",
       "  'chunk_char_count': 1546,\n",
       "  'chunk_word_count': 243,\n",
       "  'chunk_token_count': 386.5},\n",
       " {'page_number': -12,\n",
       "  'sentence_chunk': 'Data on costs, resources and cost-effectiveness were unavailable. Frequent follow up is anticipated to  be associated with additional resource requirements, which may be offset by improved adherence, BP  control and improved outcomes that are important to patients. Burden on the health system may be  reduced by involving nonphysician providers in follow up. The WHO GDG considered a one-month follow up after initiation of medications for HTN to be a  reasonable approach, whereas intervals of 3 to 6 months can be applied when patients’ BP is close to  the target and stable. Due to the lack of comparative data, these recommended intervals should be  viewed as suggestions and may be modified, based on feasibility and other contextual factors. Such  intervals were judged to be feasible and acceptable to key stakeholders. The impact of such follow-up  lengths on health equity is unclear.18',\n",
       "  'chunk_char_count': 896,\n",
       "  'chunk_word_count': 148,\n",
       "  'chunk_token_count': 224.0},\n",
       " {'page_number': -11,\n",
       "  'sentence_chunk': '3.8 Administration of treatment by nonphysician professionals 8. RECOMMENDATION ON TREATMENT BY NONPHYSICIAN PROFESSIONALS  WHO suggests that pharmacological treatment of hypertension can be provided by  nonphysician professionals such as pharmacists and nurses, as long as the following  conditions are met: proper training, prescribing authority, specific management protocols  and physician oversight. Conditional recommendation, low-certainty evidence Implementation remarks:   [ Community health care workers (HCWs) may assist in tasks such as education, delivery of  medications, blood pressure (BP) measurement and monitoring through an established  collaborative care model. The scope of hypertension care practised by community HCWs  depends on local regulations and currently varies by country.  [ Telemonitoring and community or home-based self-care are encouraged to enhance the control  of BP as a part of an integrated management system, when deemed appropriate by the treating  medical team and found feasible and affordable by patients.  [ Physician oversight can be done through innovative methods such as telemonitoring or similar  to ensure access to treatment is not delayed. Evidence and rationale PICO question 11 (see Annex 4) addressed BP management by nonphysician health care workers  (HCWs) as well as self-management by patients. The evidence base for this question consisted of  11 systematic reviews (Web Annex A). The available evidence focused on evaluating care models in  which BP control was managed by pharmacists, nurses, dietitians, and community HCWs. The outcome  assessed in these studies were BP level and control.',\n",
       "  'chunk_char_count': 1656,\n",
       "  'chunk_word_count': 250,\n",
       "  'chunk_token_count': 414.0},\n",
       " {'page_number': -11,\n",
       "  'sentence_chunk': 'There was no data on cardiovascular events. Although the certainty of evidence was in general low, the magnitude of effect showed better control  in 91–264 more patients per 1000 (pharmacist studies) and an SBP/DBP reduction of 1–8 mmHg (nurse/ HCW/dietitian studies). No study showed that nonphysician management was inferior to physician  management. A systematic review by Greer et al.,showed that pharmacist-managed care led to better BP control  (relative risk 1.44 or 170 more controlled per 1000) with no obviously reported difference in adherence,  clinical events or quality of life (73). A systematic review by Anand has shown that in LICs and MICs,  task sharing with pharmacists led to reductions of 8 mmHg SBP and 3.74 mmHg DBP. Similar results  were yielded by task sharing with nurses (5.34 mmHg lower), dieticians (4.67 mmHg lower), and  community HCWs (3.67 mmHg lower) (74). Data on undesirable effects (harms) were unavailable, which  may be due to publication bias, or reflect minimal harms. In terms of self-management, a systematic review by Tucker (75) shows that self-monitoring by patients  led to a 3.24 mmHg lower level SBP and 1.5 DBP, both statistically significant, and better BP control,  as long as self-monitoring was remotely managed by a HCW. However, the study limitation was the  inability to adequately blind participants to the intervention.',\n",
       "  'chunk_char_count': 1380,\n",
       "  'chunk_word_count': 226,\n",
       "  'chunk_token_count': 345.0},\n",
       " {'page_number': -11,\n",
       "  'sentence_chunk': 'There was minimal evidence about self- titration on BP medications. The GDG also concluded that since the evidence was from HICs, it may be less applicable to other  settings and that training of nonphysician HCWs varies considerably between countries. Overall the  certainty of evidence was low, with large anticipated desirable effects and a small magnitude of  undesirable effects. RECOMMENDATIONS 19',\n",
       "  'chunk_char_count': 403,\n",
       "  'chunk_word_count': 63,\n",
       "  'chunk_token_count': 100.75},\n",
       " {'page_number': -10,\n",
       "  'sentence_chunk': 'GUIDELINE FOR THE PHARMACOLOGICAL TREATMENT OF HYPERTENSION IN ADULTS Evidence-to-decision considerations There is significant variability in patient and provider perspectives. Overall, society and patients want  to reduce the risk of premature mortality or morbidity. Most of the available quantitative data were  focused on remote monitoring and not specifically on whether patients preferred BP being managed  by physicians vs other providers, which was the primary question. Limited information provided mixed  results, with some patients appreciating some applications of self-care while others were concerned that  being managed by others could harm the patient–doctor relationship, but these comments were related  to use of home-monitoring devices. In some studies in which BP was managed by nonphysicians, there  was good patient satisfaction and high retention, suggesting at least willingness, if not a preference, to  have BP managed by nonphysicians (76, 77). Conversely, in-depth interviews with a sample of patients  in the UK explored nurse and pharmacist prescribing and demonstrated that patients had concerns  about clinical governance, privacy and whether sufficient space was available to provide the service  in community pharmacies. Participants had less concern about nursing management (78). Another  study from Scotland explored patients’ perspectives on pharmacist prescribing and reported high  patient satisfaction, but 65% stated that they would prefer to consult a doctor (79). Presumably, health  inequities are reduced, since task shifting in the public sector increases access to those using public  health vs private health. Increasing access in underserved areas can improve inequities. Regarding costs, Jacob et al. (',\n",
       "  'chunk_char_count': 1754,\n",
       "  'chunk_word_count': 261,\n",
       "  'chunk_token_count': 438.5},\n",
       " {'page_number': -10,\n",
       "  'sentence_chunk': '80) synthesized data from 31 studies (24 from the US) and suggested that  studies that use community team approaches project a cost around USD 200/person/year to implement,  but with cost-savings for prevention of CVD outcomes such that net costs had a median cost of USD  65/person/year, with 10 studies indicating negative or cost-savings overall. Most cost/quality-adjusted  life year (QALY) estimates were between USD 3888 and USD 24 000/QALY, with pharmacist-led  programmes being more cost-effective than nurse-led ones. Only two were >USD 50 000/QALY out of  28 studies. Most of the remaining cost data presented were related to self-monitoring and not to the question of  physician-led vs nonphysician-led care. However, if it is assumed that nonphysician salaries are lower,  then potentially costs will be lower, but that assumes that only limited effort by physicians is involved in  any oversight of nonphysicians. Kulchaitanaroai et al.found similar results with a physician–pharmacist  collaborative system (81). The two available analyses, by Jacob et al.and Kulchaitanaroai et al.,focused on team-based  interventions as opposed to specifically physician vs other provider, and it is not clear if incremental cost- effectiveness ratios fit countries in all economic categories, nor whether the countries’ willingness- to- pay thresholds were analysed.',\n",
       "  'chunk_char_count': 1367,\n",
       "  'chunk_word_count': 210,\n",
       "  'chunk_token_count': 341.75},\n",
       " {'page_number': -10,\n",
       "  'sentence_chunk': 'All values appear to be below USD 50 000/QALY. For the US, the results  were highly cost-effective, with most estimates well under USD 50 000/QALY but it remains unclear  exactly how these may be translated to countries in lower economic categories. Even at USD 10 000/ QALY, however, this would be acceptable for most MICs, though perhaps not for all LICs. However, if  the costs were the same or lower in programmes led by nurses or pharmacists compared to those led by  physicians then cost-saving was likely. The GDG proposed four conditions that must be met for nonphysician-prescribing of antihypertensives. These focused on the prescribers having proper training, prescribing authority in their locale, working  within specific management protocols and having physician oversight. Community HCWs were  suggested as personnel who could assist with tasks such as education, delivery of medications, BP  measurement and monitoring through an established collaborative care model. Telemonitoring supervised by HCWs, and community- or home-based self-care, were considered as tools  to enhance BP control as part of an integrated management system.20',\n",
       "  'chunk_char_count': 1152,\n",
       "  'chunk_word_count': 181,\n",
       "  'chunk_token_count': 288.0},\n",
       " {'page_number': -9,\n",
       "  'sentence_chunk': '4 Special settings 4.1 Hypertension in disaster, humanitarian and emergency settings Hypertension (HTN) is seen in a range of humanitarian crises and disaster settings (natural or  humanmade). This includes, but is not limited to, the wars in Syria and Iraq, the impact of the Great  East Japan Earthquake and Hurricane Katrina, and the living conditions of Palestinian refugees. The  burden of HTN on those populations can be considerable (82). There are very little data on HTN control,  access to care and treatment, and patient understanding of HTN from Africa and Asia (except Japan),  despite protracted refugee situations on these continents. Violent and protracted conflicts are disastrous  to civilian populations and their health care systems, and result in interruptions to treatment and care  (83, 84). Armed conflicts are associated with increased short-term and long-term cardiac morbidity and  mortality and increases in blood pressure (BP) (85). Following exposure to conflict, research in military  populations shows that post-traumatic stress disorder and severe injury are independent risk factors for  the development of HTN (86). The rates of treatment ranged from 53.4% to 98.1% of patients with  HTN in this population (87, 88). There are currently no data regarding target BP or the best antihypertensive agent to treat disaster- related HTN. Opinion-based recommendation is that the target BP control level should be less than  140 mmHg for SBP and less than 90 mmHg for DBP.',\n",
       "  'chunk_char_count': 1500,\n",
       "  'chunk_word_count': 242,\n",
       "  'chunk_token_count': 375.0},\n",
       " {'page_number': -9,\n",
       "  'sentence_chunk': 'According to Kario et al, long-acting CCBs are  preferred because they are metabolically neutral, and best at reducing BP variability, which is an  independent predictor of clinical outcomes, especially stroke. In addition, the BP-lowering effect of  long-acting CCBs is dose-dependent, and the degree of BP reduction that can be anticipated from these  agents is known (89). Despite the challenges of working in humanitarian settings, several agencies have  produced guidelines for the identification and management of HTN. The WHO’s Interagency Emergency  Health Kit has included a supplementary module with antihypertensive medications since 2017, but it  is unclear how widely these are being used (90, 91). According to a personal communication from a  physician who treated HTN in Syrian refugees, the treatment was variable, and dependent on whatever  drug samples were available in the clinic. They had limited choices, including atenolol, lisinopril, and  verapamil. Treatment was tailored to the patient’s history. For example, patients with a history of  coronary artery disease received atenolol and lisinopril, patients with diabetes received lisinopril, and  patients with migraine received verapamil. Assessment of HTN and appropriate resourcing to treat it should be a priority for agencies providing  emergency and longer-term care for patients after or during humanitarian crises to prevent significant  mortality and morbidity. Further studies are needed to accurately estimate prevalence of HTN in crisis- affected populations throughout the world and to evaluate the best treatment approach for this  population.',\n",
       "  'chunk_char_count': 1633,\n",
       "  'chunk_word_count': 249,\n",
       "  'chunk_token_count': 408.25},\n",
       " {'page_number': -9,\n",
       "  'sentence_chunk': 'Humanitarian crises and disaster settings (natural or humanmade) can affect health care and services  in many different ways. A list of potential barriers that can affect the management of individuals with  hypertension is as follows:    [ significant decline of living standards    [ loss/destruction of health care facilities    [ flight of medical personnel causing shortage of medical care providers   [ severe shortage of medicines   [ lack or absence of essential supplies, equipment and materials   [ compromise of the provision of primary and secondary health care   [ interruption of water, food and electricity   [ lack of morbidity and mortality data due to destruction of information systems and data collection   [ high psychological stress burden on both general population and health care personnel. SPECIAL SETTINGS 21',\n",
       "  'chunk_char_count': 834,\n",
       "  'chunk_word_count': 146,\n",
       "  'chunk_token_count': 208.5},\n",
       " {'page_number': -8,\n",
       "  'sentence_chunk': 'GUIDELINE FOR THE PHARMACOLOGICAL TREATMENT OF HYPERTENSION IN ADULTS 4.2 COVID-19 and hypertension Almost all available evidence suggests that hypertension increases the risk of severe COVID-19, defined  as admission to intensive care, clinically defined severity or a combination of these; or mortality. It was  sometimes unclear, however, whether this risk was independent of other risk factors (92). Initial reports  have identified higher rates of HTN among severely ill, hospitalized COVID-19 patients, with overall  HTN rates of 50–56% (93, 94). It had been unclear if this relationship was causal or confounded by age  and other comorbidities associated with HTN, including obesity, diabetes and chronic kidney disease. Concerns regarding use of angiotensin-converting enzyme inhibitors (ACEis) in these patients were  raised due to identification of angiotensin-converting enzyme 2 (ACE2), the monocarboxypeptidase  that inactivates angiotensin II and thereby counters the activation of the classic renin–angiotensin– aldosterone system (RAAS), as the functional receptor for the severe acute respiratory syndrome  coronavirus 2 (SARS-CoV-2) (95, 96). The WHO conducted a rapid review of evidence related to the use  ACEis or ARBs in COVID patients which identified 11 observational studies. No studies were found that  were designed to directly assess whether ACEis or ARBs increase the risk of acquiring COVID-19. After  adjustment for confounders, history of ACEi or ARB use was not found to be associated with increased  severity of COVID-19 illness. There were no studies that addressed the potential benefits and harms of  initiating ACEis or ARBs as treatment for patients with COVID-19 (97). Accordingly, discontinuation of  ACEis or ARBs may yield worse outcomes than continuation of their use in patients with a diagnosis  of COVID-19.',\n",
       "  'chunk_char_count': 1854,\n",
       "  'chunk_word_count': 284,\n",
       "  'chunk_token_count': 463.5},\n",
       " {'page_number': -8,\n",
       "  'sentence_chunk': 'In contrast to the uncertainty about the potential benefit of initiating RAAS blocker use  in patients with COVID-19, there is a clear potential for harm in withdrawing these agents in high-risk  COVID-19 patients with established myocardial injury, HTN or heart failure (96). Most of the world’s  professional societies either recommend or strongly encourage continuing ACEis/ARBs in COVID-19- infected patients (98). Further research that will address key unanswered questions about the role of the  RAAS in the pathogenesis and possible treatment of COVID-19 and other coronavirus-based diseases is  urgently needed. Prospective studies – in particular, ongoing randomized, placebo-controlled trials such  as the Ramipril for the Treatment of COVID-19 (RAMIC) trial (ClinicalTrials.gov number, NCT04366050)  may provide clearer insight regarding the effect of ACEis or ARBs in patients with COVID-19.4.3 Pregnancy and hypertension Hypertension, including chronic HTN, gestational HTN, pre-eclampsia, and eclampsia, is a very common  medical condition in pregnancy (99). Due to the adverse consequences of increased morbidity  and mortality to both the women and fetus, HTN in pregnancy must be diagnosed, treated (when  appropriate), and followed up diligently. It is important to note that up to 10% of pregnancy-related  deaths are attributed to HTN, and its presence in pregnancy leads to long-term adverse cardiovascular  consequences. Unfortunately, hypertensive disorders of pregnancy are markedly increasing (100,  101). For instance, in the United States between 1998 and 2006, hypertensive disorders in pregnancy  increased from 6.7% to 8.3%, chronic HTN in pregnancy increased from 1.1% to 1.7%, and pre- eclampsia/eclampsia from 0.9% to 1.2%. The potential serious consequences of HTN and pregnancy  and the contraindication in pregnancy of some of the commonly prescribed pharmacological  antihypertensive medications discussed below should be discussed with women who are or could  become pregnant.',\n",
       "  'chunk_char_count': 2014,\n",
       "  'chunk_word_count': 301,\n",
       "  'chunk_token_count': 503.5},\n",
       " {'page_number': -8,\n",
       "  'sentence_chunk': 'The normal haemodynamic state of pregnancy is one of systemic vasodilation accompanied by an  increase in cardiac output and decrease in total peripheral resistance. This results in a normal decrease in  BP in the second trimester. HTN in pregnancy is generally diagnosed when BP is ≥140 mmHg and/or ≥90  mmHg on at least two occasions, at least six hours apart. Chronic HTN is defined as a diagnosis of HTN  before 20 weeks gestation, while gestational HTN is defined as a diagnosis of HTN at 20 weeks or later. Pre-eclampsia and eclampsia are pregnancy-specific medical conditions requiring immediate and specific  medical management.22',\n",
       "  'chunk_char_count': 638,\n",
       "  'chunk_word_count': 106,\n",
       "  'chunk_token_count': 159.5},\n",
       " {'page_number': -7,\n",
       "  'sentence_chunk': 'While BP treatment thresholds for HTN in pregnancy continue to change, it is generally recommended  for both chronic and gestational HTN that pharmacologic treatment be initiated when the SBP is  ≥160 mmHg and/or the DBP is ≥105 mmHg. In chronic HTN, frequently the woman has already been  diagnosed with HTN prior to the pregnancy and thus may already be on chronic antihypertensive  pharmacological therapy. In this case, the current regimen may be continued, with the caveat that the  medication regimen may have to be changed to preferred medications, and certain antihypertensive  medications that are contraindicated in pregnancy must be discontinued. The recommended treatment  BP goal/target also has been subject to debate and is changing. For instance, achieving a lower BP target  (DBP of 85 mmHg vs 100 mmHg) has recently been shown to decrease the maternal development  of severe HTN while not increasing maternal or fetal risk. If target organ damage is present, initiating  antihypertensive pharmacological treatment at a DBP of ≥90 mmHg should be considered. As with most, if not all, other medical conditions requiring pharmacological treatment during  pregnancy, the treatment considerations in HTN are no different from those of non-pregnant adults. Thus, since medications are not studied specifically for efficacy and safety in pregnancy, medication  selection is usually based on long-term clinical use and experience. This usually means older medications  that have had a substantial long-term track record of efficacy and safety are to be considered. For  the pharmacological treatment of HTN in pregnancy, preferred medications include methyldopa,  beta-blockers (particularly labetalol), CCBs (particularly nifedipine and, as an alternative, verapamil),  and the direct-acting vasodilators (particularly hydralazine).',\n",
       "  'chunk_char_count': 1843,\n",
       "  'chunk_word_count': 283,\n",
       "  'chunk_token_count': 460.75},\n",
       " {'page_number': -7,\n",
       "  'sentence_chunk': 'There is evidence to suggest that among  these agents, beta-blockers and CCBs appear to be more effective than methyldopa in decreasing the  development of severe HTN later in the pregnancy. The use of thiazide diuretics has been debated,  particularly if the individual is already chronically on a thiazide prior to the pregnancy. In this situation  the thiazide diuretic may be continued during the pregnancy. There are clear contraindications to the use of some antihypertensive medications during pregnancy. These include all the renin–angiotensin system inhibitors, such as the ACEis, the ARBs and, although  not used any more, the direct-acting renin inhibitors, due to direct adverse effects on the fetus, and  the mineralocorticoid receptor antagonist spironolactone due to fetal anti-androgen effects. The use  of the beta-blocker atenolol is also contraindicated due to the observation of intrauterine fetal growth  inhibition (102). In summary, HTN in pregnancy, manifested by the various hypertensive pregnancy disorders, is a very  common medical condition. HTN pregnancy disorders have serious maternal and fetal consequences. There are currently several preferred oral antihypertensive pharmacological agents available to  treat chronic HTN and gestational HTN during pregnancy. In addition, there are antihypertensive  pharmacological agents that are contraindicated in pregnancy.',\n",
       "  'chunk_char_count': 1396,\n",
       "  'chunk_word_count': 207,\n",
       "  'chunk_token_count': 349.0},\n",
       " {'page_number': -7,\n",
       "  'sentence_chunk': 'There is evidence to support the  pharmacological treatment of HTN in pregnancy at given BP thresholds without and with the presence  of end organ damage to decrease the likelihood of the development of severe HTN later in the  pregnancy. Even with the effective lowering of BP during the pregnancy and in the immediate post- partum period, the presence of hypertensive disorders of pregnancy significantly increases long-term CV  risk, including future HTN, coronary disease, and stroke. SPECIAL SETTINGS 23',\n",
       "  'chunk_char_count': 508,\n",
       "  'chunk_word_count': 82,\n",
       "  'chunk_token_count': 127.0},\n",
       " {'page_number': -6,\n",
       "  'sentence_chunk': 'GUIDELINE FOR THE PHARMACOLOGICAL TREATMENT OF HYPERTENSION IN ADULTS 5 Publication, implementation,  evaluation and research gaps 5.1 Publication  This guideline is available to download from the WHO website. Given that an overview of published  systematic reviews was used for the development of the guideline, all reviews are already published and  available online. 5.2 Implementation and dissemination  WHO regional and country offices, through their contacts with ministries of health, will encourage  implementation at country level. WHO will provide technical assistance if substantial country adaptation  is required. The HEARTS technical package, which is currently being implemented in 18 countries  and has significant partner endorsement, membership and engagement, will be the platform used to  implement and disseminate this guideline. The package will be revised to include the implementation  tools from this guideline. Separate implementation aspects are being considered as implementation or  derivative tools for nonphysician treatment and the treatment of hypertension in areas of humanitarian  crises, following publication of the guideline. Implementation support will be extended to countries  through all three levels of WHO.5.3 Evaluation  WHO will monitor uptake and implementation of the guideline in national policies and programmes by  reviewing the number of countries that have adapted or endorsed the guideline nationally. 5.4 Future updating of the guideline  The guideline is expected to be valid for a period of five years.',\n",
       "  'chunk_char_count': 1559,\n",
       "  'chunk_word_count': 235,\n",
       "  'chunk_token_count': 389.75},\n",
       " {'page_number': -6,\n",
       "  'sentence_chunk': 'This period reflects the fact that new  research findings are likely to become available in the meantime but also represents a feasible time  frame, considering the costs, time and other resources that are needed for the updating process. If the  evidence base or user needs change before the five-year mark, consideration will be given to producing  updates sooner.5.5 Research gaps Several research gaps were identified by the GDG according to the theme of the PICOs. Thresholds to determine initiation of therapy and targets to achieve for control   [ More evidence is required regarding treatment of those in the SBP 130–139 range who fall into  one or more of the following subgroups: diabetes, chronic kidney disease, heart failure, 65 years  or older.  [ There is a need for better outcomes data from, for example, trials that include heart failure and  cognitive impairment among outcomes.  [ Clinical significance of adverse events registered in clinical trials needs greater clarity.   [ There is a need to quantify the difference in estimates between blinded, placebo-controlled trials  and unblinded, active control trials using a standard framework.24',\n",
       "  'chunk_char_count': 1164,\n",
       "  'chunk_word_count': 194,\n",
       "  'chunk_token_count': 291.0},\n",
       " {'page_number': -5,\n",
       "  'sentence_chunk': '[ There is a need for periodic analysis of trials in order to capture effects of changes over time in  background epidemiology of CVD, non-BP treatments, competing risks, etc.  [ More evidence is needed in LICs, MICs and other non-North American/European countries.  [ An assessment of the feasibility, resource needs, and costs of intensive treatment in real clinical  practice is needed. The resource commitment required for more intensive treatment in LMICs  needs to be quantified.  [ The opportunity cost of directing resources towards achieving SBP <130 in high-risk individuals  needs to be established.  [ Research is needed on the feasibility, acceptability, and efficacy of intensive treatment, especially  in high-risk populations in LICs and MICs. Laboratory tests to determine initiation of treatment   [ A greater understanding of the essential tests to be performed in all patients to reduce costs and  improve outcomes is required. Role of cardiovascular risk in hypertension treatment   [ An exploration is needed of key operational aspects of the implementation of a risk-based  approach to CVD prevention and BP-lowering pharmacological treatment in primary health care  settings. Monotherapy versus combination therapy   [ A comparison is required of long-term data about hard clinical endpoints between monotherapy  and combination therapy.  [ There is a need for research studies on real-world experiences, designed and statistically powered,  to determine if there is a difference in clinical outcomes, such as reduction in MACE, mortality,  and serious adverse events, between single-pill combinations vs multiple-pill combinations.',\n",
       "  'chunk_char_count': 1656,\n",
       "  'chunk_word_count': 262,\n",
       "  'chunk_token_count': 414.0},\n",
       " {'page_number': -5,\n",
       "  'sentence_chunk': '[ Health economic analyses are needed to quantify cost-effectiveness and budget implications of  implementing incremental initial combination therapy compared with initial monotherapy. Frequency of re-assessment   [ Criteria establishing the clinical definition of stable BP control will be needed to guide the  selection of patients for less frequent follow-up visits.  [ Research is needed for early and accurate identification of patients less likely to achieve BP control  and less likely to follow up as requested by their health care provider.  [ Better evidence is needed on the timing, frequency, and intensity of interventions that improve  treatment adherence. Team-based care for hypertension   [ Evidence is needed that remote monitoring and use of community HCWs/navigators can assist in  the management of BP.  [ Evidence of the feasibility, costs, and effectiveness of community/home-based monitoring of BP is  needed. PUBLICATION, IMPLEMENTATION, EVALUATION AND RESEARCH GAPS 25',\n",
       "  'chunk_char_count': 994,\n",
       "  'chunk_word_count': 154,\n",
       "  'chunk_token_count': 248.5},\n",
       " {'page_number': -4,\n",
       "  'sentence_chunk': 'GUIDELINE FOR THE PHARMACOLOGICAL TREATMENT OF HYPERTENSION IN ADULTS 6 Implementation tools 6.1 Guideline recommendations Graphic summaries of the guideline recommendations are presented below in an algorithmic approach  (Figs 3 and 4). This maps the recommendations to a patient-care pathway. Fig.3 An approach for starting treatment with a single-pill combination  Treat adults with BP ≥140 mmHg or ≥90   (SBP ≥130 mmHg for those with CVD, DM, CKD). Start two-drug combination therapy, preferably in a single-pill combination  (ACE/ARB, dihydropyridine CCB, thiazide-like agents). Treatment targets: <140/90 mmHg  (SBP <130 mmHg for high-risk patients with CVD, DM, CKD). Follow up monthly after initiation or a change in antihypertensive  medications until patient reaches BP target. Follow up every 3–6 months for patients with BP under control. Pharmacological treatment to be initiated under the following circumstances: [  A diagnosis of HTN has already been made. [ Initiation of pharmacological HTN treatment should start no later than four weeks after diagnosis of HTN.',\n",
       "  'chunk_char_count': 1080,\n",
       "  'chunk_word_count': 165,\n",
       "  'chunk_token_count': 270.0},\n",
       " {'page_number': -4,\n",
       "  'sentence_chunk': '[  If BP level is high or there is accompanying evidence of end organ damage, initiation of treatment should  be started without delay. [ Patient should be counselled about starting medication therapy. [ Basic laboratory testing (electrolytes, creatinine, lipogram, glucose, HbA1C, urine dipstick, and ECG) to  occur as long as it does not delay treatment. [  A CV risk assessment can be conducted immediately (as long as it does not delay initiation of treatment)  or at a later visit. [ Consider using diuretics or CCB in patients 65 years or older, or those of African or Afro-Caribbean descent,  beta-blockers (BBs) post MI, ACEis/ARBs in those with DM, heart failure or CKD.26',\n",
       "  'chunk_char_count': 681,\n",
       "  'chunk_word_count': 117,\n",
       "  'chunk_token_count': 170.25},\n",
       " {'page_number': -3,\n",
       "  'sentence_chunk': 'Fig.4  An approach for starting treatment not using a single-pill combination (i.e. with monotherapy or  free combination therapy) Pharmacological treatment to be initiated under the following circumstances: [  A diagnosis of HTN has already been made. [ Initiation of pharmacological HTN treatment should start no later than four weeks after diagnosis of HTN. [  If BP level is high or there is accompanying evidence of end organ damage, initiation of treatment should  be started without delay. [ Patient should be counselled about starting medication therapy. [ Basic laboratory testing (electrolytes, creatinine, lipogram, glucose, HbA1C, urine dipstick, and ECG) to  occur as long as it does not delay treatment. [  A CV risk assessment can be conducted immediately (as long as it does not delay initiation of treatment)  or at a later visit. [ Consider using diuretics or CCB in patients 65 years or older, or those of African or Afro-Caribbean descent,  beta-blockers (BBs) post MI, ACEis/ARBs in those with DM, heart failure or CKD. Treat adults with BP ≥140 mmHg or ≥90   (SBP ≥130 mmHg for those with CVD, DM, CKD). Start with medications from any of the following three classes of pharmacological  antihypertensive medications as an initial treatment:  1) thiazide and thiazide-like agents, 2) ACEi/ARB, and 3) long-acting dihydropyridine CCB.',\n",
       "  'chunk_char_count': 1354,\n",
       "  'chunk_word_count': 224,\n",
       "  'chunk_token_count': 338.5},\n",
       " {'page_number': -3,\n",
       "  'sentence_chunk': 'Treatment targets: <140/90 mmHg  (SBP <130 mmHg for high-risk patients with CVD, DM, CKD). Follow up monthly after initiation or a change in antihypertensive medications  until patient reaches target. Follow up every 3–6 months for patients with BP under control. IMPLEMENTATION TOOLS 27',\n",
       "  'chunk_char_count': 287,\n",
       "  'chunk_word_count': 45,\n",
       "  'chunk_token_count': 71.75},\n",
       " {'page_number': -2,\n",
       "  'sentence_chunk': 'GUIDELINE FOR THE PHARMACOLOGICAL TREATMENT OF HYPERTENSION IN ADULTS 6.2 Drug- and dose-specific protocols Two examples of suggested drug and dose-specific protocols are presented below (Figs 5 and 6). These  should be viewed as examples and other approaches are possible. Algorithm 1: Initiation of treatment with a single-pill combination   [ Beginning treatment with two antihypertensive drugs from different classes is recommended  when baseline BP is ≥20/10 mmHg above goal, and should be considered when baseline BP is  ≥140/90 mmHg.  [ Drugs affecting the renin–angiotensin system (ACEis, ARBs, and aliskiren) have been associated  with serious fetal toxicity, including renal and cardiac abnormalities and death; they are  contraindicated for use during pregnancy. Fig.5 Algorithm 1 Start ARB–CCB at  half-maximal doses  (Example*: Telmisartan 40–  Amlodipine 5 mg**  once a day). Recheck BP in 4–6 weeks;  if BP is at goal, follow up  in 3–6 months. Recheck BP in 4–6 weeks;  if BP is at goal, follow up  in 3–6 months. Recheck BP in 4–6 weeks;  if BP is at goal, follow up  in 3–6 months. Recheck BP in 4–6 weeks;  if BP is at goal, follow up  in 3–6 months.',\n",
       "  'chunk_char_count': 1169,\n",
       "  'chunk_word_count': 207,\n",
       "  'chunk_token_count': 292.25},\n",
       " {'page_number': -2,\n",
       "  'sentence_chunk': 'If  BP is not at goal,  increase ARB–CCB (double  the dose to Telmisartan 80–  Amlodipine 10 mg  once a day). If BP is not at goal,  add a thiazide/thiazide-like  diuretic at half-maximal  dose (hydrochlorothiazide  25 mg or chlorthalidone  12.5 mg once a day). If BP is not at goal, increase  the thiazide/thiazide-like  diuretic (double the dose to  hydrochlorothiazide 50 mg or  chlorthalidone 25 mg  once a day). If  BP is not at goal,  refer to a specialist. NOTE: Monitor potassium and  kidney function when starting or  changing the dose of ACEi/ARB  or thiazide/thiazide-like diuretic, if  testing is readily available and does  not delay treatment. This protocol is contraindicated for women who are or could become pregnant. Neither an ACEI or ARB  should be given to pregnant women. *The medications mentioned serve as examples and can be replaced with any two medications from any of the  three drug classes (ACEis/ARBs, CCBs or thiazide/thiazide-like diuretics). Start two individual pills or, if available,  both in a single-pill combination (fixed-dose combination). **Can be replaced with other individual pills or, if available, other single-pill combinations (fixed-dose  combinations).',\n",
       "  'chunk_char_count': 1204,\n",
       "  'chunk_word_count': 208,\n",
       "  'chunk_token_count': 301.0},\n",
       " {'page_number': -1,\n",
       "  'sentence_chunk': 'Algorithm 2: Initiation of treatment not using a single-pill combination (i.e. with monotherapy  or free combination therapy)   [ A CCB, rather than a thiazide-type diuretic or ACEi/ARB, was selected as first-line medication  if one agent is used, to avoid the need for electrolyte measurements or to alleviate concerns  regarding potential change in GFR.  [ Drugs affecting the renin-angiotensin-aldosterone system (ACEis, ARBs, and aliskiren) have been  associated with serious fetal toxicity, including renal and cardiac abnormalities and death; they  are contraindicated for use during pregnancy. Fig.6 Algorithm 2 If BP is not at goal, increase  the ARB (double the dose to  Telmisartan  80 mg once a day). Recheck BP in 4–6  weeks; if BP is at  goal, follow up in  3–6 months. If BP is not at goal,  add an ARB at half maximal  dose (for example  Telmisartan  40 mg once a day). Recheck BP in 4–6  weeks; if BP is at  goal, follow up in  3–6 months. If BP is not at goal,  increase the CCB (double the  dose to Amlodipine 10 mg  once a day). Recheck BP in 4–6  weeks; if BP is at  goal, follow up in  3–6 months. Start a CCB at half maximal  dose  (Amlodipine 5 mg*  once a day).',\n",
       "  'chunk_char_count': 1185,\n",
       "  'chunk_word_count': 234,\n",
       "  'chunk_token_count': 296.25},\n",
       " {'page_number': -1,\n",
       "  'sentence_chunk': 'Recheck BP in 4–6  weeks; if BP is at  goal, follow up in  3–6 months. Recheck BP in 4–6  weeks; if BP is at  goal, follow up in  3–6 months. If BP is not at goal,  add a thiazide/thiazide-like  diuretic at half maximal dose  (hydrochlorothiazide 25 mg  or chlorthalidone 12.5 mg  once a day). If BP is not at goal, increase  the thiazide/thiazide-like  diuretic (double the dose to  hydrochlorothiazide 50 mg or  chlorthalidone 25 mg  once a day). If  BP is not at goal,  refer to a specialist. NOTE: Monitor potassium and kidney function  when starting or changing dose of ACEi/ARB or  thiazide/thiazide-like diuretic, if testing is readily  available and does not delay treatment. This protocol is contraindicated for women  who are or could become pregnant. Neither  an ACEI or ARB should be given to pregnant  women. *Can be replaced with a thiazide/thiazide-like  diuretic or an ACEi or ARB. An ACEi or ARB  is preferred for patients with proteinuria.',\n",
       "  'chunk_char_count': 957,\n",
       "  'chunk_word_count': 185,\n",
       "  'chunk_token_count': 239.25},\n",
       " {'page_number': 0,\n",
       "  'sentence_chunk': 'GUIDELINE FOR THE PHARMACOLOGICAL TREATMENT OF HYPERTENSION IN ADULTS References (1)  Cardiovascular diseases (CVDs). Key facts.17 May 2017 [website] (https://www.who.int/news- room/fact-sheets/detail/cardiovascular-diseases-(cvds), accessed 31 March 2021). (2)  Hypertension. Key facts.13 September 2019 [website] (https://www.who.int/news-room/fact- sheets/detail/hypertension, accessed 31 March 2021). (3)  Prevention of cardiovascular disease: guidelines for assessment and management of total  cardiovascular risk. Geneva: World Health Organization; 2007. (4)  Hultcrantz M, Rind D, Akl EA, Treweek S, Mustafa RA, Iorio A, et al. The GRADE Working Group  clarifies the construct of certainty of evidence.',\n",
       "  'chunk_char_count': 709,\n",
       "  'chunk_word_count': 89,\n",
       "  'chunk_token_count': 177.25},\n",
       " {'page_number': 0,\n",
       "  'sentence_chunk': 'J Clin Epidemiol.2017;87:4-13.doi: 10.1016/j. jclinepi.2017.05.006. (5)  Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J. GRADE guidelines:  3. Rating the quality of evidence. J Clin Epidemiol.2011;64(4):401-406.doi: 10.1016/j. jclinepi.2010.07.015. (6)  Shahaj O, Denneny D, Schwappach A, Pearce G, Epiphaniou E, Parke H, et al. Supporting  self-management for people with hypertension: a meta-review of quantitative and qualitative  systematic reviews.',\n",
       "  'chunk_char_count': 470,\n",
       "  'chunk_word_count': 65,\n",
       "  'chunk_token_count': 117.5},\n",
       " {'page_number': 0,\n",
       "  'sentence_chunk': 'J Hypertens.2019;37(2):264-279.doi: 10.1097/HJH.0000000000001867. (7)  Meiqari L, Nguyen T-P-L, Essink D, Zweekhorst M, Wright P, Scheele F. Access to hypertension care  and services in primary health-care settings in Vietnam: a systematic narrative review of existing  literature. Glob Health Action.2019;12(1):1-11.doi: 10.1080/16549716.2019.1610253. (8)  Kostova D, Spencer G, Mora AE, Cobb LAK, Husain MJ, Datta BK, et al. The cost effectiveness  of hypertension management in low-income and middle-income countries: a review. BMJ Public  Global Health.',\n",
       "  'chunk_char_count': 557,\n",
       "  'chunk_word_count': 77,\n",
       "  'chunk_token_count': 139.25},\n",
       " {'page_number': 0,\n",
       "  'sentence_chunk': '2020;e002213.doi: 10.1136/bmjgh-2019-002213. (9)  Murray CJ, Lauer JA, Hutubessy RC, Niessen L, Tomijima N, Rodgers A, et al. Effectiveness and  costs of interventions to lower systolic blood pressure and cholesterol: a global and regional  analysis on reduction of cardiovascular-disease risk. Lancet.2003 Mar 1;361(9359):717-25.doi:  10.1016/S0140-6736(03)12655-4. Erratum in: Lancet.2005 Jul 16-22;366(9481):204. PMID:  12620735. (',\n",
       "  'chunk_char_count': 434,\n",
       "  'chunk_word_count': 56,\n",
       "  'chunk_token_count': 108.5},\n",
       " {'page_number': 0,\n",
       "  'sentence_chunk': '10)  Constanti M, Floyd CN, Glover M, Boffa R. Wierzbicki AS, McManus RJ. Cost-effectiveness of  initiating pharmacological treatment in stage one hypertension based on 10-year cardiovascular  disease risk. Hypertension.2021;77:682–691.doi: 10.1161/HYPERTENSIONAHA.120.14913. (11)  Moran AE, Odden MC, Thanataveerat A, Tzong KY, Rasmussen PW, Guzman D. Cost- effectiveness of hypertension therapy according to 2014 guidelines. NEJM.2015;372(5):447-55. doi: 10.1056/NEJMsa1406751. (12)  Rosendaal TA, Hendriks ME, Verhagen MD, Bolarinwa OA, Sanya EO, Kolo PM, et al.',\n",
       "  'chunk_char_count': 565,\n",
       "  'chunk_word_count': 75,\n",
       "  'chunk_token_count': 141.25},\n",
       " {'page_number': 0,\n",
       "  'sentence_chunk': 'Correction: costs and cost-effectiveness of hypertension screening and treatment in adults with  hypertension in rural Nigeria in the context of a health insurance program. PLoS ONE.2016 Jun  27;11(9):e0162421.doi: 10.1371/journal.pone.0162421. (13)  Rubinstein A, Colantonio L, Bardach A, Caporale J, Martí SG, Kopitowski K, et al. Estimation of  the burden of cardiovascular disease attributable to modifiable risk factors and cost-effectiveness  analysis of preventative interventions to reduce this burden in Argentina. BMC Public Health. 2010;10:627.doi: 10.1186/1471-2458-10-627. (14)  Richman IB, Fairley M, Jørgensen ME, Schuler A, Owens DK, Goldhaber-Fiebert JD.',\n",
       "  'chunk_char_count': 671,\n",
       "  'chunk_word_count': 92,\n",
       "  'chunk_token_count': 167.75},\n",
       " {'page_number': 0,\n",
       "  'sentence_chunk': 'Cost- effectiveness of intensive blood pressure management. JAMA Cardiol.2016;1(8):872-879.doi:  10.1001/jamacardio.2016.3517.30',\n",
       "  'chunk_char_count': 128,\n",
       "  'chunk_word_count': 11,\n",
       "  'chunk_token_count': 32.0},\n",
       " {'page_number': 1,\n",
       "  'sentence_chunk': '(15)  Bress AP, Bellows BK, King JB, Hess R, Beddhu S, Zhang Z. Cost-effectiveness of intensive versus  standard blood-pressure control. NEJM.2017;377(8):745-755.doi: 10.1056/NEJMsa1616035. (16)  Odden MC, Moran AE, Coxson PG, Peralta CA, Goldman L, Bibbins-Domingo K. Gait speed as a  guide for BP targets in older adults: a modeling study. J Am Geriatr Soc.2016;64(5):1015-23. (17)  Federal Reserve Bank economic data [online database] (https://fred.stlouisfed.org/series/ NYGDPPCAPCDLMC). Cited in Kostova et al.,2020. (',\n",
       "  'chunk_char_count': 523,\n",
       "  'chunk_word_count': 74,\n",
       "  'chunk_token_count': 130.75},\n",
       " {'page_number': 1,\n",
       "  'sentence_chunk': '18)  Pedrosa RP, Drager LF, Gonzaga CC, Sousa MG, de Paula LK, Amaro ACS, et al. Obstructive  sleep apnea: the most common secondary cause of hypertension associated with resistant  hypertension. Hypertension.2011;58(5):811-7.doi: 10.1161/hypertensionaha.111.179788. (19)  Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: when, who, and how to  screen?Eur Heart J. 2013;35(19):1245-54.doi: 10.1093/eurheartj/eht534. (20)  Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al.',\n",
       "  'chunk_char_count': 523,\n",
       "  'chunk_word_count': 73,\n",
       "  'chunk_token_count': 130.75},\n",
       " {'page_number': 1,\n",
       "  'sentence_chunk': 'Heart disease  and stroke statistics – 2020 update: a report from the American Heart Association. Circulation. 2020;141(9):e139-e596.doi: 10.1161/CIR.0000000000000757. (21)  Park C, Fang J, Hawkins NA, Wang G. Comorbidity status and annual total medical  expenditures in US hypertensive adults. Am J Prev Med.2017;53(6s2):S172-s81.doi: 10.1016/j. amepre.2017.07.014. (22)  Kirkland EB, Heincelman M, Bishu KG, Schumann SO, Schreiner A, Axon RN, et al. Trends in  healthcare expenditures among US adults with hypertension: national estimates, 2003-2014.',\n",
       "  'chunk_char_count': 552,\n",
       "  'chunk_word_count': 76,\n",
       "  'chunk_token_count': 138.0},\n",
       " {'page_number': 1,\n",
       "  'sentence_chunk': 'J  Am Heart Assoc.2018;7(11):e008731.doi: 10.1161/JAHA.118.008731. (23)  Moser M. The cost of treating hypertension can we keep it under control without compromising  the level of care?Am J Hypertens.1998;11:120S–127S. doi: 10.1016/s0895-7061(98)00106-x. (24)  Karmali KN, Lloyd-Jones DM, van der Leeuw J, Goff Jr DC, Yusuf S, Zanchetti A, et al. Blood  pressure-lowering treatment strategies based on cardiovascular risk versus BP: a meta- analysis of individual participant data. PLoS Med.2018;15(3)e1002538.doi: 10.1371/journal.',\n",
       "  'chunk_char_count': 531,\n",
       "  'chunk_word_count': 72,\n",
       "  'chunk_token_count': 132.75},\n",
       " {'page_number': 1,\n",
       "  'sentence_chunk': 'pmed.1002538. (25)  Odutayo A, Gill P, Shepherd S, Akingbade A, Hopewell S, Tennankore K, et al. Income disparities  in absolute cardiovascular risk and cardiovascular risk factors in the United States, 1999- 2014. JAMA Cardiol.2017;2(7):782-790.doi:10.1001/jamacardio.2017.1658. (26)  Gaziano TA, Steyn K, Cohen DJ, Weinstein MC, Opie LH. Cost-effectiveness analysis of  hypertension guidelines in South Africa: absolute risk versus blood pressure level. Circulation. 2005;112(23):3569-76).',\n",
       "  'chunk_char_count': 491,\n",
       "  'chunk_word_count': 65,\n",
       "  'chunk_token_count': 122.75},\n",
       " {'page_number': 1,\n",
       "  'sentence_chunk': 'doi: 10.1161/CIRCULATIONAHA.105.535922. (27)  Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure  lowering for prevention of cardiovascular disease and death: a systematic review and meta- analysis. Lancet.2016;387(10022):957-967.doi: 10.1016/S0140-6736(15)01225-8. (28)  Seeley A, Prynn J, Perera R, Street R, Davis D, Etyang AO. Pharmacotherapy for hypertension in  sub-Saharan Africa: a systematic review and network meta-analysis. BMC Med.2020;18(1):75.',\n",
       "  'chunk_char_count': 496,\n",
       "  'chunk_word_count': 66,\n",
       "  'chunk_token_count': 124.0},\n",
       " {'page_number': 1,\n",
       "  'sentence_chunk': 'doi: 10.1186/s12916-020-01530-z.  (29)  Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative  Research Group. Diuretic versus alpha-blocker as first-step antihypertensive therapy. Hypertension.2003;42:239-246.doi: 10.1161/01. HYP.0000086521.95630.5A. (30)  Julius S, Kjeldsen SE, Brunner H, Hansson L, Platt F, Ekman S, et al. VALUE trial: long-term  blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am J  Hypertens.2003;16(7):544-8.doi: 10.1016/s0895-7061(03)00904-x. REFERENCES 31',\n",
       "  'chunk_char_count': 559,\n",
       "  'chunk_word_count': 67,\n",
       "  'chunk_token_count': 139.75},\n",
       " {'page_number': 2,\n",
       "  'sentence_chunk': 'GUIDELINE FOR THE PHARMACOLOGICAL TREATMENT OF HYPERTENSION IN ADULTS (31)  Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, et al.;CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease  and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292(18):2217-25.doi: 10.1001/jama.292.18.2217. (32)  Wright JT, Dunn JK, Cutler JA, Davis BR, Cushman WC, Ford CE et al; for the ALLHAT  Collaborative Research Group. Outcomes in hypertensive black and nonblack patients treated  with chlorthalidone, amlodipine, and lisinopril. JAMA.2005;293(13):1595-1608.',\n",
       "  'chunk_char_count': 655,\n",
       "  'chunk_word_count': 91,\n",
       "  'chunk_token_count': 163.75},\n",
       " {'page_number': 2,\n",
       "  'sentence_chunk': 'doi:10.1001/ jama.293.13.1595. (33)  Morgan TO, Anderson AI, MacInnis RJ. ACE inhibitors, beta-blockers, calcium blockers, and  diuretics for the control of systolic hypertension. Am J Hypertens, 2001;14(3): 241–247.doi:  10.1016/S0895-7061(00)01266-8. (34)  Sareli P, Radevski IV, Valtchanova ZP, Libhaber E, Candy GP, Den Hond E, et al. Efficacy of different  drug classes used to initiate antihypertensive treatment in black subjects: results of a randomized  trial in Johannesburg, South Africa. Arch Intern Med.2001;161(7):965.doi: 10.1001/ archinte.161.7.965. (',\n",
       "  'chunk_char_count': 567,\n",
       "  'chunk_word_count': 78,\n",
       "  'chunk_token_count': 141.75},\n",
       " {'page_number': 2,\n",
       "  'sentence_chunk': '35)  Aarabi M. Skinner J, Price CE, Jackson, PR. Patients’ acceptance of antihypertensive therapy  to prevent cardiovascular disease: a comparison between South Asians and Caucasians in  the United Kingdom. Eur J Cardiovasc Prev Rehabil.2008 Feb;15(1):59-66.doi: 10.1097/ HJR.0b013e3282f07973. (36)  Fragasso G, Maranta F, Montanaro C, Salerno A, Torlasco C, Margonato A. Pathophysiologic  therapeutic targets in hypertension: a cardiological point of view. Expert Opin Ther Targets. 2012;16(2):179-193.doi: 10.1517/14728222.2012.655724. (37)  Nugent R, Brower E, Cravioto A, Koehlmoos T. A cost-benefit analysis of a National Hypertension  Treatment Program in Bangladesh.',\n",
       "  'chunk_char_count': 673,\n",
       "  'chunk_word_count': 93,\n",
       "  'chunk_token_count': 168.25},\n",
       " {'page_number': 2,\n",
       "  'sentence_chunk': 'Prev Med.2017 Dec;105S:S56-S61.doi: 10.1016/j. ypmed.2017.08.014. (38)  Gad M, Lord J, Chalkidou K, Asare B, Lutterodt MG, Ruiz F. Supporting the development of  evidence-informed policy options: an economic evaluation of hypertension management in  Ghana. Value Health.2020;23(2):171-179.doi: 10.1016/j.jval.2019.09.2749. (39)  Ekwunife OI, Okafor CE, Ezenduka CC, Udeogaranya PO. Cost-utility analysis of antihypertensive  medications in Nigeria: a decision analysis. Cost Eff Resour Alloc.',\n",
       "  'chunk_char_count': 492,\n",
       "  'chunk_word_count': 64,\n",
       "  'chunk_token_count': 123.0},\n",
       " {'page_number': 2,\n",
       "  'sentence_chunk': '2013;11(1):2.doi:  10.1186/1478-7547-11-2. (40)  Park C, Wang G, Durthaler JM, Fang J. Cost-effectiveness analyses of antihypertensive  medicines: a systematic review. Am J Prev Med.2017;53(6S2):S131-S142.doi: 10.1016/j. amepre.2017.06.020. (41)  Rea F, Corrao G, Merlino L, Mancia G. Initial antihypertensive treatment strategies and therapeutic  inertia. Hypertension.2018;72:846–853.doi: 10.1161/HYPERTENSIONAHA.118.11308. (',\n",
       "  'chunk_char_count': 427,\n",
       "  'chunk_word_count': 49,\n",
       "  'chunk_token_count': 106.75},\n",
       " {'page_number': 2,\n",
       "  'sentence_chunk': '42)  Sherrill B, Halpern M, Khan S, Zhang J, Panjabi S. Single-pill vs free-equivalent combination  therapies for hypertension: a meta-analysis of health care costs and adherence. J Clin Hypertens. 2011;13(12):898-909.doi: 10.1111/j.1751-7176.2011.00550.x. (43)  Krousel-Wood M, Thomas S, Muntner P, Morisky D. Medication adherence: a key factor in  achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin  Cardiol.2004;19(4):357-362.doi: 10.1097/01.hco.0000126978.03828.9e. (44)  Fujikawa K, Hasebe N, Kikuchi K; NICE-Combi Study Group. Cost-effectiveness analysis of  hypertension treatment: controlled release nifedipine and candesartan low-dose combination  therapy in patients with essential hypertension – the Nifedipine and Candesartan Combination  (NICE-Combi) Study.',\n",
       "  'chunk_char_count': 815,\n",
       "  'chunk_word_count': 106,\n",
       "  'chunk_token_count': 203.75},\n",
       " {'page_number': 3,\n",
       "  'sentence_chunk': '(45)  Deshmukh KBS, Qian J, Garza K, Wright BM, Zeng P, Ganduglia Cazaban CM, et al. Health  care costs associated with addition, titration, and switching antihypertensive medications after  first-line treatment: results from a commercially insured sample. J Manag Care Spec Pharm. 2017;23(6):691-699.doi: 10.18553/jmcp.2017.23.6.691. (46)  Ren M, Xuan D, Lu Y, Fu Y, Xuan J. Economic evaluation of olmesartan/amlodipine fixed-dose  combination for hypertension treatment in China. J Med Econ.2020;23(4):394-400.doi:  10.1080/13696998.2019.1699799. (47)  Chrysant SG.',\n",
       "  'chunk_char_count': 567,\n",
       "  'chunk_word_count': 79,\n",
       "  'chunk_token_count': 141.75},\n",
       " {'page_number': 3,\n",
       "  'sentence_chunk': 'Using fixed-dose combination therapies to achieve blood pressure goals. Clin Drug  Invest.2008;28(11):713-734.doi: 10.2165/00044011-200828110-00005. (48)  Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of  hypertension prevalence and control: a systematic analysis of population-based studies from 90  countries. Circulation.2016;134:441-450.doi: 10.1161/CIRCULATIONAHA.115.018912. (49)  Salam A, Huffman M, Kanukula R, Prasad EH, Sharma A, Heller D, et al.',\n",
       "  'chunk_char_count': 499,\n",
       "  'chunk_word_count': 66,\n",
       "  'chunk_token_count': 124.75},\n",
       " {'page_number': 3,\n",
       "  'sentence_chunk': 'Two-drug fixed-dose  combinations of blood-pressure lowering drugs as WHO essential medicines: An overview of  efficacy, safety, and cost. J Clin Hypertens.2020;22:1769-1779.doi: 10.1111/jch.14009. (50)  Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, et al. Prevalence, awareness,  treatment, and control of hypertension in rural and urban communities in high-, middle-, and  low-income countries. JAMA.2013;310: 959-968.doi: 10.1001/jama.2013.184182. (51)  Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, et al.',\n",
       "  'chunk_char_count': 545,\n",
       "  'chunk_word_count': 80,\n",
       "  'chunk_token_count': 136.25},\n",
       " {'page_number': 3,\n",
       "  'sentence_chunk': 'Seventh report of  the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood  Pressure. Hypertension.2003;42: 1206-1252.doi: 10.1161/01. HYP.0000107251.49515.c2. (52)  Kishore SP, Salam A, Rodgers A, Jaffe MG, Frieden T. Fixed-dose combinations for hypertension. Lancet.2019;392(10150):819-820.doi: 10.1016/S0140-6736(18)31814-2. (53)  DiPette DJ, Skeete J, Ridley, E, Campbell, NRC, Lopez-Jaramillo P, Kishore SP, et al. Fixed-dose  combination pharmacologic therapy to improve hypertension control worldwide: Clinical  perspective and policy implications.',\n",
       "  'chunk_char_count': 594,\n",
       "  'chunk_word_count': 73,\n",
       "  'chunk_token_count': 148.5},\n",
       " {'page_number': 3,\n",
       "  'sentence_chunk': 'J Clin Hypertens.2019;21(1):4-15.doi: 10.1111/jch.13426. (54)  Marinier K, Macouillard P, de Champvalins M, Deltour N, Poulter N, Mancia G, et al. Effectiveness  of two-drug therapy versus monotherapy as initial regimen in hypertension: a propensity score- matched cohort study in the UK Clinical Practice Research Datalink. Pharmacoepidemiol Drug Saf. 2019;28(12): 1572-1582.doi: 10.1002/pds.4884. (55)  Negi S, Neupane D, Sahoo SW, Mahajan T, Swaroop K, Moran AE, et al. Prices of combination  medicines and single-molecule anti-hypertensive medicines in India’s private health care sector.',\n",
       "  'chunk_char_count': 592,\n",
       "  'chunk_word_count': 83,\n",
       "  'chunk_token_count': 148.0},\n",
       " {'page_number': 3,\n",
       "  'sentence_chunk': 'J  Clin Hypertens.2021;23(4):738-743.doi: 10.1111/jch.14143. (56)  Angeli F, Reboldi G, Mazzotta G, Garofoli M, Ramundo E, Poltonieri C, et al. Fixed-dose  combination therapy in hypertension: cons. High Blood Press Cardiovasc Prev.2012;19(2):51-54. doi: 10.1007/BF03262453. (57)  Jaffe MG Lee GA, Young JD, Sidney S, Go AS. Improved blood pressure control associated with a  large-scale hypertension program.',\n",
       "  'chunk_char_count': 409,\n",
       "  'chunk_word_count': 58,\n",
       "  'chunk_token_count': 102.25},\n",
       " {'page_number': 3,\n",
       "  'sentence_chunk': 'JAMA.2013;310(7):699-705.doi: 10.1002/pds.4884. (58)  Sprint Research Group. Randomized trial of intensive versus standard blood-pressure control. N  Engl J Med.2015;373:2103-2116.doi: 10.1056/NEJMoa1511939. (59)  Murad MH, Larrea-Mantilla L, Haddad A, Spencer-Bonilla G, Serrano V, Rodriguez-Gutierrez R, et  al. Antihypertensive agents in older adults: a systematic review and meta-analysis of randomized  clinical trials.',\n",
       "  'chunk_char_count': 424,\n",
       "  'chunk_word_count': 53,\n",
       "  'chunk_token_count': 106.0},\n",
       " {'page_number': 4,\n",
       "  'sentence_chunk': 'GUIDELINE FOR THE PHARMACOLOGICAL TREATMENT OF HYPERTENSION IN ADULTS (60)  Reboussin DM, Allen NB, Griswold ME, Guallar E, Hong Y, Lackland DT, et al. Systematic review  for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the  prevention, detection, evaluation, and management of high blood pressure in adults: a report of  the American College of Cardiology/American Heart Association Task Force on Clinical Practice  Guidelines. Circulation.2018;138(17):e595-e616.doi: 10.1161/CIR.0000000000000601. (61)  ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N  Engl J Med 2010;362:1575-1585.doi: 10.1056/NEJMoa1001286. (62)  SPS3 Study Group, Benavente OR, Coffey CS, Conwit R, Hart RG, McClure LA, Pearce LA.',\n",
       "  'chunk_char_count': 776,\n",
       "  'chunk_word_count': 106,\n",
       "  'chunk_token_count': 194.0},\n",
       " {'page_number': 4,\n",
       "  'sentence_chunk': 'Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet. 2013;382(9891):507-15.doi: 10.1016/S0140-6736(13)60852-1. (63)  Bangalore S, Toklu B, Gianos E, Schwartzbard A, Weintraub H, Ogedegbe G, et al. Optimal  systolic BP target after SPRINT: insights from a network meta-analysis of randomized trials. Am J  Med.2017;130(6):707-719.e708.doi: 10.1016/j.amjmed.2017.01.004. (64)  Bundy JD, Li C, Stuchlik P, Bu X, Kelly TN, Mills KT, et al.',\n",
       "  'chunk_char_count': 480,\n",
       "  'chunk_word_count': 67,\n",
       "  'chunk_token_count': 120.0},\n",
       " {'page_number': 4,\n",
       "  'sentence_chunk': 'Systolic BP reduction and risk of  cardiovascular disease and mortality: a systematic review and network meta-analysis. JAMA  Cardiology.2017;2(7):775-781.doi: 10.1001/jamacardio.2017.1421. (65)  Howard K, White S, Salkeld G, McDonald S, Craig J, Chadban S, et al. Cost-effectiveness of  screening and optimal management for diabetes, hypertension, and chronic kidney disease: a  modeled analysis. Value Health.2010;13(2):196-208.doi: 10.1111/j.1524-4733.2009.00668.x. (66)  Birtwhistle RV, Godwin MS, Delva MD, Casson RI, Lam M, MacDonald SE, et al.',\n",
       "  'chunk_char_count': 550,\n",
       "  'chunk_word_count': 74,\n",
       "  'chunk_token_count': 137.5},\n",
       " {'page_number': 4,\n",
       "  'sentence_chunk': 'Randomised  equivalence trial comparing three month and six month follow up of patients with hypertension  by family practitioners. BMJ.2004;328(7433):204.doi: 10.1136/bmj.37967.374063. EE. (67)  Xu W, Goldberg SI, Shubina M, Turchin A. Optimal systolic BP target, time to intensification, and  time to follow-up in treatment of hypertension: population based retrospective cohort study. BMJ.2015;350:h158.doi: 10.1136/bmj.h158. (68)  Ambrosius WT, Sink KM, Foy CG, Berlowitz DR, Cheung AK, Cushman WC, et al. The design  and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood  pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).',\n",
       "  'chunk_char_count': 690,\n",
       "  'chunk_word_count': 99,\n",
       "  'chunk_token_count': 172.5},\n",
       " {'page_number': 4,\n",
       "  'sentence_chunk': 'Clinical Trials.2014;11(5):532- 546.doi: 10.1177/1740774514537404. (69)  Cushman WC, Grimm Jr RH, Cutler JA, Gregory WE, Capes S, Corson MA, et al. Rationale  and design for the blood pressure intervention of the Action to Control Cardiovascular  Risk in Diabetes (ACCORD) trial. Am J Cardiol.2007;99(12A):44i-55i.doi: 10.1016/j. amjcard.2007.03.005. (70)  Gwadry-Sridhar FH, Manias E, Lal L, Salas M, Hughes DA, Ratzki-Leewing A, et al. Impact of  interventions on medication adherence and blood pressure control in patients with essential  hypertension: a systematic review by the ISPOR medication adherence and persistence special  interest group.',\n",
       "  'chunk_char_count': 650,\n",
       "  'chunk_word_count': 94,\n",
       "  'chunk_token_count': 162.5},\n",
       " {'page_number': 4,\n",
       "  'sentence_chunk': 'Value Health.2013;16(5):863-871.doi: 10.1016/j.jval.2013.03.1631. (71)  Walker RC, Tong A, Howard K, Palmer SC. Patient expectations and experiences of remote  monitoring for chronic diseases: Systematic review and thematic synthesis of qualitative studies. Int J Med Inform.2019;124:78-85.doi: 10.1016/j.ijmedinf.2019.01.013. (72)  Jaana M, Pare G, Sicotte C. Hypertension home telemonitoring: current evidence and  recommendations for future studies. Dis Manage Health Outcomes.',\n",
       "  'chunk_char_count': 480,\n",
       "  'chunk_word_count': 60,\n",
       "  'chunk_token_count': 120.0},\n",
       " {'page_number': 4,\n",
       "  'sentence_chunk': '2007;15(1):19-31.doi:  10.2165/00115677-200715010-00004. (73)  Greer N, Bolduc J, Geurkink E, Koeller E, Rector T, Olson K, et al. Pharmacist-led chronic disease  management: a systematic review of effectiveness and harms compared with usual care. Ann  Intern Med.2016;165(1):30-40.doi: 10.7326/M15-3058. 34',\n",
       "  'chunk_char_count': 307,\n",
       "  'chunk_word_count': 41,\n",
       "  'chunk_token_count': 76.75},\n",
       " {'page_number': 5,\n",
       "  'sentence_chunk': '(74)  Anand TN, Joseph LM, Geetha AV, Prabhakaran D, Jeemon P. Task sharing with non-physician  health-care workers for management of blood pressure in low-income and middle-income  countries: a systematic review and meta-analysis. Lancet Glob Health.2019;7(6):e761-e771.doi:  10.1016/S2214-109X(19)30077-4. (75)  Tucker P, Sheppard JP, Stevens R, Bosworth HB, Bove A, Bray EP, et al. Self-monitoring of blood  pressure in hypertension: a systematic review and individual patient data meta-analysis. PLOS  Med.2017;14(9):e1002389.doi: 10.1371/journal.pmed.1002389. (76)  Fisher NDL, Fera LE, Dunning JR, Desai S, Matta L, Liquori V, et al.',\n",
       "  'chunk_char_count': 639,\n",
       "  'chunk_word_count': 91,\n",
       "  'chunk_token_count': 159.75},\n",
       " {'page_number': 5,\n",
       "  'sentence_chunk': 'Development of an entirely  remote, non-physician led hypertension management program. Clin Cardiol.2019;42(2):285- 291.doi: 10.1002/clc.23141. (77)  Bhanbhro S, Drennan VM, Grant R, Harris R. Assessing the contribution of prescribing in primary  care by nurses and professionals allied to medicine: a systematic review of literature. BMC Health  Serv Res.2011;11:330.doi: 10.1186/1472-6963-11-330. (78)  Hobson RJ, Scott J, Sutton J. Pharmacists and nurses as independent prescribers: exploring the  patient’s perspective. Fam Pract.',\n",
       "  'chunk_char_count': 534,\n",
       "  'chunk_word_count': 73,\n",
       "  'chunk_token_count': 133.5},\n",
       " {'page_number': 5,\n",
       "  'sentence_chunk': '2010;27(1):110–120.doi: 10.1093/fampra/cmp070. (79)  Stewart DC, George J, Bond CM, Cunningham ITS, Diack HL, McCaig DJ. Exploring patients’  perspectives of pharmacist supplementary prescribing in Scotland. Pharm World Sci. 2008;30(6):892–897.doi: 10.1007/s11096-008-9248-x. (80)  Jacob V, Chattopadhyay SK, Thota AB, Proia KK, Njie G, Hopkins DP, et al. Economics of  team-based care in controlling BP: a community guide systematic review. Am J Prev Med. 2015;49(5):772-783.',\n",
       "  'chunk_char_count': 476,\n",
       "  'chunk_word_count': 65,\n",
       "  'chunk_token_count': 119.0},\n",
       " {'page_number': 5,\n",
       "  'sentence_chunk': 'doi: 10.1016/j.amepre.2015.04.003. (81)  Kulchaitanaroaj P, Brooks JM, Chaiyakunapruk N, Goedken AM, Chrischilles EA, Carter  BL. Cost-utility analysis of physician-pharmacist collaborative intervention for treating  hypertension compared with usual care. J Hypertens.2017;35(1):178-187.doi: 10.1097/ HJH.0000000000001126. (82)  Keasley J, Oyebode O, Shantikumar S, Proto W, McGranahan M, Sabouni A, Kidy F. A systematic  review of the burden of hypertension, access to services and patient views of hypertension  in humanitarian crisis settings. BMJ Glob Health.2020;5(11): e002440.doi: 10.1136/ bmjgh-2020-002440.',\n",
       "  'chunk_char_count': 615,\n",
       "  'chunk_word_count': 79,\n",
       "  'chunk_token_count': 153.75},\n",
       " {'page_number': 5,\n",
       "  'sentence_chunk': '(83)  Sekkarie M, Murad L, Al-Makki A, Al-Saghir F, Rifai O, Isreb M. End-stage kidney disease in areas  of armed conflicts: challenges and solutions. Semin Nephrol.2020;40(4):354-362.doi: 10.1016/j. semnephrol.2020.06.003. (84)  Al-Makki A, Rifai AO, Murad L, Zanabli AR, Kayal A, Soudan K, et al. The Syrian National Kidney  Foundation: response for the need of kidney patients during the crisis. Avicenna J Med.2014  Jul;4(3):54-7.doi: 10.4103/2231-0770.133331. (85)  Jawad M, Vamos EP, Najim M, Roberts B, Millett C. Impact of armed conflict on cardiovascular  disease risk: a systematic review.',\n",
       "  'chunk_char_count': 599,\n",
       "  'chunk_word_count': 92,\n",
       "  'chunk_token_count': 149.75},\n",
       " {'page_number': 5,\n",
       "  'sentence_chunk': 'Heart.2019;105:1388–94.doi: 10.1136/heartjnl-2018-314459. (86)  Howard JT, Sosnov JA, Janak JC, Gunlapalli AV, Pettey WB, Walker LE, et al. Associations of initial  injury severity and posttraumatic stress disorder diagnoses with long-term hypertension risk after  combat injury. Hypertension.2018;71:824–32.doi: 10.1161/HYPERTENSIONAHA.117.10496. (87)  Doocy S, Lyles E, Fahed Z, Mikanna A, Kontunen K, Burnham G. Characteristics of Syrian and  Lebanese diabetes and hypertension patients in Lebanon. Open Hypertens J. 2018;10:60–75.',\n",
       "  'chunk_char_count': 534,\n",
       "  'chunk_word_count': 69,\n",
       "  'chunk_token_count': 133.5},\n",
       " {'page_number': 5,\n",
       "  'sentence_chunk': 'doi: 10.2174/1876526201810010060. (88)  Sun X-C, Zhou X-F, Chen S, Liu Y-X, Wang Y-J, Zhang W, et al. Clinical characteristics of  hypertension among victims in temporary shield district after Wenchuan earthquake in China.  Eur Rev Med Pharmacol Sci.2013;17:912–6. PMID: 23640437. REFERENCES 35',\n",
       "  'chunk_char_count': 294,\n",
       "  'chunk_word_count': 44,\n",
       "  'chunk_token_count': 73.5},\n",
       " {'page_number': 6,\n",
       "  'sentence_chunk': 'GUIDELINE FOR THE PHARMACOLOGICAL TREATMENT OF HYPERTENSION IN ADULTS (89)  Kario K. Disaster hypertension - its characteristics, mechanism, and management. Circ J.  2012;76(3):553-62.doi: 10.1253/circj.cj-11-1510. (90)  Médecins Sans Frontières. Clinical guidelines: diagnostic and treatment manual. Author; 2013. (91)  WHO. Interagency emergency health kit 2017 [website] (https://www.who.int/emergencies/kits/ iehk/en/, accessed March 2021). (92)  COVID-19 and hypertension. Scientific Brief.',\n",
       "  'chunk_char_count': 495,\n",
       "  'chunk_word_count': 60,\n",
       "  'chunk_token_count': 123.75},\n",
       " {'page_number': 6,\n",
       "  'sentence_chunk': 'Geneva: World Health Organization; June 2021  (WHO/2019-nCoV/Sci_Brief/Hypertension/2021.1, accessed July 2021). (93)  Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, the Northwell COVID-19  Research Consortium, et al. Presenting characteristics, comorbidities, and outcomes among 5700  patients hospitalized with COVID-19 in the New York City Area. JAMA.2020;323(20):2052-2059. doi: 10.1001/jama.2020.6775. Erratum in: JAMA.2020 May 26;323(20):2098. (94)  Xie J, Tong Z, Guan X, Du B, Qiu H. Clinical characteristics of patients who died of  coronavirus disease 2019 in China. JAMA Netw Open.',\n",
       "  'chunk_char_count': 607,\n",
       "  'chunk_word_count': 85,\n",
       "  'chunk_token_count': 151.75},\n",
       " {'page_number': 6,\n",
       "  'sentence_chunk': '2020;3(4):e205619.doi: 10.1001/ jamanetworkopen.2020.5619. Erratum in: JAMA Netw Open.2020 May 1;3(5):e208147. (95)  Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2  cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell.2020;181(2):271-280.e8.doi: 10.1016/j.cell.2020.02.052. (96)  Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD.',\n",
       "  'chunk_char_count': 448,\n",
       "  'chunk_word_count': 60,\n",
       "  'chunk_token_count': 112.0},\n",
       " {'page_number': 6,\n",
       "  'sentence_chunk': 'Renin- angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 2020;382(17):1653-1659.doi: 10.1056/NEJMsr2005760. (97)  COVID-19 and the use of angiotensin-converting enzyme inhibitors and receptor blockers. Scientific Brief. Geneva: World Health Organization; May 2020 (WHO/2019-nCoV/Sci_Brief/ ACE-I/2020.1, accessed July 2021). (98)  Sparks MA, Hiremath S, et al. ACE2 and hypertension [website]. (http://www.nephjc.com/news/ covidace2, accessed 19 February 2021). (',\n",
       "  'chunk_char_count': 496,\n",
       "  'chunk_word_count': 59,\n",
       "  'chunk_token_count': 124.0},\n",
       " {'page_number': 6,\n",
       "  'sentence_chunk': '99)  Kompotiatis P, Garovic VD. Diagnosis, treatment, and outcomes of hypertensive pregnancy  disorders. In: Edwards EW, DiPette DJ, editors. Hypertension: a case-based approach. New Delhi:  Jaypee Brothers Medical Publishers Ltd; 2020. (100) Kuklina EV, Ayala C, Callaghan WM. Hypertensive disorders and severe obstetric morbidity in the  United States. Obstet Gynecol.2009;113(6):1299-306.doi: 10.1097/AOG.0b013e3181a45b25. (',\n",
       "  'chunk_char_count': 427,\n",
       "  'chunk_word_count': 56,\n",
       "  'chunk_token_count': 106.75},\n",
       " {'page_number': 6,\n",
       "  'sentence_chunk': '101) Creanga AA, Berg CJ, Syverson C, Seed K, Bruce FC, Callaghan WM. Pregnancy-related  mortality in the United States, 2006-2010. Obstet Gynecol.2015;125(1):5-12.doi: 10.1097/ AOG.0000000000000564. (102) Abalos E, Duley L, Steyn DW, Gialdini C. Antihypertensive drug therapy for mild to moderate  hypertension during pregnancy. Cochrane Database of Syst Rev. 2018;10(10):CD002252.doi:  10.1002/14651858. CD002252.pub4.36',\n",
       "  'chunk_char_count': 422,\n",
       "  'chunk_word_count': 54,\n",
       "  'chunk_token_count': 105.5},\n",
       " {'page_number': 7,\n",
       "  'sentence_chunk': 'Annex 1: List of contributors The World Health Organization (WHO) would like to thank the members of the Guideline Development  Group, the scientists who provided systematic reviews and the external peer reviewers for their  contributions to the development of these recommendations. Professor K Srinath chaired the meeting  with the assistance of the deputy chair, Professor Nizal Sarafzadeggan. WHO Steering Group Name Department/Office Bernadette Cappello Department of Essential Medicines and Products Neerja Chowdhury Department of Mental Health  Gampo Dorji Regional Office of South East Asia (SEARO) Jill Farrington Regional Office of Europe (EURO) Taskeen Khan Department of Noncommunicable Diseases Pedro Ordunez Pan American Health Organization/Regional Office of the Americas  (PAHO/AMRO) Steven Shongwe Regional Office for Africa (AFRO)  Slim Slama Regional Office of the Eastern Mediterranean (EMRO) Cherian Varghese Department of Noncommunicable Diseases Marco Vitoria Department of HIV/AIDS Temo Waqanivalu Department of Noncommunicable Diseases Guideline Development Group Name Affiliations Expertise Region Shrish Acharya Consultant Physician and Head of Internal  Medicine, Colonial War Memorial Hospital,  Fiji Chair, National Medicine and Therapeutics  Committee, Ministry of Health, Fiji Internal medicine Clinical practice  guideline development WPRO Akram   Al-Makki Director of Graduate Medical Education,  Medical Director of Acute (Inpatient) Dialysis  Unit, Indiana University, IN, USA  Health-Arnett, Affiliate Faculty of Pharmacy  Practice, Purdue University, College of  Pharmacy HTN management  in disaster and  humanitarian settings,  pharmacology of  hypertensive medicines  and HTN management,  Nephrology AMRO Hind Mamoun  Beheiry Associate Professor of Physiology, Dean  Faculty of Nursing Sciences, International  University of Africa (IUA), Sudan Nursing and HTN,  guideline development,  access to HTN care in  low-resource settings,  pathophysiology of HTN,  HTN management and  prevention at community  level EMRO ANNEXES 37',\n",
       "  'chunk_char_count': 2065,\n",
       "  'chunk_word_count': 301,\n",
       "  'chunk_token_count': 516.25},\n",
       " {'page_number': 8,\n",
       "  'sentence_chunk': 'GUIDELINE FOR THE PHARMACOLOGICAL TREATMENT OF HYPERTENSION IN ADULTS Beatriz  Champagne CLAS Coalición Latinoamérica Saludable/ Coalition for Americas’ Health @CLASenLA Advocacy, coalition  building, policy change,  patient perspectives,  implementation  research, behavioural  sciences AMRO Ugyen Choden Chief Analyst, Department of Financial  Regulation and Supervision, Royal Monetary  Authority, Bhutan Patient perspective,  drafting guidelines,  policies and  implementing policies SEARO Kenneth  Connell Deputy Dean of Internationalization  & Recruitment and Lecturer in Clinical  Pharmacology, The UWI, Cave Hill Campus Consultant Internist, Queen Elizabeth  Hospital, Barbados  Governor of the American College of  Physicians Caribbean Chapter Internal medicine, HTN  & ethnicity, medical  education  AMRO Marie Therese  Cooney Clinical Professor, University College Dublin,  Ireland  Consultant Physician in Geriatric and  General Medicine, St Vincent’s University  Hospital, Ireland  Cardiovascular  risk estimation,  cardiovascular disease  prevention, frailty and  multi-morbidity EURO Donald  DiPette Distinguished Health Sciences Professor,  University of South Carolina and University  of South Carolina School of Medicine,  Columbia, SC, USA  Clinical pharmacology  and pharmacology  of HTN medications,  HTN management,  pathophysiology of  HTN, health care and  policy making including  primary care AMRO Nnenna  Ezeigwe Consultant Public Health Physician; Director/ National Coordinator, Non-Communicable  Diseases (NCDs), Federal Ministry of Health,  Abuja, Nigeria Public health, policy- making, programme  implementation AFRO Tom Gaziano Associate Professor, Harvard Medical School Center for Health Decision Science, Harvard  TH Chan School of Public Health Clinical Director, iHeart Champion Program Director, Global Cardiovascular Health Policy  and Prevention Unit Cardiovascular Medicine Division, Brigham &  Women’s Hospital Implementation of HTN  treatment guideline,  cost-effectiveness,  global health policy,  epidemiology, screening  strategies AMRO Agaba Gidio  Consultant Physician (endocrinologist)/Head  Adult Diabetes Clinic Mulago National referral Hospital, Kampala  Uganda Endocrine HTN, HTN in  patients with Diabetes AFRO Vilma Irazola Director, Instituto de Efectividad Clinica  y Sanitaria (IECS); Institute for Clinical  Effectiveness and Health Policy (IECS) Deputy Director of the Master’s Degree  Program in Clinical Effectiveness, University  of Buenos Aires Senior Researcher, National Scientific Council  (CONICET), Argentina Implementation science,  NCDs epidemiology,  prevention and  management;  cardiovascular health,  global health,   health policy  AMRO 38',\n",
       "  'chunk_char_count': 2716,\n",
       "  'chunk_word_count': 393,\n",
       "  'chunk_token_count': 679.0},\n",
       " {'page_number': 9,\n",
       "  'sentence_chunk': 'Patricio Lopez  Jaramillo Director, Masira Research Institute,  Universidad de Santander (UDES)  Scientific Director, Centro Integral  para la Prevencion de la Enfermedades  Cardiometabolicas (CIPCA), Bucaramanga,  Colombia Endocrinology, clinical  management of HTN,  research AMRO Unab Khan Diplomate, American Board of Family  Medicine and Adolescent Medicine Associate Professor and Chair, Department  of Family Medicine, Aga Khan University,  Karachi, Pakistan NCDs, educational  programmes for  primary care physicians,  workplace/employee  wellness and safety,  program implementation  research EMRO Vindya  Kumarapeli Consultant Community Physician, Director  (Non-Communicable Diseases), Ministry of  Health, Sri Lanka Access to HTN care in  low-resource settings,  public health, policy- making, programme  implementation, primary  health care SEARO Andrew  Moran Director, Global Hypertension Control,  Resolve to Save Lives, an initiative of Vital  Strategies Associate Professor of Medicine, Columbia  University Irving Medical Center, New York,  NY, USA HTN, primary care,  health economic  evaluation, HTN program  evaluation AMRO Margaret  Mswema  Silwimba Clinical Pharmacist and Head of  Pharmaceutical services, Premium  Department (UTH) Part-time Lecturer (Faculty of Pharmacy)  Lusaka Apex Medical University, Zambia HTN pharmaceuticals,  pharmacy education AFRO Brian Rayner Emeritus Professor and Senior Research  Scholar, Division of Nephrology and  Hypertension, Department of Medicine,  University of Cape Town, Cape Town,  South Africa Guidelines, resistant HTN  especially in individuals  of African descent,  genetics of HTN, diabetic  kidney disease AFRO K Srinath  Reddy President, Public Health Foundation of India Cardiology, prevention  and control of NCDs,  epidemiology, health  systems and policy,  universal health  coverage, public health SEARO Nizal  Sarrafzadegan Distinguished Professor of Medicine  and Cardiology, Director of Isfahan  Cardiovascular Research Institute, a WHO  Collaborating Centre in Iran Affiliate Professor, School of Population  and Public Health, Faculty of Medicine,  University of British Columbia, Vancouver,  Canada Cardiology,  epidemiology,  prevention and  control of NCDs, public  health, programme  implementation and  evaluation, global health EMRO Apichard  Sukonthasan Cardiac Specialist and Head of Medicine  Department, Bangkok Hospital Chiang Mai Guideline development,  cardiovascular disease  prevention, HTN  management SEARO ANNEXES 39',\n",
       "  'chunk_char_count': 2519,\n",
       "  'chunk_word_count': 379,\n",
       "  'chunk_token_count': 629.75},\n",
       " {'page_number': 10,\n",
       "  'sentence_chunk': 'GUIDELINE FOR THE PHARMACOLOGICAL TREATMENT OF HYPERTENSION IN ADULTS Paul Whelton Show Chwan Chair in Global Public Health,  Department of Epidemiology, Tulane  University School of Public Health and  Tropical Medicine, Tulane, USA Epidemiology  and prevention of  cardiovascular and  renal disease, research,  guidelines development,  global health,   health policy AMRO Jing Yu MD, PhD, Professor of Internal Medicine,  Chief of Cardiology, Director, Center of  Hypertension, Director, Department of  Cardiology, Lanzhou University Second  Hospital, China Chairman of Hypertension League in Gansu,  Ningxia and Qinghai Region of China Acute and chronic  complications of HTN,  access to HTN care in  low-resource settings,  pharmacology of  hypertensive medicines,  cardiovascular  complications WPRO Consultant and Systematic Review Team Methodologist: M Hassan Murad (Professor of Medicine at the Mayo Clinic, Rochester, USA) Systematic Review Team: Reem Mustapha, Abdallah Al Alayli, Romina Brignardello, Sara Jdiaa, Veena  Manja (University of Kansas Medical Center, Kansas, USA) External Review Group Name Affiliation Region Mabel Aoun Head of the Department of Nephrology, Saint-Georges Hospital  Ajaltoun Assistant Professor, Medical School, Saint-Joseph University of  Beirut, Lebanon EMRO Antoinette Péchère  Bertschi Head Hypertension Unit and Centre, Service of Nephrology and  Hypertension, University Hospital of Geneva, Switzerland EURO Jennifer Cohn Senior Vice President, Cardiovascular Health Assistant Professor, Division of Infectious Diseases, University of  Pennsylvania, PA, USA AMRO Prabhdeep Kaur Scientist E and Head of Division of Noncommunicable Diseases,  ICMR-National Institute of Epidemiology, Chennai, India SEARO Daniel T Lackland Professor of Epidemiology and Neurology Director, Division of Translational Neurosciences and Population  Studies, Medical University of South Carolina, Charleston, SC, USA AMRO Venus Mushininga Program Manager, Non Communicable Diseases, Ministry of Health  and Child Care, Harare, Zimbabwe AFRO Marcelo Orias Chief of Nephrology at Sanatorio Allende Professor in Internal Medicine at National University of Córdoba,  Associate Professor of Internal Medicine, Yale University, CT, USA AMRO 40',\n",
       "  'chunk_char_count': 2260,\n",
       "  'chunk_word_count': 327,\n",
       "  'chunk_token_count': 565.0},\n",
       " {'page_number': 11,\n",
       "  'sentence_chunk': 'Xin Hua Zhang Professor of Medicine Vice-Director of Beijing Hypertension League Institute, Beijing,  China President, World Hypertension League, WHL Global Office Director, WHL Asia-Pacific Regional Office WPRO Overall coordination and writing of the guideline  The guideline process was coordinated by the WHO Department of Noncommunicable Diseases. The  first draft was written by Taskeen Khan. Drafts were reviewed by the Guideline Development Group and  External Review Group, and subsequently revised by Taskeen Khan. ANNEXES 41',\n",
       "  'chunk_char_count': 534,\n",
       "  'chunk_word_count': 78,\n",
       "  'chunk_token_count': 133.5},\n",
       " {'page_number': 12,\n",
       "  'sentence_chunk': 'GUIDELINE FOR THE PHARMACOLOGICAL TREATMENT OF HYPERTENSION IN ADULTS Annex 2. Managing declarations of  interest and conflicts of interest  The steering group followed the current Compliance, Risk Management and Ethics (CRE) policy. All members of the Guideline Development Group (GDG) were asked to fill in the standard WHO  Declaration of Interest (DOI) forms, which were reviewed. The WHO Secretariat reviewed the curriculum  vitae of each potential participant and conducted internet searches (PubMed, Open Payments Data,  Google Scholar) for information on potential financial and academic conflicts of interest related to the  subject of the meeting. All DOIs are on file at the WHO Department of Noncommunicable Diseases. The WHO Steering Group published the names and brief biographies of potential GDG members on the  WHO website for more than two weeks, together with a description of the objective of the meeting, for  public review and comment. There were no concerns raised about any members. None of the declared interests was judged sufficient to affect any of the experts’ objective judgement  during the guidelines development process or on the recommendations, or therefore to preclude their  full participation in the development of the guidelines. During the course of the development of the guideline, one GDG member’s status of conflict of interest  changed as she accepted a temporary appointment as a staff member at WHO. She was removed from  further GDG engagements immediately upon accepting appointment.',\n",
       "  'chunk_char_count': 1532,\n",
       "  'chunk_word_count': 243,\n",
       "  'chunk_token_count': 383.0},\n",
       " {'page_number': 12,\n",
       "  'sentence_chunk': 'All members of the GDG and all meeting observers were required to sign a confidentiality agreement  before participating in the meeting. All members of the External Review Group (ERG) were asked to fill in the standard WHO DOI forms,  which were reviewed. None of the declared interests was judged sufficient to affect any of the  judgement during the review process, or therefore to preclude their participation as expert reviewers.42',\n",
       "  'chunk_char_count': 435,\n",
       "  'chunk_word_count': 72,\n",
       "  'chunk_token_count': 108.75},\n",
       " {'page_number': 13,\n",
       "  'sentence_chunk': 'Annex 3: Treatment outcomes  relevant to hypertension Members of the WHO Steering Group, in consultation with the GDG and methodologist, developed a  list of treatment outcomes most relevant to the care of individuals with hypertension. The GDG then  rated each outcome on a scale from 1 to 9 and indicated whether it considered each outcome critical  (rated 7–9), important (rated 4–6) or not important (rated 1–3) for decision-making (Fig. A3.1). Fig. A3.1 Rating of outcomes Importance of outcomes for decision making 8.6 8.4 8.1 8.0 7.9 7.8 7.6 6.9 6.9 6.8 6.8 6.3 6.0 4.4 Limited importance Important Critical Any adverse events (eg, edema)  Stroke  MI  CAD  CV death  Heart failure  ESRD  Adherence  Adverse events leading to discontinuation of BP meds  All-cause mortality  Serious adverse events (eg, syncope)  Time to BP control  Patient satisfaction  Pill/medication burden  ANNEXES 43',\n",
       "  'chunk_char_count': 895,\n",
       "  'chunk_word_count': 156,\n",
       "  'chunk_token_count': 223.75},\n",
       " {'page_number': 14,\n",
       "  'sentence_chunk': 'GUIDELINE FOR THE PHARMACOLOGICAL TREATMENT OF HYPERTENSION IN ADULTS Annex 4: PICO questions  The eleven questions in population, intervention, comparison, and outcomes (PICO) format used to  guide the systematic reviews. In addition, relevant subgroups (s) were identified.1  At what level of blood pressure should pharmacological therapy be started to  prevent cardiovascular events?P Adult men and women I Specific systolic and diastolic blood pressure thresholds:* systolic (mmHg): ≥120, ≥130, ≥140, ≥150 diastolic (mmHg): ≥80, ≥90 C Placebo or systolic or diastolic blood pressure threshold that is higher than intervention  thresholds O Death (all-cause mortality), cardiovascular death (death from MI, sudden cardiac death or  stroke), stroke, myocardial infarction, end-stage renal disease, cognitive impairment/dementia,  heart failure events and adverse events s Based on different effect modifiers such as: estimated cardiovascular risk; pre-existing CAD,  stroke, diabetes, age, sex, chronic kidney disease and race/ethnicity * Each BP threshold in the intervention category (I) will be compared with a higher threshold. For example, I  (<140) will be compared to C (≥140) 2  Is any laboratory testing necessary prior to initiation or during titration of  pharmacological treatments P Adult men and women requiring antihypertensive treatment I Initiation or titration of antihypertensives without lab tests C Initiation or titration of antihypertensives with lab tests O Death (all-cause mortality), cardiovascular death (death from MI, sudden cardiac death or  stroke), stroke, myocardial infarction, end-stage renal disease and heart failure events, cognitive  impairment/decline BP control Time to control BP Adherence Adverse effects Patient satisfaction s Individual drugs and doses Patients with no comorbidities Baseline blood pressure Type of lab test (ECG, blood, etc) 44',\n",
       "  'chunk_char_count': 1893,\n",
       "  'chunk_word_count': 276,\n",
       "  'chunk_token_count': 473.25},\n",
       " {'page_number': 15,\n",
       "  'sentence_chunk': '3  Should cardiovascular risk assessment be used to guide initiation of  antihypertensive medications?P Adult men and women without pre-identified CVD I Initiating antihypertensives drug therapy based on a formal CVD risk estimation C Initiating antihypertensives drug therapy without formal CVD risk assessment (i.e. using only  BP threshold) O Death (all-cause mortality), cardiovascular death (death from MI, sudden cardiac death or  stroke), stroke, myocardial infarction, end-stage renal disease heart failure events, cognitive  impairment/dementia, and adverse events Proportion of people prescribed with antihypertensives BP levels s BP levels 4  In adults with hypertension requiring pharmacological treatment, which drugs  should be used as first-line agents? P Adult men and women with hypertension requiring pharmacological treatment I BB, CCB, diuretics, ACEi, or ARB C Placebo O Death (all-cause mortality), cardiovascular death (death from MI, sudden cardiac death or  stroke), stroke, cognitive impairment/dementia, myocardial infarction, end-stage renal disease  and heart failure events Adverse effects such as bradycardia, acute kidney injury, angioedema, asthma, electrolyte  abnormalities or hypotension BP reduction and control (if data on CVD events are absent) s Based on different effect modifiers such as: estimated cardiovascular risk; pre-existing CAD,  stroke, diabetes, age, sex, chronic kidney disease and race/ethnicity, level of baseline BP 5  In adults with hypertension requiring pharmacological treatment, which drugs  (BB, CCB, diuretics, ACEi, or ARB vs BB, CCB, diuretics, ACEi, or ARB in head-to- head studies) should be used as first-line agents? P Adult men and women with HTN requiring pharmacological treatment I BB, CCB, diuretics, ACEi, or ARB C BB, CCB, diuretics, ACEi, or ARB (head-to-head studies) O Death (all-cause mortality), cardiovascular death (death from MI, sudden cardiac death or  stroke), stroke, cognitive impairment/dementia, myocardial infarction, end-stage renal disease  and heart failure events Adverse effects such as bradycardia, acute kidney injury, angioedema, asthma, electrolyte  abnormalities or hypotension Blood pressure reduction and control (if data on CVD events are absent) s Based on different effect modifiers such as: estimated cardiovascular risk; pre-existing CAD,  stroke, diabetes, age, sex, chronic kidney disease and race/ethnicity, level of baseline blood  pressure ANNEXES 45',\n",
       "  'chunk_char_count': 2465,\n",
       "  'chunk_word_count': 356,\n",
       "  'chunk_token_count': 616.25},\n",
       " {'page_number': 16,\n",
       "  'sentence_chunk': 'GUIDELINE FOR THE PHARMACOLOGICAL TREATMENT OF HYPERTENSION IN ADULTS 6  In adults with hypertension requiring pharmacological treatment, which drugs  (monotherapy using BB, CCB, diuretics, ACEi or ARB vs combination therapy using  BB, CCB, diuretics, ACEi or ARB) should be used as first-line agents? P Adult men and women with HTN requiring pharmacological treatment I BB, CCB, diuretics, ACEi, or ARB C Combination therapy O Death (all-cause mortality), cardiovascular death (death from MI, sudden cardiac death or  stroke), stroke, cognitive impairment/dementia, myocardial infarction, end-stage renal disease  and heart failure events Adverse effects such as bradycardia, acute kidney injury, angioedema, asthma, electrolyte  abnormalities or hypotension BP reduction and control (if data on CVD events are absent) s Based on different effect modifiers such as: estimated cardiovascular risk; pre-existing CAD,  stroke, diabetes, age, sex, chronic kidney disease and race/ethnicity, level of baseline BP 7  In adults with hypertension requiring pharmacological treatment, which  combination therapy of two or more drugs (BB, CCB, diuretics, ACEi, or ARB) vs  different combination therapy of two or more drugs (BB, CCB, diuretics, ACEi, or  ARB) should be used as first-line agents?P Adult men and women with HTN requiring pharmacological treatment I Combination therapy of two or more drugs (BB, CCB, diuretics, ACEi, or ARB) C Different combination therapy of two or more drugs (BB, CCB, diuretics, ACEi, or ARB) O Death (all-cause mortality), cardiovascular death (death from MI, sudden cardiac death or  stroke), stroke, cognitive impairment/dementia, myocardial infarction, end-stage renal disease  and heart failure events Adverse effects such as bradycardia, acute kidney injury, angioedema, asthma, electrolyte  abnormalities or hypotension BP reduction and control (if data on CVD events are absent) s Based on different effect modifiers such as: estimated cardiovascular risk; pre-existing CAD,  stroke, diabetes, age, sex, chronic kidney disease and race/ethnicity, level of baseline BP 46',\n",
       "  'chunk_char_count': 2105,\n",
       "  'chunk_word_count': 314,\n",
       "  'chunk_token_count': 526.25},\n",
       " {'page_number': 17,\n",
       "  'sentence_chunk': '8  In adults with hypertension requiring pharmacological intervention, is use of  a single-pill combination of antihypertensive drugs associated with improved  outcomes?P Adult men and women with HTN requiring pharmacological intervention I Single-pill combination (FDC) of antihypertensive drugs – five classes (any two or more from the  five) C Pharmacological interventions that do not involve use of single-pill combinations O Death (all-cause mortality), cardiovascular death (death from MI, sudden cardiac death or  stroke), stroke, myocardial infarction, end-stage renal disease and heart failure events. Adverse effects Patient satisfaction Adherence BP level/change Number of antihypertensive medications s Based on different effect modifiers such as: estimated cardiovascular risk; pre-existing CAD,  stroke, diabetes, age, sex, chronic kidney disease and race/ethnicity, level of baseline BP 9  What target blood pressure should pharmacological treatment aim to achieve?P Adult men and women I Specific systolic and diastolic blood pressure targets: systolic (mmHg): <120, <130, <140, <150 diastolic (mmHg): <70, <80, <90 C Systolic or diastolic blood pressure targets that are higher than the intervention targets O Death (all-cause mortality), cardiovascular death (death from MI, sudden cardiac death or  stroke), stroke, myocardial infarction, end-stage renal disease heart failure events, cognitive  impairment/dementia, and adverse events s Based on different effect modifiers such as: estimated cardiovascular risk; pre-existing CAD,  stroke, diabetes, age, sex, chronic kidney disease and race/ethnicity 10 In adults with hypertension given pharmacological treatment, when should blood  pressure be reassessed?P Adult men and women with HTN receiving a pharmacological intervention I Specific interval C Alternative interval O Death (all-cause mortality), cardiovascular death (death from MI, sudden cardiac death or  stroke), stroke, myocardial infarction, end stage renal disease and heart failure events Adverse effects BP control Adherence Patient satisfaction s Titration phase vs controlled HTN follow up, level of initial BP, other conditions, remote  monitoring vs clinical visit ANNEXES 47',\n",
       "  'chunk_char_count': 2217,\n",
       "  'chunk_word_count': 313,\n",
       "  'chunk_token_count': 554.25},\n",
       " {'page_number': 18,\n",
       "  'sentence_chunk': 'GUIDELINE FOR THE PHARMACOLOGICAL TREATMENT OF HYPERTENSION IN ADULTS 11 Can pharmacological management of hypertension be provided by nonphysician  care providers?P Adult men and women I Pharmacological management by nonphysician care providers C Pharmacological management by medically qualified practitioners (doctors) O Death (all-cause mortality), cardiovascular death (death from MI, sudden cardiac death or  stroke), stroke, myocardial infarction, end-stage renal disease and heart failure events BP control Adherence Serious adverse effects Patient satisfaction s Initiation vs follow up Self-care vs CHW vs nurse vs pharmacist vs physician assistant vs in or out of clinic Levels of care Rural vs urban settings Ethnicity 48',\n",
       "  'chunk_char_count': 733,\n",
       "  'chunk_word_count': 104,\n",
       "  'chunk_token_count': 183.25}]"
      ]
     },
     "execution_count": 45,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pages_and_chunks_over_min_token_len = df[df[\"chunk_token_count\"]> min_token_length].to_dict(orient=\"records\")\n",
    "pages_and_chunks_over_min_token_len\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "id": "18ad27c3",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Sentence: The Sentence Transformer Library provides an easy way to create embeddings\n",
      "Embedding: [-3.17512788e-02  3.37267555e-02 -2.52437796e-02  5.22288419e-02\n",
      " -2.35249791e-02 -6.19116891e-03  1.35025457e-02 -6.25501350e-02\n",
      "  7.50831934e-03 -2.29684897e-02  2.98145972e-02  4.57555614e-02\n",
      " -3.26700620e-02  1.39847612e-02  4.18013632e-02 -5.92969507e-02\n",
      "  4.26310077e-02  5.04655251e-03 -2.44552530e-02  3.98591487e-03\n",
      "  3.55898216e-02  2.78742742e-02  1.84098873e-02  3.67699228e-02\n",
      " -2.29961611e-02 -3.01796887e-02  5.99619874e-04 -3.64504606e-02\n",
      "  5.69104776e-02 -7.49941776e-03 -3.70004103e-02 -3.04364343e-03\n",
      "  4.64355052e-02  2.36149481e-03  9.06849550e-07  7.00036297e-03\n",
      " -3.92289162e-02 -5.95697155e-03  1.38653331e-02  1.87106046e-03\n",
      "  5.34202717e-02 -6.18613772e-02  2.19613519e-02  4.86051328e-02\n",
      " -4.25697267e-02 -1.69858467e-02  5.04178256e-02  1.54733518e-02\n",
      "  8.12860429e-02  5.07106557e-02 -2.27496810e-02 -4.35721017e-02\n",
      " -2.18382338e-03 -2.14091577e-02 -2.01758258e-02  3.06832269e-02\n",
      " -3.51334475e-02 -1.37516176e-02 -1.47074908e-02  3.83924209e-02\n",
      " -3.63251083e-02  4.24920134e-02  6.66146539e-03 -3.98761891e-02\n",
      "  7.14551657e-02 -1.35859232e-02 -6.60983995e-02 -8.44912231e-03\n",
      "  4.74620378e-03  6.11576810e-02  2.99039204e-03 -2.55231559e-02\n",
      " -3.34806219e-02 -8.54001008e-03  3.12245674e-02  2.98417136e-02\n",
      " -4.85905148e-02 -1.11949453e-02  7.23602623e-02  3.28173973e-02\n",
      "  1.77807861e-03  5.02722114e-02  2.30483785e-02 -4.10619751e-02\n",
      " -3.49083841e-02 -4.36537117e-02  5.07546552e-02 -4.66824248e-02\n",
      " -3.67540866e-02 -2.16351505e-02 -8.07572715e-03  2.78772563e-02\n",
      "  3.41444165e-02 -2.42737066e-02  9.37788747e-03  1.27494680e-02\n",
      " -7.16165230e-02 -3.23407464e-02 -8.06693453e-03 -2.30582468e-02\n",
      "  6.39590845e-02  1.22526139e-02 -1.84588169e-03  4.58422955e-03\n",
      " -8.37132260e-02  6.05703630e-02 -3.02917860e-03 -4.53537889e-03\n",
      " -2.79873610e-02 -2.37172246e-02 -4.24651876e-02 -1.20252073e-02\n",
      " -6.66096583e-02  6.39968086e-03 -1.92155708e-02 -6.99941963e-02\n",
      " -4.53624390e-02  5.89809008e-02 -3.09233777e-02  2.02953424e-02\n",
      "  1.01700276e-02  1.30998520e-02  7.79714808e-03  2.21275315e-02\n",
      " -9.14812367e-03  1.98615845e-02 -2.74215788e-02 -2.36939732e-02\n",
      " -2.22199373e-02  2.53693443e-02 -3.28815840e-02  5.13044335e-02\n",
      "  6.19513020e-02 -7.44251581e-03 -4.78575751e-02  9.91810020e-03\n",
      "  1.66845974e-02 -3.57198305e-02  3.01708952e-02  4.00398374e-02\n",
      " -5.39104547e-03  1.51401367e-02  5.59856882e-03 -4.78387550e-02\n",
      "  6.58323392e-02  2.69618887e-03  1.13033419e-02 -4.28623520e-02\n",
      "  2.22742800e-02  2.74195876e-02 -5.09937927e-02  1.17162719e-01\n",
      "  1.34981992e-02 -3.71388197e-02 -6.41477332e-02 -2.63016224e-02\n",
      "  7.84799457e-02  5.48545606e-02  5.46070784e-02 -9.82335210e-03\n",
      "  5.09111360e-02 -3.13068565e-04 -6.86397869e-03  1.70785207e-02\n",
      " -1.35588748e-02 -2.16213986e-03 -2.34771725e-02 -1.55508872e-02\n",
      " -8.23167094e-04  8.29926580e-02 -9.48119164e-03  7.00235590e-02\n",
      "  3.33337113e-03  1.47000505e-02  2.84736045e-02  6.13352396e-02\n",
      "  6.53134286e-02  1.27842948e-02  8.42677280e-02  2.58606095e-02\n",
      " -3.99192087e-02  2.62350738e-02 -3.68678980e-02  5.22657596e-02\n",
      "  1.86432656e-02  3.53657268e-02 -2.45990101e-02  8.81066322e-02\n",
      "  2.56001297e-03  5.99748921e-03 -2.03187894e-02 -3.80547829e-02\n",
      "  1.56885125e-02 -4.86830547e-02 -1.02307480e-02  5.31377606e-02\n",
      " -3.93920764e-02  5.00219092e-02 -4.20133211e-03 -6.84148371e-02\n",
      " -8.43475107e-03  3.83050703e-02  3.40062706e-03  6.75314143e-02\n",
      "  4.67102528e-02  1.85773596e-02  1.75162572e-02 -3.13067473e-02\n",
      " -3.83051522e-02  8.36634114e-02  3.01607791e-02 -1.63155347e-02\n",
      " -2.75369287e-02 -7.45281801e-02  3.94692421e-02 -1.40284508e-04\n",
      "  1.06907282e-02 -2.64681615e-02 -9.52930469e-03  2.35250071e-02\n",
      "  6.30769953e-02 -3.58120091e-02  3.75604331e-02  3.86091322e-02\n",
      " -2.86414512e-02 -2.03893669e-02  3.76558281e-03  2.92671267e-02\n",
      "  1.12931076e-02  3.38566266e-02 -1.25356959e-02  6.60268366e-02\n",
      "  6.35566860e-02 -4.86964807e-02 -4.31394838e-02  6.28765002e-02\n",
      " -2.69191805e-02 -8.75512585e-02  8.27588327e-03 -1.02666564e-01\n",
      "  2.47256588e-02  1.35638434e-02 -5.55747282e-03 -1.86810177e-02\n",
      " -1.44041413e-02 -8.57948512e-03  8.13291594e-02 -4.46740314e-02\n",
      " -4.09447076e-03  3.33538428e-02  4.34364714e-02 -3.02401092e-02\n",
      "  6.42347476e-03  4.94938232e-02  1.72628257e-02 -2.46238802e-02\n",
      " -2.80704759e-02 -1.87670474e-03  4.09032218e-02 -5.85711142e-03\n",
      " -1.95791610e-02  1.88911203e-02 -1.10968966e-02 -2.61494368e-02\n",
      " -3.96250252e-04  2.14644577e-02 -3.54524702e-02 -5.03614321e-02\n",
      "  2.74636829e-03  1.68064423e-02 -9.64396726e-03  1.37958024e-02\n",
      "  2.89547145e-02  1.18163545e-02  3.01219597e-02 -4.64622714e-02\n",
      "  1.53108360e-02 -6.87962398e-03  2.01097820e-02  4.71905246e-02\n",
      " -6.08274452e-02 -4.23219427e-02 -3.57370973e-02  2.87291706e-02\n",
      " -2.81011965e-02  6.10911325e-02 -5.18230982e-02 -7.50938058e-03\n",
      " -3.07047013e-02  8.13312072e-04  1.45775108e-02  1.22668892e-02\n",
      "  3.79741639e-02 -4.22005504e-02 -9.40954126e-03  1.26129901e-02\n",
      "  8.55632946e-02  3.77735160e-02  1.41396117e-03  6.41736761e-02\n",
      "  5.05688749e-02 -5.77934971e-03 -1.09078176e-02  6.78479765e-03\n",
      " -2.00583003e-02  4.89428155e-02 -8.49455781e-03 -2.42428808e-03\n",
      " -7.37103447e-03  1.85880195e-02  8.08327924e-03 -1.03385327e-02\n",
      " -2.87857875e-02  3.13182957e-02 -3.78199643e-03 -4.82103042e-03\n",
      "  3.10750282e-03 -3.02711199e-03 -2.93274540e-02 -2.47740690e-02\n",
      "  3.53625864e-02  5.44219569e-04  3.12252603e-02 -4.56644483e-02\n",
      " -3.05787642e-02 -4.38935347e-02 -3.39478664e-02 -4.15794030e-02\n",
      "  6.44758493e-02 -1.55901851e-03  3.98300542e-03 -2.27166456e-03\n",
      " -6.35489682e-03 -3.55863199e-02  2.65947897e-02  4.69325259e-02\n",
      "  1.64104868e-02  1.79546867e-02  1.33658713e-02 -2.66937129e-02\n",
      " -2.39923447e-02 -2.06165258e-02 -2.48198602e-02 -5.12003824e-02\n",
      " -5.54500427e-03  1.81241687e-02  2.81455573e-02 -1.52694536e-02\n",
      " -3.62992845e-02  1.41980154e-02 -1.03263156e-02 -1.53739620e-02\n",
      " -1.90759934e-02  7.37818144e-03 -4.32782173e-02  6.44605383e-02\n",
      "  4.22289148e-02  3.69748496e-03 -2.10980158e-02  9.27728484e-04\n",
      "  7.00220838e-02 -1.28834406e-02 -4.43938375e-02  7.84376264e-03\n",
      " -5.62279858e-02 -2.58354973e-02  4.93662944e-03 -4.98834923e-02\n",
      "  2.39316281e-02 -2.46321899e-04  3.04042874e-03  1.11720385e-02\n",
      " -1.84925310e-02  8.85111019e-02  5.27525507e-02 -4.00967188e-02\n",
      "  3.53580415e-02 -3.67238931e-02  3.67109738e-02  9.71163530e-03\n",
      "  3.12656388e-02 -1.22500740e-01 -3.10587641e-02 -3.13424924e-03\n",
      " -3.61339599e-02  4.28802557e-02  2.79515458e-04  4.80144378e-03\n",
      " -9.82156396e-02  2.61312630e-02  1.68510899e-02  4.25127484e-02\n",
      " -4.40636389e-02 -1.92942265e-02 -4.17811759e-02  1.10101774e-02\n",
      " -1.29304640e-02 -3.19889896e-02 -2.09932923e-02  6.59042224e-03\n",
      " -5.12905568e-02 -5.68091273e-02 -1.73661802e-02 -2.85681952e-02\n",
      " -5.78577816e-02  3.06151528e-02 -1.91639367e-04  5.92039227e-02\n",
      "  2.28506885e-03 -3.68659683e-02 -7.59676471e-02 -2.37930920e-02\n",
      " -5.88499047e-02  2.44147927e-02  3.55509929e-02 -2.30707694e-02\n",
      " -2.64748670e-02  6.83393283e-03  3.58307362e-02 -3.77269536e-02\n",
      " -3.35451514e-02  2.75023971e-02  8.47893059e-02 -2.30223546e-03\n",
      "  5.99636277e-03 -4.39461209e-02  1.90635230e-02  2.43068449e-02\n",
      "  4.97597307e-02  3.48220840e-02 -1.22428332e-02 -9.52080009e-04\n",
      "  8.12207162e-03  7.42876809e-03 -4.32638302e-02 -4.86899652e-02\n",
      "  3.33769210e-02 -9.35187750e-03  4.57262248e-02 -8.49949718e-02\n",
      " -3.17020044e-02  5.82108684e-02  2.98859831e-02  3.27124074e-02\n",
      "  3.13586625e-03  7.53517123e-03  1.71621249e-03 -5.69137000e-02\n",
      " -1.17816748e-02  1.43012814e-02  1.84576176e-02  2.41326112e-02\n",
      " -1.80390477e-02  5.36695197e-02  3.78649272e-02  1.19280983e-02\n",
      " -3.06920595e-02 -3.29276770e-02 -4.37397510e-02  9.22678411e-03\n",
      "  2.39838380e-02  1.34406211e-02  1.18268859e-02 -3.75344008e-02\n",
      "  3.63410451e-02  4.29438949e-02  4.53460179e-02 -7.29761124e-02\n",
      " -1.10598328e-02  1.17620332e-02 -2.06151865e-02  1.47658978e-02\n",
      "  3.64490151e-02 -3.24941357e-03  4.32062428e-03 -6.36857599e-02\n",
      "  4.23910767e-02  1.79281142e-02 -7.00057521e-02  1.53178563e-02\n",
      " -5.22550270e-02 -1.89471617e-02 -2.84225997e-02  5.57509437e-03\n",
      " -6.22838782e-03  1.74789242e-02 -1.05596513e-01 -3.59372795e-02\n",
      " -5.49096242e-02  2.42201909e-02  4.82034013e-02  2.00591180e-02\n",
      "  1.22003090e-02 -1.89718567e-02 -3.32487747e-02  8.26579891e-03\n",
      "  3.25944112e-03  6.27234504e-02  4.37995754e-02 -1.64107904e-02\n",
      " -1.29950326e-02  2.99947038e-02 -3.55265476e-02 -1.05935270e-02\n",
      " -6.53243661e-02 -1.05157429e-02 -3.01193688e-02 -1.06331259e-02\n",
      " -1.90696120e-02 -1.08426809e-02 -4.72781993e-02  4.36234251e-02\n",
      " -3.26108374e-02  5.00925891e-02 -3.29291262e-02  2.48312019e-03\n",
      "  7.13983104e-02 -1.29911955e-02  5.38316965e-02 -1.64794233e-02\n",
      " -2.57684607e-02  6.63955882e-02  6.69528618e-02 -6.91024661e-02\n",
      " -1.29960133e-02  2.54568621e-03  1.08204195e-02 -3.45112868e-02\n",
      " -4.18824293e-02  4.11806479e-02 -2.14523915e-02 -1.99216045e-03\n",
      "  2.75431536e-02  1.97311700e-03 -5.62766641e-02 -1.72103141e-02\n",
      "  4.73647453e-02  2.71155015e-02 -2.16401331e-02 -1.61213651e-02\n",
      " -3.51910703e-02 -6.50478005e-02 -5.54161426e-03  3.18600982e-02\n",
      " -9.87860188e-03  1.18842507e-02 -1.54758189e-02  2.12222952e-02\n",
      "  1.55511675e-02 -1.70723889e-02 -1.55686205e-02  3.15090157e-02\n",
      " -1.18929259e-02 -7.12359697e-02 -3.30978222e-02 -4.32606606e-33\n",
      " -4.62589189e-02  1.22969747e-02 -3.20229791e-02 -2.78884917e-02\n",
      " -1.08436020e-02 -1.10652093e-02  8.93466361e-03  2.52347514e-02\n",
      "  2.32202504e-02  3.27641144e-02  7.82627985e-03 -2.69480851e-02\n",
      "  1.19924461e-02  1.65210236e-02 -2.60641542e-03  2.92153563e-02\n",
      "  2.84571089e-02 -2.02488396e-02  9.00312699e-03  8.76457710e-03\n",
      "  1.29353320e-02  4.02023718e-02  4.33696769e-02 -2.80212779e-02\n",
      " -2.89619360e-02  1.52371349e-02 -8.27926677e-03  2.36268927e-04\n",
      "  3.45984101e-02  4.76797558e-02 -2.41581071e-02  1.96413491e-02\n",
      " -1.51803195e-02  2.42424887e-02 -1.42624322e-02  7.18389228e-02\n",
      " -5.58839180e-02 -1.55399963e-02  4.14171517e-02 -1.92338917e-02\n",
      " -2.55287662e-02 -4.58723418e-02 -2.71275584e-02 -4.43420112e-02\n",
      "  3.60833891e-02  5.78193320e-03  3.51143144e-02 -4.16080793e-03\n",
      " -8.40502325e-03 -3.97925312e-03 -7.85549209e-02 -2.72270944e-03\n",
      "  6.03275048e-03  1.87141038e-02  1.59001928e-02 -1.67094855e-04\n",
      "  2.86227767e-03  6.50428841e-03 -9.02043004e-03 -9.05950181e-03\n",
      " -3.17575000e-02  2.61157174e-02  2.27600820e-02 -4.73466218e-02\n",
      " -4.33875658e-02  5.98783903e-02 -3.70311216e-02 -3.92582007e-02\n",
      " -7.42959278e-03  3.97704169e-02  2.05766018e-02  4.45614830e-02\n",
      "  5.17226644e-02  6.47154897e-02 -1.12156002e-02  1.98144410e-02\n",
      " -1.74945984e-02 -1.85965206e-02  2.05232743e-02  2.25114985e-03\n",
      "  4.36831303e-02  3.15700285e-02  2.36150678e-02 -1.29921287e-02\n",
      " -1.68885868e-02  3.43265827e-03  1.92206935e-04 -6.20984025e-02\n",
      "  3.11526451e-02  1.04307113e-02 -3.49925607e-02  7.67283142e-03\n",
      "  3.18957157e-02 -2.56586932e-02  4.89981333e-03  1.79350208e-02\n",
      " -1.52581343e-02  2.70325914e-02 -8.59264564e-03  3.45437601e-02\n",
      "  8.93352088e-03 -3.48193198e-02  1.24013191e-03 -8.79185181e-03\n",
      "  2.69112475e-02  1.40880449e-02  3.80622335e-02 -9.51180421e-03\n",
      " -7.63270408e-02 -1.83740223e-03 -4.29712608e-03 -5.61364815e-02\n",
      " -5.31258173e-02  2.93393782e-03 -1.72041245e-02  2.31317785e-02\n",
      " -1.01896329e-02 -1.86987501e-03  3.17086913e-02 -6.50321925e-03\n",
      " -2.88115144e-02 -2.14221291e-02  3.67089733e-02  3.45961489e-02\n",
      " -2.46727411e-02 -1.98293310e-02 -4.26006392e-02  4.03007343e-02\n",
      "  5.03497720e-02 -6.73352480e-02  1.44804092e-02 -1.37580838e-03\n",
      "  1.72852523e-07  3.70796211e-02  6.15184866e-02  4.44693640e-02\n",
      "  6.80567638e-04 -1.33423321e-02 -2.72832159e-02  6.99471077e-03\n",
      "  6.66199550e-02  2.50287500e-04  2.30058767e-02  1.88476313e-02\n",
      " -1.44463154e-02  1.54894637e-02  2.89910901e-02 -1.31518707e-01\n",
      "  2.14487109e-02 -2.88340747e-02 -2.95150522e-02 -4.65547442e-02\n",
      " -1.54500939e-02  1.24013700e-01  1.09433211e-01  4.62636352e-02\n",
      "  4.23713885e-02 -1.23258252e-02 -2.99533382e-02  3.81512456e-02\n",
      "  3.16715450e-03 -3.14146951e-02 -1.89234763e-02 -2.20976993e-02\n",
      " -2.07271241e-02 -1.20526571e-02 -9.80346557e-03 -2.79675424e-02\n",
      "  2.28399169e-02  1.71222966e-02  8.59399512e-03  2.80325324e-03\n",
      " -1.35173637e-03 -3.63583416e-02 -9.39921662e-03 -1.85964070e-02\n",
      " -4.00974676e-02  5.22999913e-02 -8.10100138e-02 -1.47647960e-02\n",
      " -3.93798649e-02 -3.35375406e-02  4.06395867e-02  8.97642504e-03\n",
      " -2.16666199e-02 -3.90349552e-02  1.56783797e-02  4.90158573e-02\n",
      "  1.02829309e-02 -1.40258279e-02 -7.82714263e-02 -4.19594347e-02\n",
      "  4.97719599e-03 -1.97147951e-02 -1.22225406e-02 -2.03673821e-02\n",
      " -3.36222798e-02  5.23180962e-02  6.24341541e-04  1.15819946e-02\n",
      "  2.02652976e-34  4.07035649e-02  2.52484679e-02  4.51186001e-02\n",
      "  6.06567785e-02  3.35382298e-02 -5.01598492e-02  1.34424064e-02\n",
      "  1.49852792e-02  1.83794945e-02 -7.26791844e-02 -3.15447412e-02]\n",
      "\n",
      "Sentence: Sentences can be embeedded on by one or in a lost\n",
      "Embedding: [ 6.53346926e-02  1.34846438e-02 -1.23828100e-02  5.49484976e-03\n",
      " -7.76961595e-02  4.54625487e-03 -2.75814964e-04 -2.55513645e-04\n",
      " -3.36746760e-02 -1.69810071e-03  9.99134779e-02 -2.79720239e-02\n",
      "  6.06727339e-02 -5.72197698e-02  2.03068219e-02 -6.11278713e-02\n",
      "  2.02645771e-02  1.64150354e-02 -4.57718335e-02  1.20298704e-02\n",
      " -1.73516292e-02  5.30331358e-02 -2.40588747e-03  5.00045530e-02\n",
      "  2.28756946e-02 -1.87871419e-02 -3.52982134e-02  3.16132535e-03\n",
      " -2.10266989e-02  6.43045967e-03  3.67804877e-02  3.05798347e-03\n",
      " -2.72581223e-02 -6.75487816e-02  2.01595208e-06  1.64004806e-02\n",
      " -3.47633511e-02 -5.11025377e-02 -2.85023451e-02  1.52979260e-02\n",
      "  4.01272147e-04  2.80468017e-02  4.70044948e-02  1.12442877e-02\n",
      " -1.24816298e-02  1.16284601e-02  5.23391739e-02  3.62378880e-02\n",
      "  1.88269019e-02  4.51694950e-02 -6.39879471e-03 -4.46840934e-02\n",
      " -5.42165898e-03 -3.44588794e-02  4.10798080e-02 -1.18068028e-02\n",
      "  6.34193607e-03 -4.35347892e-02  6.19732309e-03  5.34540601e-03\n",
      " -7.54803978e-03  4.37417403e-02 -1.06550064e-02 -2.29249466e-02\n",
      "  1.43970009e-02 -1.33356871e-02 -2.71972939e-02 -1.12267947e-02\n",
      " -2.29366366e-02 -6.36670785e-03  1.42609421e-02  2.82337032e-02\n",
      "  1.60896629e-02  4.44564503e-03 -2.32552062e-03  6.65895129e-03\n",
      " -8.97821039e-03  3.58325318e-02 -3.24929096e-02  2.18878444e-02\n",
      " -4.90191020e-03  2.18004640e-03 -8.90984107e-03  8.29173438e-03\n",
      "  8.29284918e-03  2.10649315e-02  3.22966985e-02  2.04381980e-02\n",
      " -4.87034842e-02 -1.50113460e-03 -6.72888681e-02 -1.58078950e-02\n",
      " -1.34238480e-02 -1.92871429e-02 -1.19967537e-03 -2.10535945e-03\n",
      " -4.19632643e-02 -5.51796891e-02 -6.09254092e-03 -5.42461574e-02\n",
      "  3.21712866e-02 -3.79169895e-03 -3.88355218e-02  1.62414853e-02\n",
      "  5.03156334e-03 -1.74707770e-02  1.76266078e-02 -1.16005680e-02\n",
      " -8.38303491e-02  1.69080291e-02 -2.01535132e-02 -4.52385470e-02\n",
      " -8.73252377e-02  8.28212872e-02 -8.89235362e-03 -4.12955396e-02\n",
      " -6.06545322e-02 -3.07094306e-02  6.79448023e-02 -1.59725714e-02\n",
      " -8.48129988e-02 -1.52924957e-04 -3.24230194e-02  1.10080047e-02\n",
      "  4.41663042e-02 -5.16659766e-03 -4.62864991e-04  5.73855229e-02\n",
      "  3.18209045e-02 -6.50203303e-02 -1.83800757e-02  9.72134434e-03\n",
      "  5.06859198e-02 -1.09188333e-02 -1.15864454e-02  4.39351331e-03\n",
      "  1.24636954e-02 -6.70198724e-03 -4.32961658e-02 -2.34660096e-02\n",
      " -3.24346013e-02 -1.30431959e-02 -3.83932777e-02 -2.42142230e-02\n",
      " -3.39214131e-02  7.95649830e-03  3.87049317e-02 -6.08554780e-02\n",
      "  1.99398119e-02  2.40699835e-02  1.92420685e-03  5.26232980e-02\n",
      "  1.28083741e-02 -5.41757606e-03 -1.14741372e-02 -4.43864817e-04\n",
      "  8.49099606e-02  4.33264636e-02  7.69040640e-03  1.01036411e-02\n",
      "  2.76409220e-02  2.94903424e-02 -1.07347313e-02 -8.31548183e-04\n",
      " -1.60249658e-02 -7.24586751e-03 -4.69780574e-03 -1.19480770e-02\n",
      "  3.57543640e-02  1.74490474e-02 -1.61712114e-02  4.00457606e-02\n",
      " -3.76845188e-02  1.05493777e-01  3.64143178e-02  6.17555045e-02\n",
      "  1.47664789e-02 -3.30679938e-02 -3.72030027e-02 -2.70022871e-03\n",
      " -2.24253442e-03  5.73650263e-02  8.92936159e-03 -1.65748019e-02\n",
      "  4.21948843e-02  8.05932749e-03  7.23758265e-02 -1.84319969e-02\n",
      " -3.16551775e-02 -3.32632139e-02 -5.14773130e-02  4.81949933e-02\n",
      " -1.14939222e-02 -4.35839221e-02 -1.50930360e-02  1.82139676e-03\n",
      " -1.90985855e-02  6.65893685e-03  1.17011750e-02 -7.00105131e-02\n",
      " -1.15179922e-03  1.69869345e-02 -3.90133969e-02  1.09209036e-02\n",
      "  5.20331180e-03  3.45475301e-02 -6.82056881e-04 -4.90121059e-02\n",
      "  6.59796894e-02  4.31949235e-02 -4.59314557e-03  3.72201093e-02\n",
      "  4.87701446e-02 -1.18295727e-02  2.99171358e-02 -3.71316355e-03\n",
      "  3.74215730e-02 -3.75810191e-02 -1.00449204e-01  5.05549014e-02\n",
      " -3.26249488e-02  7.36014545e-03  3.30391824e-02  2.13059057e-02\n",
      "  6.23847172e-02 -2.08257399e-02 -4.55249771e-02  7.93347787e-03\n",
      " -2.68934830e-03 -2.60152761e-02 -4.90027154e-03  3.71408649e-02\n",
      "  1.51394308e-03 -1.04779135e-02 -1.03499398e-01 -4.02742153e-04\n",
      " -4.37743329e-02 -7.64013454e-02 -2.52435822e-02 -8.98764804e-02\n",
      " -3.85349174e-03 -3.47300544e-02  2.64924802e-02 -5.15946560e-03\n",
      " -5.01990020e-02 -8.48377198e-02  1.04386337e-01 -7.60095101e-03\n",
      "  3.69149968e-02 -2.44262163e-02 -4.72880760e-03 -4.78054583e-03\n",
      " -2.89607272e-02 -2.88710687e-02  5.77904023e-02 -6.20432757e-02\n",
      " -7.69251734e-02  5.47505580e-02  6.47750404e-03  1.10222800e-02\n",
      " -1.52533762e-02 -6.57982798e-03  4.93906299e-03  1.67393722e-02\n",
      "  8.15764442e-03 -1.00907823e-02 -3.36963125e-02 -2.13015135e-02\n",
      " -2.59035658e-02 -1.37003069e-03  1.14852386e-02 -9.43424273e-03\n",
      "  4.43792343e-02  1.83932978e-04  1.36136962e-02  7.97820464e-03\n",
      " -3.11907344e-02  1.29394662e-02  2.05121450e-02  4.56907712e-02\n",
      "  1.11112697e-03 -4.28575873e-02 -1.68115702e-02  6.84094429e-03\n",
      " -1.09174047e-02  1.62134971e-02 -1.81789733e-02 -4.52449434e-02\n",
      " -7.10894838e-02  1.20733855e-02  2.28709541e-02 -1.20452633e-02\n",
      "  2.27397792e-02 -5.44570833e-02  2.39494238e-02 -4.56745923e-03\n",
      "  1.02275051e-01  2.41213907e-02 -1.19158616e-02  1.06103674e-01\n",
      " -8.08951538e-03 -2.24534310e-02  1.11177675e-02 -4.31467816e-02\n",
      "  1.34041614e-03 -3.17812376e-02 -2.35571284e-02  1.46071473e-02\n",
      " -4.39984091e-02  1.59079209e-02  6.95499778e-02  1.34809855e-02\n",
      " -1.62645914e-02  6.69167414e-02 -1.53685873e-02  5.51739288e-03\n",
      " -8.38694870e-02 -6.51564673e-02 -7.57943140e-03  1.07148634e-02\n",
      "  6.45703287e-04 -1.97144654e-02  3.06152012e-02  2.85724252e-02\n",
      " -2.96526253e-02 -2.35295203e-02  9.24727134e-03  3.93106826e-02\n",
      "  7.07942471e-02 -4.69343029e-02  2.69276127e-02  3.33776064e-02\n",
      " -5.74008934e-02 -2.24628299e-02 -1.86129417e-02  7.41343349e-02\n",
      "  8.76246765e-03 -2.52409223e-02 -1.97105445e-02  2.55987328e-02\n",
      "  1.66701376e-02 -2.12324746e-02  2.13593747e-02 -6.94178119e-02\n",
      " -2.63860617e-02  2.02717725e-02  2.40454059e-02  3.66527177e-02\n",
      " -8.11543763e-02 -2.69247293e-02 -3.90644483e-02 -2.55767480e-02\n",
      " -4.83106310e-03 -3.06305531e-02 -2.98471339e-02  1.30730839e-02\n",
      "  5.53114042e-02 -4.48722057e-02 -3.94727811e-02 -8.85887146e-02\n",
      "  4.36557606e-02  7.45522454e-02 -3.96989733e-02  2.06559245e-02\n",
      "  2.91357487e-02  7.10216537e-03  5.15210703e-02 -2.97021940e-02\n",
      " -4.37400639e-02 -1.99749824e-02  5.57907522e-02 -2.95753833e-02\n",
      " -2.70345109e-03  3.20032947e-02 -2.39901859e-02  1.04818596e-02\n",
      "  3.05749923e-02 -6.20010607e-02  1.22066913e-02 -5.90188801e-03\n",
      "  4.02612425e-03 -3.20611000e-02 -9.38345399e-03  1.47865517e-02\n",
      " -1.68785285e-02  8.56864266e-03  1.98612399e-02 -3.66612636e-02\n",
      " -7.47138858e-02  7.84703642e-02  3.69416736e-02  3.24455872e-02\n",
      " -5.77946492e-02 -2.32109744e-02 -2.07851976e-02  5.09499647e-02\n",
      " -7.37154623e-04  4.13903669e-02 -4.18699905e-03  2.09378023e-02\n",
      "  2.61419825e-02  8.30847099e-02  4.89751138e-02 -7.72541538e-02\n",
      " -2.00580675e-02  4.16455604e-02 -1.66005343e-02  2.50205118e-02\n",
      " -2.84976903e-02 -5.06837629e-02 -1.43440319e-02 -5.08176954e-03\n",
      " -4.21701279e-03  2.42090356e-02  3.75290774e-02  1.98649280e-02\n",
      " -1.93881802e-02 -3.09815276e-02  8.50027427e-04 -1.12590883e-02\n",
      " -1.67070553e-02  3.26536298e-02  2.94289589e-02 -4.63019423e-02\n",
      " -4.89947060e-03 -2.76446790e-02 -9.43060219e-03  2.21966039e-02\n",
      " -5.51456772e-03  1.40251992e-02 -2.95841396e-02 -3.39327715e-02\n",
      " -1.14977947e-02  5.88350929e-03 -1.76907610e-02 -2.30355766e-02\n",
      " -1.66274235e-02 -1.22728907e-02  1.75569337e-02 -7.10405335e-02\n",
      " -1.82228647e-02 -2.05856096e-02  1.39334410e-01  2.40283236e-02\n",
      "  4.89458926e-02 -3.58219235e-03  3.49573581e-03  4.76993844e-02\n",
      " -2.36322414e-02  1.37624154e-02  1.35022970e-02 -2.62479093e-02\n",
      "  2.04518065e-02  1.00736506e-02 -3.68745765e-03 -1.92734115e-02\n",
      " -6.90971762e-02 -7.43886083e-02 -2.69727800e-02  4.74732406e-02\n",
      " -7.66675163e-04  4.12309915e-02 -3.72735821e-02  8.02645646e-03\n",
      " -2.48918012e-02  6.90753432e-03 -7.95762241e-03 -2.38242596e-02\n",
      "  4.33866307e-02  2.98836194e-02 -4.50271089e-03  7.47871678e-03\n",
      "  3.75967734e-02  9.93943494e-03  3.54239568e-02  8.85647722e-03\n",
      " -1.07185682e-02 -1.57686174e-02 -7.70560354e-02  1.58977211e-02\n",
      "  2.68970616e-02  3.96398231e-02 -2.05925815e-02 -2.67656744e-02\n",
      " -3.51756588e-02  3.75366700e-03  1.58818942e-02 -3.78303565e-02\n",
      " -1.55439200e-02  4.66054939e-02 -2.02842969e-02  1.77157596e-02\n",
      " -2.43076161e-02  2.68635945e-03 -8.71594716e-03 -1.64059568e-02\n",
      " -3.61950463e-03  9.86964256e-03  3.24530825e-02 -3.53400521e-02\n",
      " -6.74874149e-03  3.82543392e-02  5.30812144e-03  7.65119120e-02\n",
      " -4.92954552e-02  2.38875225e-02 -2.72688060e-03 -1.36071527e-02\n",
      "  3.25053409e-02 -2.45515611e-02 -6.31635636e-02 -8.18673987e-04\n",
      " -3.18495221e-02 -1.97580438e-02  1.35007908e-03  4.47509438e-03\n",
      "  4.78079319e-02 -3.99466231e-02  2.78388914e-02  2.44063302e-03\n",
      "  5.33951400e-03  7.96792284e-03  5.11851311e-02  6.88225217e-03\n",
      " -8.61685537e-03  1.67645924e-02 -1.67612396e-02 -1.03314752e-02\n",
      "  1.36523359e-02  2.60582939e-02 -6.27878234e-02  2.47436371e-02\n",
      "  1.16577540e-02  2.16564741e-02 -3.09920497e-02  1.48408189e-02\n",
      "  2.94965524e-02  1.45247253e-02  2.80524790e-02  3.41434926e-02\n",
      "  3.37322801e-02 -1.93633977e-02  1.02895178e-01 -2.92372773e-03\n",
      "  5.10978373e-03  1.45269269e-02  2.88330168e-02  3.93327102e-02\n",
      "  3.42088342e-02 -4.62287813e-02 -6.02966994e-02  4.05471995e-02\n",
      " -5.48967384e-02  2.06187684e-02  3.15159000e-02 -6.61551396e-33\n",
      " -3.11311949e-02 -3.75434943e-03 -4.38990742e-02  3.82234566e-02\n",
      " -4.17073071e-02 -5.27840480e-02 -1.94395054e-02  9.90784019e-02\n",
      "  2.07508374e-02  5.44748344e-02 -2.65066419e-02  5.27189337e-02\n",
      "  2.59078220e-02  6.58414187e-03  9.58168730e-02 -9.92060639e-03\n",
      "  1.17473928e-02  3.81831378e-02 -3.23625989e-02 -4.00503241e-02\n",
      "  2.05302984e-02 -2.05143495e-03  6.50184527e-02  1.25775468e-02\n",
      "  3.35916169e-02 -3.37437764e-02 -5.46083786e-02  2.54147276e-02\n",
      " -1.15700858e-02 -3.69806364e-02 -9.83829610e-04  3.95897254e-02\n",
      " -2.06695590e-02  2.03535911e-02 -1.69778895e-02  3.34242508e-02\n",
      "  5.23392558e-02 -6.65731877e-02  2.95767952e-02 -7.91237748e-04\n",
      " -4.41697724e-02 -8.34101215e-02  1.88039839e-02 -1.05479555e-02\n",
      "  3.71760279e-02 -1.15841543e-02  3.36023271e-02  1.07220653e-02\n",
      "  8.97989329e-03  5.73393479e-02 -1.83300916e-02 -5.24147414e-03\n",
      " -2.02221107e-02 -4.07940894e-02 -1.36348074e-02  2.82017905e-02\n",
      " -9.87960398e-03 -1.92400180e-02 -6.22938238e-02  3.54319103e-02\n",
      " -3.41798924e-02  7.47458339e-02 -3.31990570e-02 -6.54024407e-02\n",
      " -4.35594954e-02  7.08827227e-02  1.17712626e-02 -1.65766980e-02\n",
      " -3.00840344e-02  2.40295921e-02 -1.80959199e-02  6.98261112e-02\n",
      "  1.39838988e-02  3.46406624e-02 -6.37088297e-03 -6.41408488e-02\n",
      " -3.74333858e-02  3.42172151e-03  5.22984713e-02 -1.43255712e-02\n",
      "  3.24882716e-02  3.80858444e-02 -2.70623192e-02 -3.93412970e-02\n",
      " -3.53501476e-02 -5.78950942e-02  4.89380490e-03  1.30529506e-02\n",
      "  7.70993205e-03 -6.99946284e-03  4.11913358e-03 -2.72491407e-02\n",
      "  1.15242545e-02  3.12081371e-02 -4.12799269e-02 -5.81133589e-02\n",
      " -4.13426151e-03  1.14363525e-02 -2.89083831e-03  3.42345983e-02\n",
      " -1.06739775e-04 -1.38290003e-02 -1.16799045e-02  6.11081794e-02\n",
      "  2.95428075e-02  2.97634136e-02  1.58291366e-02 -1.14937527e-02\n",
      " -1.19391963e-01 -1.09164938e-02 -2.14069709e-03 -6.31358624e-02\n",
      " -2.27007866e-02 -4.07326072e-02 -1.18335243e-02 -1.09512862e-02\n",
      " -1.77771375e-02  4.68782000e-02 -4.43509705e-02 -2.49138679e-02\n",
      " -2.79974341e-02 -1.16013503e-02  1.21258758e-03  1.99814551e-02\n",
      " -1.79586206e-02  7.83388317e-03 -1.27507783e-02  3.84962037e-02\n",
      "  2.49630958e-02 -2.95631797e-03 -4.98060090e-03  7.61911360e-05\n",
      "  2.68317848e-07  7.06368387e-02 -1.37990760e-02  2.91091353e-02\n",
      "  2.33443249e-02 -1.04143973e-02  9.80504416e-03 -1.04229897e-02\n",
      "  1.71097666e-02 -4.98635396e-02  2.46998761e-03  1.66787654e-02\n",
      " -1.08785164e-02  2.41296161e-02 -1.71322487e-02 -3.13616358e-02\n",
      "  7.30215162e-02 -1.26253394e-03  4.50513186e-03 -1.04106022e-02\n",
      " -3.06997988e-02  8.13144669e-02  8.16343538e-03  4.63980660e-02\n",
      "  2.79299673e-02 -1.94988493e-02 -1.33059165e-02 -1.93172265e-02\n",
      "  3.37517783e-02 -1.22076683e-02  5.10637835e-03  1.49663892e-02\n",
      "  3.51913758e-02 -3.38504766e-03  2.14193128e-02 -2.30247108e-03\n",
      " -1.58199221e-02  1.11809880e-01  5.70242628e-02 -2.92370897e-02\n",
      "  7.62606189e-02 -3.59567292e-02  3.54555412e-03 -6.53618574e-02\n",
      "  1.26569746e-02  2.15363540e-02 -5.24462610e-02 -2.43243631e-02\n",
      "  2.37028934e-02  7.10775657e-03  4.21609469e-02  5.12063131e-02\n",
      "  4.50734049e-02 -2.08432581e-02 -3.13646756e-02  9.71613172e-03\n",
      " -1.78592261e-02 -3.20728449e-03 -1.14321141e-02 -1.19987130e-02\n",
      "  4.51047346e-02  8.19463097e-03 -1.50956912e-02  2.46165739e-03\n",
      "  4.60810550e-02  1.72082856e-02 -5.46289273e-02 -5.75303845e-02\n",
      "  1.79715695e-34  6.32123351e-02 -4.22458015e-02  1.62727926e-02\n",
      "  9.75573957e-02 -8.83478858e-03 -4.37781774e-02  3.73172909e-02\n",
      " -2.01579323e-03  4.78681456e-03 -2.77309399e-02 -1.80873778e-02]\n",
      "\n",
      "Sentence: I like horses!\n",
      "Embedding: [-2.67144553e-02  1.31017953e-01 -3.86219397e-02  8.03857762e-03\n",
      "  2.97368690e-02  4.18423526e-02 -2.23039389e-02  2.32260749e-02\n",
      "  4.10415418e-02 -2.95187850e-02 -3.46263908e-02 -1.83776096e-02\n",
      " -4.16668765e-02 -3.50136682e-02 -2.38867779e-03 -3.45176533e-02\n",
      "  3.66863608e-02 -9.95051768e-03 -1.36514157e-02  3.32558267e-02\n",
      "  2.50876807e-02  4.92446348e-02 -4.98318970e-02 -3.70693356e-02\n",
      " -8.86958558e-03  1.86221469e-02 -3.02469656e-02 -8.31605271e-02\n",
      "  4.80911732e-02  5.41727208e-02 -4.70784605e-02 -3.58009674e-02\n",
      "  2.20623910e-02 -5.00787189e-03  1.42282158e-06 -1.15013402e-03\n",
      " -5.59793934e-02  3.81627604e-02  1.37144299e-02  2.09261160e-02\n",
      "  1.77285820e-02 -4.40464877e-02 -1.82883460e-02 -3.46980169e-02\n",
      "  1.40275108e-02  6.92681922e-03  3.91350314e-02  1.17347622e-02\n",
      " -8.34458228e-03  2.72799078e-02 -6.54870644e-03  1.99990999e-02\n",
      " -6.94846064e-02  3.48816789e-03  2.37389132e-02  3.51725556e-02\n",
      "  1.91240720e-02 -5.14322557e-02  2.78950538e-02  7.01133220e-04\n",
      " -1.24892010e-03 -7.77337924e-02  5.04701165e-03  7.82279018e-03\n",
      "  1.70377195e-02 -2.29361365e-04 -2.19660532e-02 -6.28656475e-03\n",
      "  8.83765798e-03  1.61731597e-02  4.74317046e-03  1.63856596e-02\n",
      "  1.98698584e-02  2.87377834e-02 -1.13958130e-02  1.21814059e-02\n",
      " -3.25761712e-03  7.47990385e-02  2.07088399e-03  2.13710894e-03\n",
      "  2.36543384e-03  6.81824284e-03  1.78420115e-02 -6.76717330e-03\n",
      " -1.13652460e-02  3.47163491e-02  3.99641618e-02  6.02481130e-04\n",
      "  2.50220317e-02  3.51954699e-02 -3.58677320e-02 -1.77029185e-02\n",
      "  4.12770770e-02  4.19989452e-02 -4.30353396e-02 -3.04895602e-02\n",
      "  1.79912057e-02  3.39752324e-02  5.67291677e-02 -3.72519121e-02\n",
      "  7.71261659e-03  2.32814699e-02 -3.23418565e-02 -2.01844312e-02\n",
      " -2.13816576e-02 -2.77470984e-02  1.32658659e-02 -3.97538655e-02\n",
      "  6.59546331e-02 -1.38212405e-02 -9.20054037e-03  8.39999784e-03\n",
      "  2.81347148e-02  4.15299982e-02 -5.64223155e-03 -4.35979478e-03\n",
      "  1.77122168e-02  2.02861018e-02 -1.31513048e-02  1.41240377e-02\n",
      " -4.01487052e-02 -6.16061017e-02  3.30247842e-02  4.27827202e-02\n",
      " -3.56697738e-02  8.99661332e-03 -4.70690802e-02  3.80768813e-02\n",
      " -4.82298359e-02 -4.26932089e-02 -7.96992891e-03  5.02463756e-03\n",
      "  2.38699168e-02 -4.13715951e-02  3.72231305e-02  5.26337288e-02\n",
      " -1.24458782e-02  5.02834620e-04  1.85009632e-02 -1.01251025e-02\n",
      "  3.01014353e-02  7.05216313e-03 -3.35082710e-02  7.10088480e-03\n",
      "  1.53239900e-02  9.82497726e-03  2.05332600e-02  1.51320617e-03\n",
      " -9.56339296e-03  3.18279602e-02  7.05032796e-03  2.75495164e-02\n",
      " -8.35546404e-02  7.22261961e-04 -3.07107195e-02 -2.28449097e-03\n",
      " -3.29813473e-02 -1.86590720e-02  2.09018365e-02  4.57936898e-02\n",
      "  5.31819910e-02  6.56175846e-03 -1.76374300e-03 -2.55267676e-02\n",
      " -3.00172400e-02 -6.81450218e-02  2.76180860e-02 -1.68421715e-02\n",
      "  2.72241086e-02 -3.77175920e-02  3.64565402e-02 -2.31930576e-02\n",
      " -3.39562111e-02 -2.45280154e-02  6.90310076e-02 -7.11452775e-03\n",
      "  9.94261801e-02  3.98893654e-02  2.19163075e-02 -4.04605009e-02\n",
      "  3.13975513e-02 -6.93094581e-02  3.09213717e-02  1.91144999e-02\n",
      "  4.83726598e-02  1.97971817e-02  3.27672735e-02  4.79416102e-02\n",
      " -2.59468937e-03  5.95346000e-03  1.48088802e-02 -1.33875543e-02\n",
      " -1.18511301e-02  1.80749185e-02 -2.51697353e-03  2.23802291e-02\n",
      "  2.03120969e-02 -5.51623888e-02  5.08649014e-02 -1.74926966e-02\n",
      "  1.03711113e-02  5.48303835e-02 -4.66479221e-03  4.06192429e-02\n",
      "  1.64949186e-02 -1.50219549e-03 -3.87123115e-02 -4.08393191e-03\n",
      "  2.24078335e-02 -2.66852751e-02  7.18928576e-02 -1.56481061e-02\n",
      "  2.15382148e-02 -3.24763544e-03  4.30514887e-02  5.54415733e-02\n",
      "  1.54590132e-02 -2.34077889e-02 -4.02784906e-02  1.09013185e-01\n",
      " -3.61077599e-02 -3.90353869e-03  9.66882110e-02  3.55334245e-02\n",
      " -2.49859784e-02  4.56151552e-02  1.12770777e-02  3.19718868e-02\n",
      " -8.21712241e-03 -1.45097235e-02 -1.38146905e-02  2.27995007e-03\n",
      "  5.81482835e-02 -1.65187637e-03  3.89424362e-03 -3.25091137e-03\n",
      "  4.48074266e-02  4.96553145e-02 -1.68224704e-02 -4.11297791e-02\n",
      " -1.91904104e-03 -9.49495006e-03  5.89223346e-03  4.09448184e-02\n",
      "  1.46514166e-03 -5.32164760e-02 -2.95555070e-02  1.46509223e-02\n",
      " -3.67850214e-02  1.48291560e-02 -5.90046830e-02 -2.52038483e-02\n",
      " -5.49021401e-02  2.71408688e-02 -2.80362810e-03 -3.59128825e-02\n",
      " -3.64186279e-02 -1.44418050e-02  1.95452981e-02 -6.66407794e-02\n",
      "  9.53727439e-02 -9.99760348e-03 -2.48823818e-02  6.06881566e-02\n",
      " -4.30383608e-02  4.59874459e-02  1.21795386e-02 -4.70494591e-02\n",
      " -1.12133659e-02  4.05426277e-03 -1.83669068e-02 -2.00734306e-02\n",
      "  8.09294451e-03  5.61419781e-03  2.90125026e-03 -4.12397692e-03\n",
      " -2.45109294e-02 -6.07830398e-02  3.15642804e-02  3.81212048e-02\n",
      " -2.57495064e-02 -9.00125131e-03  3.79892811e-02  3.19090709e-02\n",
      " -1.12440437e-02  1.84567459e-02 -1.08609805e-02  2.46243291e-02\n",
      "  2.10186001e-02 -5.99229857e-02 -1.32948188e-02  1.88184492e-02\n",
      " -9.76739824e-03  9.56679229e-03  2.00247020e-02 -2.43597161e-02\n",
      " -7.47997761e-02 -5.50076663e-02  2.16926215e-03 -1.73597205e-02\n",
      " -1.04215108e-02  2.91755013e-02  2.50065140e-02  2.84176059e-02\n",
      "  3.87750044e-02  1.19252205e-02  3.72133479e-02  3.90469693e-02\n",
      " -1.65001154e-02  6.95834085e-02 -1.63944121e-02 -7.37079009e-02\n",
      " -3.43169086e-02  2.05580937e-03  9.86350849e-02  5.81433252e-02\n",
      " -2.93991771e-02 -3.82711403e-02  3.70078944e-02  4.88188080e-02\n",
      " -1.09365433e-02  2.00260505e-02  3.07365917e-02  3.93032655e-02\n",
      " -5.45122065e-02  9.67301242e-03  3.63564305e-02 -8.13302491e-03\n",
      "  3.40572074e-02 -2.40374319e-02  1.62689742e-02 -6.15116302e-03\n",
      "  6.18251562e-02  1.78102031e-02  2.62790900e-02 -4.31745313e-02\n",
      "  2.31975205e-02  4.30519804e-02 -1.22824982e-02  2.35075993e-03\n",
      "  1.26593336e-02 -2.33552996e-02 -5.29602543e-02 -4.72016409e-02\n",
      " -4.13431972e-02 -3.42140384e-02 -6.31478056e-02 -5.49499281e-02\n",
      " -4.36869729e-03 -3.53800617e-02 -1.97227653e-02 -7.51122553e-03\n",
      "  2.12547882e-03  4.76517603e-02  1.09922616e-02  3.04179173e-02\n",
      "  1.46337878e-02  3.07518095e-02 -1.45270266e-02 -1.70470737e-02\n",
      "  3.67471762e-02  4.42354605e-02  3.12824808e-02 -2.07042471e-02\n",
      " -3.52868475e-02 -2.42242180e-02  1.73001941e-02 -5.09645827e-02\n",
      " -5.22649959e-02 -6.42454671e-03 -2.20864303e-02 -2.42288839e-02\n",
      " -1.85502600e-02  2.09545903e-02 -2.66731381e-02  7.72047117e-02\n",
      "  3.55064943e-02  4.87249270e-02  6.55237660e-02 -1.83372926e-02\n",
      "  4.43752408e-02 -1.96081810e-02 -4.16709995e-03  1.72038507e-02\n",
      " -7.87352547e-02  1.13609973e-02  3.29830758e-02 -3.34833674e-02\n",
      " -5.91834225e-02 -5.16826753e-03  3.64363380e-02  5.87293785e-03\n",
      " -6.47325665e-02 -6.63173571e-02  2.19204556e-02 -1.38641652e-02\n",
      " -7.08775148e-02  3.66111994e-02  1.24158673e-02  1.85580403e-02\n",
      " -9.74492822e-03  7.25327581e-02  3.39582078e-02 -3.37732062e-02\n",
      " -1.80621538e-02  1.93781052e-02  2.81449445e-02  5.28941723e-03\n",
      "  4.20942381e-02 -1.23083323e-01 -7.94750676e-02  9.75957699e-03\n",
      " -2.79009454e-02  1.05112037e-02  3.45770782e-03 -1.75462998e-02\n",
      "  1.61945187e-02 -3.45510691e-02  4.52589616e-03 -2.37183063e-03\n",
      " -1.51141342e-02 -2.47375350e-02 -1.73723586e-02 -2.17887294e-02\n",
      " -3.81727591e-02 -2.62229126e-02  5.28297722e-02  4.99212779e-02\n",
      " -7.42873084e-03 -9.25541855e-04 -3.52285579e-02  7.01325526e-03\n",
      "  2.04047635e-02 -2.87854616e-02 -6.26717657e-02 -3.56784761e-02\n",
      " -9.65089723e-03  3.77316214e-02 -2.32007354e-02 -5.49367703e-02\n",
      " -4.15531695e-02  4.60585579e-02 -2.85465848e-02 -1.02311978e-02\n",
      "  4.15115282e-02  4.87313755e-02 -5.12896627e-02 -2.63645463e-02\n",
      "  4.78796810e-02  4.24948754e-03 -1.24509810e-02  1.37372212e-02\n",
      " -2.45817285e-02  3.30335349e-02 -3.50701925e-03 -5.78271085e-03\n",
      "  5.48207993e-03 -7.99308196e-02  1.17996689e-02  2.62448732e-02\n",
      "  7.02878386e-02  3.68168927e-03 -2.48584803e-02  1.60750598e-02\n",
      "  9.65151819e-04  1.82267223e-02  9.39316396e-03 -2.96558645e-02\n",
      "  3.92307900e-03 -5.14190905e-02 -1.69606209e-02 -1.98428910e-02\n",
      " -3.49024311e-03  3.12085394e-02  3.27818170e-02  5.27704209e-02\n",
      "  4.46241209e-03  1.18340831e-02  2.50518750e-02 -4.76561785e-02\n",
      " -7.44547695e-02  5.99202290e-02 -5.69956470e-03 -1.62264938e-03\n",
      " -1.20001531e-03 -3.23642828e-02  3.44792125e-03 -2.37544365e-02\n",
      "  4.43043001e-03 -3.08272950e-02 -3.59355249e-02  4.43712622e-03\n",
      " -4.75262851e-02 -8.31952393e-02  4.26743738e-03  6.36712536e-02\n",
      "  2.90642250e-02 -6.99088350e-02  1.03362007e-02  1.88462250e-02\n",
      " -3.32860835e-02  3.96924876e-02 -9.97589435e-03  6.79316148e-02\n",
      "  2.69873664e-02 -3.28907673e-03 -1.17855035e-02  3.25969129e-04\n",
      " -1.81754529e-02 -2.56632431e-03  1.76420901e-02 -7.90651701e-03\n",
      " -4.59221117e-02 -1.44925807e-02  7.05569237e-02  7.63443857e-02\n",
      " -2.13224683e-02 -7.01023415e-02 -2.44030021e-02 -4.42189611e-02\n",
      " -1.92245319e-02 -3.43546341e-03 -5.37867751e-03  1.60381347e-02\n",
      "  4.31604916e-03  2.63602696e-02  9.25268140e-03 -5.00051603e-02\n",
      " -2.23820824e-02  2.37112232e-02 -3.18208523e-02  1.91108976e-03\n",
      "  2.22122837e-02 -2.86415406e-02 -3.01541239e-02  4.24447991e-02\n",
      "  3.16200480e-02 -4.11088904e-03 -1.94385368e-02  4.66424637e-02\n",
      " -2.17027348e-02 -2.05979799e-03  2.94458531e-02 -8.11043382e-02\n",
      " -3.00531108e-02  8.84201564e-03  5.94104528e-02 -4.32767197e-02\n",
      " -3.30853201e-02 -3.78850512e-02 -7.49538234e-03 -2.94030830e-02\n",
      " -2.78828647e-02 -6.97876513e-02 -1.04949586e-01 -6.08098693e-33\n",
      " -5.51380776e-02  5.61126135e-03 -2.12247726e-02 -1.64441243e-02\n",
      " -1.91945732e-02 -6.31383732e-02  7.29616433e-02  5.43050878e-02\n",
      "  9.38582048e-03  5.87568693e-02 -4.03265916e-02 -1.17488978e-02\n",
      " -3.14356550e-03  3.06384452e-03  1.02370474e-02  9.91447270e-03\n",
      "  4.25155312e-02  1.35757653e-02 -1.42615545e-03 -1.04992837e-02\n",
      "  1.34479851e-02  1.84357651e-02  2.05373317e-02 -2.03614999e-02\n",
      "  5.92006594e-02  4.36169282e-02 -1.34567376e-02 -2.44422425e-02\n",
      "  1.97254214e-02  7.98829272e-02 -2.71733152e-03 -2.49470882e-02\n",
      " -5.54748951e-03 -5.11282571e-02 -1.14621650e-02  7.02912807e-02\n",
      " -3.59583311e-02  6.75164117e-03  7.97251612e-03  2.47955527e-02\n",
      "  8.60149860e-02 -6.06778152e-02  5.15737422e-02 -8.29937384e-02\n",
      " -6.10616896e-03  5.53290034e-03  3.96847278e-02  4.83613014e-02\n",
      "  5.62811047e-02  3.28994542e-02 -3.95440087e-02 -6.64222613e-02\n",
      " -6.01473683e-03 -2.22541876e-02  4.40150984e-02 -1.99889746e-02\n",
      "  4.15038541e-02  4.01954958e-03  6.46278076e-03 -7.56387040e-03\n",
      " -2.00565476e-02 -4.12345752e-02 -5.27454279e-02  1.99447833e-02\n",
      " -2.42805183e-02  9.00406837e-02 -1.36345578e-03 -2.23540682e-02\n",
      "  1.24887982e-03  2.67293602e-02 -4.62033674e-02 -4.11434751e-03\n",
      "  1.04217213e-02 -2.03547683e-02 -3.05199856e-03  2.12044213e-02\n",
      " -2.47737933e-02 -2.73369998e-02 -7.42391646e-02  2.22837124e-02\n",
      "  1.23512661e-02 -1.80122361e-03 -1.29682040e-02  2.24856846e-02\n",
      "  2.74916161e-02  4.72554453e-02  1.47988442e-02 -7.57993804e-03\n",
      " -6.21416122e-02 -1.62537023e-02  2.41619907e-02  1.02008460e-02\n",
      " -1.31030967e-02 -8.06464627e-03 -2.23883130e-02 -8.22521839e-03\n",
      " -2.31066477e-02 -4.72937711e-02 -9.15291160e-03 -8.02167226e-03\n",
      "  6.06632680e-02 -5.54486783e-03 -1.17455982e-02  1.09999832e-02\n",
      "  1.48121417e-02  7.78211653e-03  1.76356062e-02 -2.45958827e-02\n",
      " -6.22097589e-02  4.78604436e-02  4.24467697e-04  4.90715355e-02\n",
      "  4.79640290e-02  1.08700097e-01  4.72227819e-02 -2.13420223e-02\n",
      "  1.43254809e-02  5.01378179e-02 -5.37697859e-02 -6.70107361e-03\n",
      "  5.06177219e-03 -1.76747721e-02 -8.18694010e-02  1.33881660e-03\n",
      "  9.54762753e-03 -2.69555524e-02 -8.88636615e-03 -6.27400428e-02\n",
      " -3.88119556e-02 -2.61610113e-02  1.80817824e-02 -1.85252372e-02\n",
      "  2.16867434e-07 -3.05570774e-02 -1.17482934e-02  3.86133455e-02\n",
      "  3.74167338e-02  2.54942067e-02  5.64584360e-02 -1.09359222e-02\n",
      " -3.30965733e-03  1.25073530e-02  9.65327844e-02 -1.43617261e-02\n",
      "  3.24686654e-02  3.97202112e-02 -4.94118547e-03 -2.60986947e-03\n",
      " -6.81308508e-02 -1.66516211e-02 -2.99731903e-02  3.99056589e-03\n",
      " -8.14002845e-03 -9.24562141e-02 -2.10931301e-02 -1.69721972e-02\n",
      " -2.74126674e-03 -1.28149167e-02  2.96035912e-02 -6.09656272e-04\n",
      " -3.85000445e-02  4.86924546e-03  3.31277363e-02 -6.07115924e-02\n",
      "  3.97328585e-02 -2.65968889e-02  1.81749649e-02  2.81270444e-02\n",
      " -1.95649471e-02 -1.59012657e-02 -2.35991143e-02  1.40775442e-02\n",
      "  6.34064749e-02 -3.07723526e-02  1.13034442e-01 -2.16424130e-02\n",
      "  4.25004214e-02  8.88849236e-03  5.16530462e-02  1.31782715e-03\n",
      " -1.07091159e-01  4.95355166e-02 -1.30839292e-02 -2.18527783e-02\n",
      " -2.33551324e-03  2.22141910e-02 -8.58249608e-04  7.25459633e-03\n",
      " -2.40629888e-03  4.42729006e-03 -4.03266698e-02  8.73126369e-03\n",
      " -4.62856181e-02 -9.82047245e-03  7.88556505e-03 -5.59527613e-03\n",
      "  4.54911478e-02 -8.76699109e-03 -4.82472368e-02 -1.01598717e-01\n",
      "  1.12966327e-34  1.71271935e-02 -4.39228304e-02 -3.20055448e-02\n",
      "  2.03909520e-02  2.53922865e-02 -1.92606356e-02  5.61988577e-02\n",
      " -2.65362766e-02  6.99775591e-02  1.96202416e-02 -2.20129006e-02]\n",
      "\n"
     ]
    }
   ],
   "source": [
    "from sentence_transformers import SentenceTransformer\n",
    "embedding_model = SentenceTransformer(model_name_or_path=\"all-mpnet-base-v2\", device=\"cpu\")\n",
    "\n",
    "sentences = [\"The Sentence Transformer Library provides an easy way to create embeddings\", \"Sentences can be embeedded on by one or in a lost\", \"I like horses!\"] \n",
    "\n",
    "\n",
    "embeddings = embedding_model.encode(sentences)\n",
    "embeddings_dict = dict(zip(sentences, embeddings))\n",
    "\n",
    "for sentence, embedding in embeddings_dict.items():\n",
    "    print(f\"Sentence: {sentence}\")\n",
    "    print(f\"Embedding: {embedding}\")\n",
    "    print(\"\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "id": "5a8c6878",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "8179e9c84d8843768f83b518c93afc92",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "  0%|          | 0/144 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "CPU times: total: 2min 58s\n",
      "Wall time: 28.5 s\n"
     ]
    }
   ],
   "source": [
    "%%time\n",
    "\n",
    "\n",
    "# Extract the sentence chunks\n",
    "text_chunks = [item[\"sentence_chunk\"] for item in pages_and_chunks_over_min_token_len]\n",
    "\n",
    "# Generate embeddings on CPU\n",
    "for item in tqdm(pages_and_chunks_over_min_token_len):\n",
    "    item[\"embedding\"] = embedding_model.encode(item[\"sentence_chunk\"], device='cpu')\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "id": "9a1c5c28",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "CPU times: total: 5min 30s\n",
      "Wall time: 28.5 s\n"
     ]
    }
   ],
   "source": [
    "%%time \n",
    "text_chunks = [item[\"sentence_chunk\"] for item in pages_and_chunks_over_min_token_len]\n",
    "text_chunk_embeddings = embedding_model.encode(text_chunks, batch_size =32, convert_to_tensor=True )\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "id": "31b5c383",
   "metadata": {},
   "outputs": [],
   "source": [
    "## Save Embeddings \n",
    "text_chunks_and_embeddings_df = pd.DataFrame(pages_and_chunks_over_min_token_len)\n",
    "embeddings_df_save_path = \"text_chunk_and_embeddings_df.csv\"\n",
    "text_chunks_and_embeddings_df.to_csv(embeddings_df_save_path, index=False)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "id": "3584cf41",
   "metadata": {},
   "outputs": [],
   "source": [
    "text_chunks_and_embeddings_df_load = pd.read_csv(\"text_chunk_and_embeddings_df.csv\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 51,
   "id": "ba0314c6",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>page_number</th>\n",
       "      <th>sentence_chunk</th>\n",
       "      <th>chunk_char_count</th>\n",
       "      <th>chunk_word_count</th>\n",
       "      <th>chunk_token_count</th>\n",
       "      <th>embedding</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>-38</td>\n",
       "      <td>Guideline for the pharmacological treatment of...</td>\n",
       "      <td>1397</td>\n",
       "      <td>208</td>\n",
       "      <td>349.25</td>\n",
       "      <td>[0.0322975218, -0.0188721679, 0.014344709, -0....</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>-38</td>\n",
       "      <td>Suggested citation. Guideline for the pharmaco...</td>\n",
       "      <td>489</td>\n",
       "      <td>60</td>\n",
       "      <td>122.25</td>\n",
       "      <td>[0.0216960125, 0.00495383004, 0.00708221132, -...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>-38</td>\n",
       "      <td>If you wish to reuse material from this work t...</td>\n",
       "      <td>1447</td>\n",
       "      <td>238</td>\n",
       "      <td>361.75</td>\n",
       "      <td>[0.00337434001, -0.0488039851, -0.0180421919, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>-37</td>\n",
       "      <td>Contents Acknowledgements  v Acronyms and abbr...</td>\n",
       "      <td>1666</td>\n",
       "      <td>317</td>\n",
       "      <td>416.50</td>\n",
       "      <td>[0.0141956815, -0.00343135116, -0.0108614815, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>-36</td>\n",
       "      <td>GUIDELINE FOR THE PHARMACOLOGICAL TREATMENT OF...</td>\n",
       "      <td>477</td>\n",
       "      <td>84</td>\n",
       "      <td>119.25</td>\n",
       "      <td>[-0.01271402, -0.00567622669, 0.0340060741, -0...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>139</th>\n",
       "      <td>14</td>\n",
       "      <td>GUIDELINE FOR THE PHARMACOLOGICAL TREATMENT OF...</td>\n",
       "      <td>1893</td>\n",
       "      <td>276</td>\n",
       "      <td>473.25</td>\n",
       "      <td>[0.0176240001, 0.0242444444, 0.0281273257, 0.0...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>140</th>\n",
       "      <td>15</td>\n",
       "      <td>3  Should cardiovascular risk assessment be us...</td>\n",
       "      <td>2465</td>\n",
       "      <td>356</td>\n",
       "      <td>616.25</td>\n",
       "      <td>[-0.0361399166, 0.00163900817, 0.0244934186, -...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>141</th>\n",
       "      <td>16</td>\n",
       "      <td>GUIDELINE FOR THE PHARMACOLOGICAL TREATMENT OF...</td>\n",
       "      <td>2105</td>\n",
       "      <td>314</td>\n",
       "      <td>526.25</td>\n",
       "      <td>[-0.00463372748, 0.00236869091, 0.0237291511, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>142</th>\n",
       "      <td>17</td>\n",
       "      <td>8  In adults with hypertension requiring pharm...</td>\n",
       "      <td>2217</td>\n",
       "      <td>313</td>\n",
       "      <td>554.25</td>\n",
       "      <td>[-0.0135790417, 0.0218906719, 0.0332062095, 0....</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>143</th>\n",
       "      <td>18</td>\n",
       "      <td>GUIDELINE FOR THE PHARMACOLOGICAL TREATMENT OF...</td>\n",
       "      <td>733</td>\n",
       "      <td>104</td>\n",
       "      <td>183.25</td>\n",
       "      <td>[0.0179205332, 0.0302137714, 0.0263680629, -0....</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>144 rows × 6 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "     page_number                                     sentence_chunk  \\\n",
       "0            -38  Guideline for the pharmacological treatment of...   \n",
       "1            -38  Suggested citation. Guideline for the pharmaco...   \n",
       "2            -38  If you wish to reuse material from this work t...   \n",
       "3            -37  Contents Acknowledgements  v Acronyms and abbr...   \n",
       "4            -36  GUIDELINE FOR THE PHARMACOLOGICAL TREATMENT OF...   \n",
       "..           ...                                                ...   \n",
       "139           14  GUIDELINE FOR THE PHARMACOLOGICAL TREATMENT OF...   \n",
       "140           15  3  Should cardiovascular risk assessment be us...   \n",
       "141           16  GUIDELINE FOR THE PHARMACOLOGICAL TREATMENT OF...   \n",
       "142           17  8  In adults with hypertension requiring pharm...   \n",
       "143           18  GUIDELINE FOR THE PHARMACOLOGICAL TREATMENT OF...   \n",
       "\n",
       "     chunk_char_count  chunk_word_count  chunk_token_count  \\\n",
       "0                1397               208             349.25   \n",
       "1                 489                60             122.25   \n",
       "2                1447               238             361.75   \n",
       "3                1666               317             416.50   \n",
       "4                 477                84             119.25   \n",
       "..                ...               ...                ...   \n",
       "139              1893               276             473.25   \n",
       "140              2465               356             616.25   \n",
       "141              2105               314             526.25   \n",
       "142              2217               313             554.25   \n",
       "143               733               104             183.25   \n",
       "\n",
       "                                             embedding  \n",
       "0    [0.0322975218, -0.0188721679, 0.014344709, -0....  \n",
       "1    [0.0216960125, 0.00495383004, 0.00708221132, -...  \n",
       "2    [0.00337434001, -0.0488039851, -0.0180421919, ...  \n",
       "3    [0.0141956815, -0.00343135116, -0.0108614815, ...  \n",
       "4    [-0.01271402, -0.00567622669, 0.0340060741, -0...  \n",
       "..                                                 ...  \n",
       "139  [0.0176240001, 0.0242444444, 0.0281273257, 0.0...  \n",
       "140  [-0.0361399166, 0.00163900817, 0.0244934186, -...  \n",
       "141  [-0.00463372748, 0.00236869091, 0.0237291511, ...  \n",
       "142  [-0.0135790417, 0.0218906719, 0.0332062095, 0....  \n",
       "143  [0.0179205332, 0.0302137714, 0.0263680629, -0....  \n",
       "\n",
       "[144 rows x 6 columns]"
      ]
     },
     "execution_count": 51,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import random\n",
    "import torch\n",
    "import numpy as np\n",
    "import pandas as pd\n",
    "\n",
    "\n",
    "text_chunks_and_embeddings_df = pd.read_csv(\"text_chunk_and_embeddings_df.csv\")\n",
    "\n",
    "text_chunks_and_embeddings_df[\"embedding\"] = text_chunks_and_embeddings_df[\"embedding\"].apply(lambda x:np.fromstring(x.strip(\"[]\") , sep=\" \"))\n",
    "\n",
    "embeddings = torch.tensor(np.stack(text_chunks_and_embeddings_df[\"embedding\"].tolist(), axis=0), dtype=torch.float32).to(\"cpu\")\n",
    "\n",
    "pages_and_chunks = text_chunks_and_embeddings_df.to_dict(orient=\"records\")\n",
    "\n",
    "text_chunks_and_embeddings_df\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "id": "447aab99",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "torch.Size([144, 768])"
      ]
     },
     "execution_count": 52,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "embeddings.shape\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 53,
   "id": "e28dec53",
   "metadata": {},
   "outputs": [],
   "source": [
    "from sentence_transformers import util, SentenceTransformer\n",
    "\n",
    "embedding_model = SentenceTransformer(model_name_or_path=\"all-mpnet-base-v2\", device=\"cpu\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 54,
   "id": "9e0edf5e",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Query : hypertension special settings\n",
      "[INFO] Time taken to get scores on 144 embeddings: 0.00026 seconds\n"
     ]
    }
   ],
   "source": [
    "query = \"hypertension special settings\"\n",
    "print(f'Query : {query}')\n",
    "\n",
    "#Embed query\n",
    "query_embedding = embedding_model.encode(query,convert_to_tensor=True).to(\"cpu\")\n",
    "\n",
    "#Get similarity scores\n",
    "from time import perf_counter as timer\n",
    "\n",
    "start_time = timer()\n",
    "dot_scores = util.dot_score(a = query_embedding, b = embeddings)[0]\n",
    "end_time= timer()\n",
    "\n",
    "print(f\"[INFO] Time taken to get scores on {len(embeddings)} embeddings: {end_time - start_time:.5f} seconds\")\n",
    "\n",
    "#Get the top-k results \n",
    "\n",
    "top_results_dot_product = torch.topk(dot_scores, k = 1)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "id": "5f9958c2",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Embeddings shape: torch.Size([14400, 768])\n",
      "[INFO] Time taken to get scores on 14400 embeddings: 0.00186 seconds\n"
     ]
    }
   ],
   "source": [
    "large_embeddings = torch.randn(100*embeddings.shape[0],768).to(\"cpu\")\n",
    "print(f'Embeddings shape: {large_embeddings.shape}')\n",
    "\n",
    "# Perform dot product\n",
    "start_time = timer()\n",
    "dot_scores = util.dot_score(a=query_embedding, b=large_embeddings)[0]\n",
    "end_time = timer()\n",
    "\n",
    "print(\n",
    "    f\"[INFO] Time taken to get scores on {len(large_embeddings)} embeddings: {end_time - start_time:.5f} seconds\"\n",
    ")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 56,
   "id": "f087a191",
   "metadata": {},
   "outputs": [],
   "source": [
    "import textwrap\n",
    "\n",
    "\n",
    "def print_wrapped(text, wrap_length=80):\n",
    "    wrapped_text = textwrap.fill(text, wrap_length)\n",
    "    print(wrapped_text)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 57,
   "id": "d1a95d16",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'page_number': -38,\n",
       " 'sentence_chunk': 'Guideline for the pharmacological treatment of hypertension in adults ISBN 978-92-4-003398-6 (electronic version)  ISBN 978-92-4-003397-9 (print version) © World Health Organization 2021 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial- ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO;   https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial  purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there  should be no suggestion that WHO endorses any specific organization, products or services. The use of  the WHO logo is not permitted. If you adapt the work, then you must license your work under the same  or equivalent Creative Commons licence. If you create a translation of this work, you should add the  following disclaimer along with the suggested citation: “This translation was not created by the World  Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The  original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the  mediation rules of the World Intellectual Property Organization   (http://www.wipo.int/amc/en/mediation/rules/).',\n",
       " 'chunk_char_count': 1397,\n",
       " 'chunk_word_count': 208,\n",
       " 'chunk_token_count': 349.25,\n",
       " 'embedding': array([ 3.22975218e-02, -1.88721679e-02,  1.43447090e-02, -2.66964622e-02,\n",
       "         3.43373837e-03,  1.82119869e-02,  1.90887600e-02, -1.11000137e-02,\n",
       "         8.12107548e-02,  2.11275928e-02,  2.72885431e-02, -1.05765238e-02,\n",
       "        -9.34975687e-03,  9.03329812e-03,  5.91743831e-03, -1.18050282e-03,\n",
       "        -4.38040756e-02,  7.49394391e-03,  3.80738825e-02, -1.14302812e-02,\n",
       "        -2.70191934e-02, -3.14859897e-02, -1.31126996e-02,  1.94425080e-02,\n",
       "         3.58131826e-02, -3.91526818e-02,  7.61329830e-02, -4.32887152e-02,\n",
       "        -8.62727116e-04, -3.53886858e-02, -2.01980416e-02,  2.48719603e-02,\n",
       "        -8.26726295e-03, -1.15557894e-01,  3.09743155e-06, -3.99945714e-02,\n",
       "         3.63798477e-02,  6.18425980e-02,  2.27072611e-02, -1.79825556e-02,\n",
       "         9.46065225e-03, -9.55304950e-02,  3.51105165e-03, -1.03901261e-02,\n",
       "        -1.66794024e-02, -2.42831483e-02,  6.98222360e-03,  4.76635015e-03,\n",
       "        -3.13130654e-02,  4.82774386e-03,  4.02465276e-03,  3.22799268e-03,\n",
       "        -1.99425109e-02, -6.37501292e-03,  2.79707536e-02, -9.14524421e-02,\n",
       "         2.30470933e-02,  3.43801230e-02,  4.93892431e-02,  1.90126020e-02,\n",
       "         9.87414550e-03, -1.87981613e-02, -2.41269227e-02,  3.24840695e-02,\n",
       "        -2.61236932e-02, -1.33941434e-02, -1.07591823e-02, -7.93359131e-02,\n",
       "        -9.62349586e-03,  2.44085509e-02,  2.91075781e-02,  8.20722505e-02,\n",
       "         2.91824508e-02,  4.08463366e-02, -1.60138514e-02, -3.47619541e-02,\n",
       "        -1.78610478e-02, -4.52163741e-02, -4.35434543e-02, -2.52587777e-02,\n",
       "         2.51231454e-02,  7.50783784e-03, -1.18468376e-02, -5.36513589e-02,\n",
       "        -1.25599448e-02, -6.73306882e-02, -3.33828997e-04,  5.18361852e-02,\n",
       "         3.25978622e-02,  8.85474868e-03, -2.48237569e-02,  4.57156589e-03,\n",
       "         1.01503199e-02, -5.33168763e-02,  3.85023397e-03,  2.23939605e-02,\n",
       "         3.03025488e-02, -3.63887437e-02,  7.32616782e-02, -5.01205921e-02,\n",
       "         2.08819509e-02,  1.31519968e-02,  4.48604338e-02, -7.77534023e-03,\n",
       "        -1.28066698e-02, -5.70052955e-03, -2.65075229e-02, -6.00968860e-03,\n",
       "        -6.83372244e-02,  4.64199707e-02, -3.87456343e-02,  6.40795939e-03,\n",
       "        -4.50904928e-02, -4.49417206e-03,  6.65302426e-02, -4.07234095e-02,\n",
       "        -9.90709662e-02, -2.09153760e-02, -1.79022681e-02, -2.62336098e-02,\n",
       "        -2.57806107e-02,  2.49912441e-02,  6.22665733e-02, -1.21830627e-02,\n",
       "         1.05981936e-03,  7.16724023e-02, -2.76470203e-02,  2.59986278e-02,\n",
       "         1.63663633e-03, -4.39908206e-02,  4.83433679e-02, -3.01071610e-02,\n",
       "        -4.03430760e-02,  3.10345218e-02,  3.21266614e-02, -3.98130529e-02,\n",
       "        -2.28761025e-02,  7.74260387e-02,  3.31197046e-02, -4.38013971e-02,\n",
       "         3.04180924e-02,  2.87037790e-02,  2.04679742e-02, -3.00640911e-02,\n",
       "         4.55002673e-02, -4.70755026e-02,  5.78831509e-02,  4.59700786e-02,\n",
       "        -2.33491622e-02,  3.47397439e-02, -2.81580947e-02, -2.78233867e-02,\n",
       "        -1.92730669e-02,  6.01607040e-02,  2.09780801e-02, -1.65860336e-02,\n",
       "        -4.25837422e-03, -3.10731046e-02,  2.29959842e-03, -1.99237578e-02,\n",
       "        -1.66523026e-03,  4.60742769e-04, -2.29916628e-02, -1.34802214e-03,\n",
       "         3.72296311e-02, -3.34172770e-02,  6.57342514e-03,  5.64235672e-02,\n",
       "        -7.11413892e-03,  2.53095273e-02, -8.95557478e-02, -1.26197962e-02,\n",
       "        -3.77141498e-02,  2.09671706e-02, -1.40471952e-02, -2.13351399e-02,\n",
       "        -7.03548826e-03,  2.83961929e-02, -2.06697918e-02, -6.77736700e-02,\n",
       "         3.69501933e-02, -3.25887166e-02, -2.94372365e-02, -3.35832089e-02,\n",
       "        -1.54105583e-02,  3.69961262e-02, -2.54970267e-02, -2.78951619e-02,\n",
       "         5.15146703e-02,  8.95992736e-04,  1.02256536e-02, -1.64773948e-02,\n",
       "        -3.71756330e-02, -3.02370470e-02,  1.61087094e-03, -2.67526247e-02,\n",
       "        -1.89748127e-02, -7.60347722e-03,  1.33226160e-03,  2.52706860e-03,\n",
       "        -2.15296205e-02,  5.96117862e-02, -3.17773968e-03,  1.19562848e-02,\n",
       "        -1.61557514e-02,  2.63723824e-02,  8.07959139e-02, -7.98418373e-03,\n",
       "         4.04929221e-02, -2.73276009e-02, -1.38382521e-02, -2.10894421e-02,\n",
       "         1.54059874e-02, -3.28796059e-02, -1.82944605e-05,  1.25989290e-02,\n",
       "        -2.35876217e-02,  5.11244349e-02, -2.12062299e-02,  1.74664631e-02,\n",
       "        -5.73828584e-03, -3.69545557e-02, -5.77850193e-02,  5.02878381e-03,\n",
       "        -5.55351302e-02,  9.94330738e-04, -4.68935538e-03,  3.21929380e-02,\n",
       "        -5.93386479e-02, -5.52629158e-02,  3.45459729e-02,  3.17675993e-02,\n",
       "         1.62870623e-02, -2.00597066e-02,  2.57017836e-02, -3.48660871e-02,\n",
       "         5.06080352e-02,  4.09096247e-03, -2.45375298e-02, -3.29556167e-02,\n",
       "         5.55878505e-02, -2.77733020e-02, -6.89626783e-02, -2.00263839e-02,\n",
       "        -6.44716024e-02,  2.97272671e-02,  3.69627471e-03,  2.76165530e-02,\n",
       "        -2.80755442e-02,  2.03937963e-02,  3.55308950e-02,  2.25641001e-02,\n",
       "        -7.78185651e-02,  8.03952590e-02, -8.54090601e-02,  4.45283391e-02,\n",
       "        -4.93112653e-02,  2.15207599e-02,  5.34339622e-02,  1.63140316e-02,\n",
       "        -4.59511951e-02,  1.29298707e-02, -6.51500607e-03,  6.63666753e-03,\n",
       "        -5.33735286e-03,  7.72897387e-03, -2.36742031e-02, -1.66950189e-02,\n",
       "        -1.78193264e-02,  8.43217224e-03,  1.46623962e-02, -4.81772684e-02,\n",
       "         2.38449629e-02,  3.01006008e-02, -6.54913038e-02,  9.30720940e-03,\n",
       "        -2.97754873e-02,  1.13850711e-02,  6.87549543e-03, -4.42126254e-03,\n",
       "         3.38176601e-02,  8.37246254e-02,  5.52111343e-02,  2.68383208e-03,\n",
       "         3.87425050e-02,  2.03741863e-02, -5.90816932e-03,  1.49609605e-02,\n",
       "         1.09565780e-01, -6.00155257e-02,  5.71284862e-03, -2.65564816e-03,\n",
       "         3.11115179e-02,  1.39688337e-02,  4.31690142e-02,  5.49172573e-02,\n",
       "         1.22196479e-02, -2.53880639e-02, -4.27486785e-02, -6.58086985e-02,\n",
       "         5.74420067e-03,  1.50645608e-02,  2.88689788e-02,  4.24459763e-03,\n",
       "         1.61030819e-03, -2.91156564e-02,  2.61622574e-02, -2.26662448e-03,\n",
       "        -7.48487413e-02,  4.89873067e-02, -2.49912608e-02, -4.57491522e-04,\n",
       "        -3.42647242e-03, -6.26227856e-02,  1.57139394e-02,  1.05998991e-02,\n",
       "        -8.58441666e-02, -3.34452763e-02, -1.67322420e-02, -8.05425365e-03,\n",
       "         2.54414584e-02,  1.37061886e-02,  7.17417011e-03,  1.37818558e-02,\n",
       "         5.98659273e-03, -2.12004017e-02,  4.15600128e-02, -1.95847973e-02,\n",
       "        -1.10515162e-01, -4.97230031e-02, -1.91536490e-02,  4.97083403e-02,\n",
       "         2.83556543e-02,  6.33101240e-02, -2.81853951e-03, -2.19721366e-02,\n",
       "         1.99505780e-02,  3.94901447e-02, -2.72856560e-02,  7.46693881e-03,\n",
       "        -5.72792348e-03, -3.94847877e-02,  1.10400282e-02, -9.88842547e-03,\n",
       "        -2.18824241e-02, -3.15370001e-02,  2.12452319e-02,  1.32668193e-03,\n",
       "         3.95138487e-02,  2.03410909e-02, -5.96693605e-02, -5.24467230e-03,\n",
       "        -1.14461379e-02,  1.55417575e-02,  2.09925417e-02, -9.17613804e-02,\n",
       "         6.40934631e-02, -4.08439040e-02,  2.47670561e-02,  8.04748666e-03,\n",
       "         3.20774652e-02,  4.29222807e-02,  2.07121503e-02, -2.08163727e-02,\n",
       "         3.22384760e-02,  5.39339408e-02, -1.87944006e-02,  6.71603717e-04,\n",
       "        -6.02775812e-02, -1.62512418e-02, -1.59023628e-02,  4.03882414e-02,\n",
       "         2.24557333e-02,  5.85476942e-02,  3.45357694e-02, -2.62313127e-03,\n",
       "         6.31557638e-03, -4.35232036e-02, -4.79299948e-02, -2.14784909e-02,\n",
       "        -2.90725399e-02, -3.23144272e-02,  8.06774478e-03, -3.50276567e-02,\n",
       "         5.71393184e-02,  3.38241481e-03,  2.99446452e-02, -6.46017119e-02,\n",
       "         5.73415831e-02, -2.96261422e-02,  5.73098250e-02,  5.23217674e-03,\n",
       "         5.49462810e-02,  4.70462750e-04, -5.82052814e-03,  1.66039411e-02,\n",
       "        -7.57852755e-03, -5.51330261e-02, -7.13249110e-03,  2.83401180e-02,\n",
       "         4.23184335e-02, -6.69114739e-02, -4.40008454e-02,  2.18514707e-02,\n",
       "         4.03512232e-02,  3.40934098e-02, -1.33237457e-02,  1.40224546e-02,\n",
       "         7.48985335e-02,  3.60664055e-02,  1.00199496e-02, -2.80785523e-02,\n",
       "         1.72430687e-02, -1.79973692e-02,  7.94468820e-02,  3.91411260e-02,\n",
       "         1.74382310e-02, -1.60188973e-02,  4.84322570e-02, -8.28487650e-02,\n",
       "         6.93666562e-03,  1.47127116e-03, -4.14061286e-02,  1.37383034e-02,\n",
       "        -3.57825756e-02, -5.51628694e-02,  7.91229308e-02, -2.10923944e-02,\n",
       "        -2.07069442e-02,  1.16765415e-02,  8.25649798e-02,  1.83055848e-02,\n",
       "         2.25208793e-02, -2.12509781e-02, -9.37141012e-03,  1.04235820e-02,\n",
       "        -2.05751583e-02,  1.72824971e-02,  1.18819140e-02,  1.68001503e-02,\n",
       "        -4.03227247e-02,  2.99254972e-02,  2.87831444e-02, -3.31080658e-03,\n",
       "        -1.60645954e-02,  6.78694770e-02,  1.12725915e-02,  9.96113420e-02,\n",
       "         2.12889556e-02,  5.04098684e-02,  3.99744622e-02,  3.24400817e-03,\n",
       "         1.40258325e-02,  3.47711034e-02,  2.87647098e-02, -7.30561931e-03,\n",
       "         4.69268486e-02, -1.48480302e-02,  5.28928712e-02, -5.65216467e-02,\n",
       "         2.93047912e-02,  6.69661863e-03,  1.04227308e-02, -1.60686113e-02,\n",
       "         3.32085490e-02,  1.16370972e-02, -6.39018193e-02,  5.14257997e-02,\n",
       "        -6.59370869e-02, -4.59795631e-02,  2.60117464e-02, -1.97195951e-02,\n",
       "        -1.75524130e-02, -1.93403580e-03,  4.39215824e-02, -3.93873081e-02,\n",
       "        -1.24997813e-02,  3.10957208e-02, -6.02143584e-03,  5.39917424e-02,\n",
       "         7.84883741e-03, -1.91799775e-02, -1.62216276e-02,  1.47729162e-02,\n",
       "         5.37798274e-03,  1.07574640e-02, -1.45823788e-02, -4.19772137e-03,\n",
       "         1.15060969e-03,  7.10010082e-02, -5.97669836e-03, -2.66300719e-02,\n",
       "         1.80799689e-04, -4.66044918e-02, -7.54591227e-02, -5.19303754e-02,\n",
       "        -3.32341976e-02,  4.16592956e-02, -2.71989126e-02, -2.66121887e-02,\n",
       "         5.67773990e-02,  4.34896760e-02,  1.54653927e-02,  1.25670992e-02,\n",
       "         1.61687657e-02,  6.67834356e-02, -5.56170717e-02,  2.16152482e-02,\n",
       "        -4.95965332e-02, -3.02838311e-02,  6.03533350e-03,  7.76753412e-04,\n",
       "        -1.73563100e-02,  1.59982312e-02,  3.44542079e-02,  4.30489741e-02,\n",
       "         3.27333882e-02, -1.28766662e-02,  1.59021933e-02,  6.41988777e-03,\n",
       "         9.56492871e-03, -3.32992189e-02, -7.37552941e-02,  2.09627599e-02,\n",
       "         9.52999573e-03,  1.19899190e-03, -1.91597603e-02, -9.99218971e-03,\n",
       "        -2.48669647e-02,  5.93343787e-02, -7.55426520e-03, -3.77330668e-02,\n",
       "         1.14455009e-02, -6.82893395e-02,  3.24456650e-03, -5.33772707e-02,\n",
       "         3.05011924e-02,  2.42391247e-02, -6.91996887e-02,  1.84734371e-02,\n",
       "        -1.27323566e-03, -1.99862998e-02,  1.07812537e-02,  3.16214561e-02,\n",
       "        -9.36948601e-03,  4.32701558e-02, -9.38609540e-02,  2.66311336e-02,\n",
       "        -3.34047563e-02, -8.30050111e-02, -2.80496944e-02,  3.47739942e-02,\n",
       "        -3.38427648e-02,  3.40093933e-02,  1.51001499e-03, -6.68736165e-33,\n",
       "         4.87065166e-02,  4.01695371e-02,  1.65394172e-02, -5.26678674e-02,\n",
       "         8.99447035e-03,  4.63078022e-02, -4.97598611e-02, -1.73900428e-03,\n",
       "        -2.24274360e-02,  1.17354058e-01, -3.29760388e-02, -5.46621643e-02,\n",
       "         2.58640740e-02,  1.39712039e-02, -9.29755718e-03, -7.07339570e-02,\n",
       "        -3.32288928e-02,  3.17111947e-02,  5.04760332e-02, -2.93705631e-02,\n",
       "        -4.11515012e-02,  4.42631580e-02,  5.30697778e-03, -5.20455651e-02,\n",
       "         3.74335982e-02, -2.47458369e-02,  1.07156085e-02, -2.69272011e-02,\n",
       "         2.46206820e-02,  4.33503278e-02,  3.00485212e-02,  3.35879326e-02,\n",
       "        -2.62087584e-03, -2.14605276e-02, -4.30148095e-04,  1.10574318e-02,\n",
       "        -3.25776935e-02, -2.72523332e-03,  3.64492163e-02, -8.51020589e-02,\n",
       "        -3.44209000e-02,  2.62467861e-02,  5.34831807e-02, -1.89524260e-03,\n",
       "        -1.85400546e-02, -1.14442464e-02, -2.20410898e-02, -4.95231077e-02,\n",
       "        -2.83622518e-02,  2.18016817e-03, -4.81533222e-02,  5.94406016e-03,\n",
       "         4.87245023e-02,  3.24721783e-02, -3.99536006e-02,  7.98947886e-02,\n",
       "        -1.25904456e-02, -5.52912392e-02, -4.50209863e-02, -5.65307308e-03,\n",
       "         4.86442214e-03,  1.75018527e-03, -2.11248137e-02,  1.75699349e-02,\n",
       "         1.77472513e-02, -4.20522802e-02, -5.82044497e-02,  1.93607099e-02,\n",
       "         1.20775392e-02,  3.37495953e-02, -5.15921675e-02, -1.49018280e-02,\n",
       "        -5.46210865e-03,  2.44798362e-02, -1.98853556e-02, -2.25247405e-02,\n",
       "         3.09313671e-03,  6.14981651e-02, -1.47396708e-02, -7.92224484e-04,\n",
       "        -1.78160202e-02, -1.05845705e-02, -3.75126898e-02, -4.37495206e-03,\n",
       "         3.61872204e-02, -8.46307352e-03, -2.42442060e-02, -3.62341106e-02,\n",
       "        -1.87591724e-02,  2.08204277e-02,  4.25640084e-02,  3.17410305e-02,\n",
       "         5.33559956e-02, -4.81179878e-02, -2.61453842e-03, -5.17187044e-02,\n",
       "         3.18492576e-02, -1.00842249e-02,  9.45940521e-03, -3.82244959e-02,\n",
       "         1.28320418e-02,  1.17225200e-02,  6.45543486e-02,  1.83675308e-02,\n",
       "        -1.69785675e-02,  1.37553187e-02,  1.71683244e-02, -2.57604346e-02,\n",
       "         2.00562142e-02,  1.56888086e-02, -1.87179875e-02,  1.90548729e-02,\n",
       "         7.31883291e-03,  3.15272692e-03, -1.86898690e-02,  4.35456783e-02,\n",
       "         4.77571264e-02,  5.10328673e-02, -2.27961205e-02, -1.53678097e-02,\n",
       "        -1.41724776e-02, -1.29513652e-03,  5.47715230e-03, -5.36107924e-03,\n",
       "        -4.95731607e-02, -6.16313331e-03,  2.34915894e-02,  3.65602449e-02,\n",
       "         1.27264280e-02,  2.44065356e-02,  1.26942825e-02, -1.57922003e-02,\n",
       "         3.51236224e-07, -1.79756843e-02, -1.35527654e-02,  3.58335041e-02,\n",
       "        -6.82010651e-02, -1.51341362e-02, -1.73621008e-03, -4.02853414e-02,\n",
       "         1.34250764e-02, -4.15619612e-02, -9.71113145e-03,  4.72563133e-02,\n",
       "        -4.39952761e-02,  3.27311233e-02, -2.55728737e-02,  3.68844829e-02,\n",
       "        -3.94093245e-02, -2.35997736e-02, -8.13142210e-02, -1.53770735e-02,\n",
       "        -2.62237843e-02,  1.91220064e-02,  1.09370314e-02, -5.58528602e-02,\n",
       "        -6.20016158e-02,  2.97558657e-03,  2.34457683e-02, -3.14095318e-02,\n",
       "        -3.71435471e-02, -7.19450042e-02,  3.51491049e-02,  4.27907892e-03,\n",
       "         1.52539248e-02,  2.17533130e-02,  7.14204414e-03, -1.77767575e-02,\n",
       "        -4.08050083e-02,  1.32528357e-02,  1.31408824e-02, -6.15327246e-02,\n",
       "         3.73415500e-02,  1.30344229e-02, -4.85938340e-02,  2.28793081e-02,\n",
       "        -4.39747274e-02, -1.84706952e-02,  1.90774277e-02, -6.05159961e-02,\n",
       "        -9.69295856e-03,  1.95444580e-02, -5.54769002e-02,  4.80095372e-02,\n",
       "         1.36437058e-03, -1.02733728e-03,  5.73014021e-02,  1.85126681e-02,\n",
       "         6.10446595e-02, -1.25680724e-02,  1.87071003e-02,  6.39143512e-02,\n",
       "        -5.62251955e-02,  6.47333171e-03,  3.29170786e-02,  2.53634918e-02,\n",
       "         1.87106784e-02,  5.32836234e-03, -4.62738723e-02, -3.23137343e-02,\n",
       "         3.13739718e-34,  1.45874415e-02, -2.94409413e-02, -9.88411531e-03,\n",
       "        -7.96213076e-02,  9.11928788e-02, -1.56503767e-02, -2.68203486e-02,\n",
       "        -1.13336947e-02,  6.93819532e-03, -4.71478887e-02, -6.44995365e-03])}"
      ]
     },
     "execution_count": 57,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pages_and_chunks[0]\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 58,
   "id": "a625c711",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Query: hypertension special settings \n",
      "\n",
      "Results:\n",
      "Score: 0.7077\n",
      "Text:\n",
      "GUIDELINE FOR THE PHARMACOLOGICAL TREATMENT OF HYPERTENSION IN ADULTS 6\n",
      "Implementation tools 6.1 Guideline recommendations Graphic summaries of the\n",
      "guideline recommendations are presented below in an algorithmic approach  (Figs\n",
      "3 and 4). This maps the recommendations to a patient-care pathway. Fig.3 An\n",
      "approach for starting treatment with a single-pill combination  Treat adults\n",
      "with BP ≥140 mmHg or ≥90   (SBP ≥130 mmHg for those with CVD, DM, CKD). Start\n",
      "two-drug combination therapy, preferably in a single-pill combination  (ACE/ARB,\n",
      "dihydropyridine CCB, thiazide-like agents). Treatment targets: <140/90 mmHg\n",
      "(SBP <130 mmHg for high-risk patients with CVD, DM, CKD). Follow up monthly\n",
      "after initiation or a change in antihypertensive  medications until patient\n",
      "reaches BP target. Follow up every 3–6 months for patients with BP under\n",
      "control. Pharmacological treatment to be initiated under the following\n",
      "circumstances: [  A diagnosis of HTN has already been made. [ Initiation of\n",
      "pharmacological HTN treatment should start no later than four weeks after\n",
      "diagnosis of HTN.\n",
      "Page Number: -4\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "query = \"hypertension special settings\"\n",
    "print(f'Query: {query} \\n')\n",
    "print('Results:')\n",
    "for score, idx in zip(top_results_dot_product[0], top_results_dot_product[1]):\n",
    "    print(f\"Score: {score:.4f}\")\n",
    "    print(\"Text:\")\n",
    "    print_wrapped(pages_and_chunks[idx][\"sentence_chunk\"])\n",
    "    print(f\"Page Number: {pages_and_chunks[idx]['page_number']}\")\n",
    "    print('\\n')\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 59,
   "id": "6dd84d6f",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1300x1000 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import fitz\n",
    "\n",
    "pdf_path = \"HyperTension.pdf\"\n",
    "doc = fitz.open(pdf_path)\n",
    "page = doc.load_page(5 + 41)\n",
    "\n",
    "img  = page.get_pixmap(dpi=300)\n",
    "\n",
    "doc.close()\n",
    "\n",
    "img_array = np.frombuffer(img.samples_mv, dtype = np.uint8).reshape((img.h, img.w, img.n))\n",
    "\n",
    "\n",
    "import matplotlib.pyplot as plt\n",
    "plt.figure(figsize = (13,10))\n",
    "plt.imshow(img_array)\n",
    "plt.title(f\"Query: {query}' | Most Relavent Page:\")\n",
    "plt.axis('off')\n",
    "plt.show()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 60,
   "id": "0f57b940",
   "metadata": {},
   "outputs": [],
   "source": [
    "def retrieve_relavent_resources(query: str, embeddings: torch.tensor, \n",
    "                                model: SentenceTransformer= embedding_model, \n",
    "                                n_resources_to_return: int=5, \n",
    "                                print_time: bool = True):\n",
    "    \n",
    "    \"\"\"\n",
    "    Embeds a query with model and returns top k scores and indices from embeddings\n",
    "    \"\"\"\n",
    "\n",
    "    #Embed the query\n",
    "    query_embedding = model.encode(query, convert_to_tensor=True)\n",
    "\n",
    "    start_time = timer()\n",
    "    dot_scores = util.dot_score(query_embedding, embeddings)[0]\n",
    "    end_time = timer()\n",
    "\n",
    "    if print_time:\n",
    "        print(f\"[INFO] Time taken to get scores on ({len(embeddings)}) embeddings: {end_time-start_time:.5f}seconds\")\n",
    "    \n",
    "    scores, indices = torch.topk(input=dot_scores, k = n_resources_to_return)\n",
    "\n",
    "    return scores, indices\n",
    "\n",
    "def print_top_results_and_scores(query:str, \n",
    "                                 embeddings: torch.tensor, \n",
    "                                 pages_and_chunks: list[dict]=pages_and_chunks,\n",
    "                                 n_resources_to_return: int=5):\n",
    "    scores, indices = retrieve_relavent_resources(query=query, embeddings=embeddings,n_resources_to_return=n_resources_to_return)\n",
    "    print(\"Results:\")\n",
    "    for score, idx in zip(scores, indices):\n",
    "        print(f\"Score: {score:.4f}\")\n",
    "        print(\"Text:\")\n",
    "        print_wrapped(pages_and_chunks[idx][\"sentence_chunk\"])\n",
    "        print(f\"Page Number: {pages_and_chunks[idx]['page_number']}\")\n",
    "        print(\"\\n\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 61,
   "id": "2355011c",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[INFO] Time taken to get scores on (144) embeddings: 0.00026seconds\n",
      "[INFO] Time taken to get scores on (144) embeddings: 0.00010seconds\n",
      "Results:\n",
      "Score: 0.7043\n",
      "Text:\n",
      "Geneva: World Health Organization; June 2021\n",
      "(WHO/2019-nCoV/Sci_Brief/Hypertension/2021.1, accessed July 2021). (93)\n",
      "Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, the Northwell\n",
      "COVID-19  Research Consortium, et al. Presenting characteristics, comorbidities,\n",
      "and outcomes among 5700  patients hospitalized with COVID-19 in the New York\n",
      "City Area. JAMA.2020;323(20):2052-2059. doi: 10.1001/jama.2020.6775. Erratum in:\n",
      "JAMA.2020 May 26;323(20):2098. (94)  Xie J, Tong Z, Guan X, Du B, Qiu H.\n",
      "Clinical characteristics of patients who died of  coronavirus disease 2019 in\n",
      "China. JAMA Netw Open.\n",
      "Page Number: 6\n",
      "\n",
      "\n",
      "Score: 0.6978\n",
      "Text:\n",
      "GUIDELINE FOR THE PHARMACOLOGICAL TREATMENT OF HYPERTENSION IN ADULTS 4.2\n",
      "COVID-19 and hypertension Almost all available evidence suggests that\n",
      "hypertension increases the risk of severe COVID-19, defined  as admission to\n",
      "intensive care, clinically defined severity or a combination of these; or\n",
      "mortality. It was  sometimes unclear, however, whether this risk was independent\n",
      "of other risk factors (92). Initial reports  have identified higher rates of HTN\n",
      "among severely ill, hospitalized COVID-19 patients, with overall  HTN rates of\n",
      "50–56% (93, 94). It had been unclear if this relationship was causal or\n",
      "confounded by age  and other comorbidities associated with HTN, including\n",
      "obesity, diabetes and chronic kidney disease. Concerns regarding use of\n",
      "angiotensin-converting enzyme inhibitors (ACEis) in these patients were  raised\n",
      "due to identification of angiotensin-converting enzyme 2 (ACE2), the\n",
      "monocarboxypeptidase  that inactivates angiotensin II and thereby counters the\n",
      "activation of the classic renin–angiotensin– aldosterone system (RAAS), as the\n",
      "functional receptor for the severe acute respiratory syndrome  coronavirus 2\n",
      "(SARS-CoV-2) (95, 96). The WHO conducted a rapid review of evidence related to\n",
      "the use  ACEis or ARBs in COVID patients which identified 11 observational\n",
      "studies. No studies were found that  were designed to directly assess whether\n",
      "ACEis or ARBs increase the risk of acquiring COVID-19. After  adjustment for\n",
      "confounders, history of ACEi or ARB use was not found to be associated with\n",
      "increased  severity of COVID-19 illness. There were no studies that addressed\n",
      "the potential benefits and harms of  initiating ACEis or ARBs as treatment for\n",
      "patients with COVID-19 (97). Accordingly, discontinuation of  ACEis or ARBs may\n",
      "yield worse outcomes than continuation of their use in patients with a diagnosis\n",
      "of COVID-19.\n",
      "Page Number: -8\n",
      "\n",
      "\n",
      "Score: 0.6676\n",
      "Text:\n",
      "Renin- angiotensin-aldosterone system inhibitors in patients with Covid-19. N\n",
      "Engl J Med. 2020;382(17):1653-1659.doi: 10.1056/NEJMsr2005760. (97)  COVID-19\n",
      "and the use of angiotensin-converting enzyme inhibitors and receptor blockers.\n",
      "Scientific Brief. Geneva: World Health Organization; May 2020\n",
      "(WHO/2019-nCoV/Sci_Brief/ ACE-I/2020.1, accessed July 2021). (98)  Sparks MA,\n",
      "Hiremath S, et al. ACE2 and hypertension [website]. (http://www.nephjc.com/news/\n",
      "covidace2, accessed 19 February 2021). (\n",
      "Page Number: 6\n",
      "\n",
      "\n",
      "Score: 0.6266\n",
      "Text:\n",
      "GUIDELINE FOR THE PHARMACOLOGICAL TREATMENT OF HYPERTENSION IN ADULTS (89)\n",
      "Kario K. Disaster hypertension - its characteristics, mechanism, and management.\n",
      "Circ J.  2012;76(3):553-62.doi: 10.1253/circj.cj-11-1510. (90)  Médecins Sans\n",
      "Frontières. Clinical guidelines: diagnostic and treatment manual. Author; 2013.\n",
      "(91)  WHO. Interagency emergency health kit 2017 [website]\n",
      "(https://www.who.int/emergencies/kits/ iehk/en/, accessed March 2021). (92)\n",
      "COVID-19 and hypertension. Scientific Brief.\n",
      "Page Number: 6\n",
      "\n",
      "\n",
      "Score: 0.5955\n",
      "Text:\n",
      "In contrast to the uncertainty about the potential benefit of initiating RAAS\n",
      "blocker use  in patients with COVID-19, there is a clear potential for harm in\n",
      "withdrawing these agents in high-risk  COVID-19 patients with established\n",
      "myocardial injury, HTN or heart failure (96). Most of the world’s  professional\n",
      "societies either recommend or strongly encourage continuing ACEis/ARBs in\n",
      "COVID-19- infected patients (98). Further research that will address key\n",
      "unanswered questions about the role of the  RAAS in the pathogenesis and\n",
      "possible treatment of COVID-19 and other coronavirus-based diseases is  urgently\n",
      "needed. Prospective studies – in particular, ongoing randomized, placebo-\n",
      "controlled trials such  as the Ramipril for the Treatment of COVID-19 (RAMIC)\n",
      "trial (ClinicalTrials.gov number, NCT04366050)  may provide clearer insight\n",
      "regarding the effect of ACEis or ARBs in patients with COVID-19.4.3 Pregnancy\n",
      "and hypertension Hypertension, including chronic HTN, gestational HTN, pre-\n",
      "eclampsia, and eclampsia, is a very common  medical condition in pregnancy (99).\n",
      "Due to the adverse consequences of increased morbidity  and mortality to both\n",
      "the women and fetus, HTN in pregnancy must be diagnosed, treated (when\n",
      "appropriate), and followed up diligently. It is important to note that up to 10%\n",
      "of pregnancy-related  deaths are attributed to HTN, and its presence in\n",
      "pregnancy leads to long-term adverse cardiovascular  consequences.\n",
      "Unfortunately, hypertensive disorders of pregnancy are markedly increasing (100,\n",
      "101). For instance, in the United States between 1998 and 2006, hypertensive\n",
      "disorders in pregnancy  increased from 6.7% to 8.3%, chronic HTN in pregnancy\n",
      "increased from 1.1% to 1.7%, and pre- eclampsia/eclampsia from 0.9% to 1.2%. The\n",
      "potential serious consequences of HTN and pregnancy  and the contraindication in\n",
      "pregnancy of some of the commonly prescribed pharmacological  antihypertensive\n",
      "medications discussed below should be discussed with women who are or could\n",
      "become pregnant.\n",
      "Page Number: -8\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "query = \"hypertension covid\"\n",
    "retrieve_relavent_resources(query=query, embeddings=embeddings)\n",
    "print_top_results_and_scores(query=query, embeddings=embeddings)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 62,
   "id": "03231488",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "a112fc15cde0482b9dbbfb35a7a7e605",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Loading checkpoint shards:   0%|          | 0/2 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Some parameters are on the meta device because they were offloaded to the disk and cpu.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<bos>Write me a poem about Machine Learning.\n",
      "\n",
      "A tapestry of data, woven tight,\n",
      "A million threads of knowledge, shining bright.\n",
      "Machine learning, a weaver's art,\n",
      "Unravel\n"
     ]
    }
   ],
   "source": [
    "from transformers import AutoTokenizer, AutoModelForCausalLM\n",
    "import torch\n",
    "\n",
    "tokenizer = AutoTokenizer.from_pretrained(\"google/gemma-2-2b-it\")\n",
    "model = AutoModelForCausalLM.from_pretrained(\n",
    "    \"google/gemma-2-2b-it\",\n",
    "    device_map=\"auto\",\n",
    "    torch_dtype=torch.bfloat16,\n",
    ")\n",
    "\n",
    "input_text = \"Write me a poem about Machine Learning.\"\n",
    "input_ids = tokenizer(input_text, return_tensors=\"pt\").to(\"cpu\")\n",
    "\n",
    "outputs = model.generate(**input_ids, max_new_tokens=32)\n",
    "print(tokenizer.decode(outputs[0]))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 63,
   "id": "382f6569",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "e78b9f7ac40e4c52b43dbfd73049cefa",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Loading checkpoint shards:   0%|          | 0/2 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "What is the impact of hypertension on cardiovascular health?\n",
      "\n",
      "Hypertension, also known as high blood pressure, is a major risk factor for cardiovascular disease (CVD). It puts a strain on your heart and blood vessels, increasing the likelihood of various heart problems. \n",
      "\n",
      "Here's a breakdown of the impact of hypertension on cardiovascular health:\n",
      "\n",
      "**1. Heart Attack and Stroke:**\n",
      "\n",
      "* **Increased risk:** Hypertension significantly elevates the risk of both heart attacks and strokes. \n",
      "* **Damage to blood vessels:** High blood pressure damages the\n"
     ]
    }
   ],
   "source": [
    "import torch\n",
    "from transformers import AutoTokenizer, AutoModelForCausalLM\n",
    "\n",
    "# Define model ID\n",
    "model_id = \"google/gemma-2-2b-it\"\n",
    "\n",
    "# Load the tokenizer\n",
    "tokenizer = AutoTokenizer.from_pretrained(model_id)\n",
    "\n",
    "# Load the model for CPU use\n",
    "llm_model = AutoModelForCausalLM.from_pretrained(\n",
    "    model_id,\n",
    "    torch_dtype=torch.float32,  # use float16 only if your CPU supports it (rare)\n",
    "    low_cpu_mem_usage=True\n",
    ")\n",
    "\n",
    "# Move model to CPU explicitly (optional, but safe)\n",
    "llm_model.to(\"cpu\")\n",
    "\n",
    "# Example prompt\n",
    "prompt = \"What is the impact of hypertension on cardiovascular health?\"\n",
    "\n",
    "# Tokenize input\n",
    "inputs = tokenizer(prompt, return_tensors=\"pt\")\n",
    "\n",
    "# Generate response\n",
    "with torch.no_grad():\n",
    "    outputs = llm_model.generate(**inputs, max_new_tokens=100)\n",
    "\n",
    "# Decode and print response\n",
    "response = tokenizer.decode(outputs[0], skip_special_tokens=True)\n",
    "print(response)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 64,
   "id": "dadc88dd",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Gemma2ForCausalLM(\n",
       "  (model): Gemma2Model(\n",
       "    (embed_tokens): Embedding(256000, 2304, padding_idx=0)\n",
       "    (layers): ModuleList(\n",
       "      (0-25): 26 x Gemma2DecoderLayer(\n",
       "        (self_attn): Gemma2Attention(\n",
       "          (q_proj): Linear(in_features=2304, out_features=2048, bias=False)\n",
       "          (k_proj): Linear(in_features=2304, out_features=1024, bias=False)\n",
       "          (v_proj): Linear(in_features=2304, out_features=1024, bias=False)\n",
       "          (o_proj): Linear(in_features=2048, out_features=2304, bias=False)\n",
       "        )\n",
       "        (mlp): Gemma2MLP(\n",
       "          (gate_proj): Linear(in_features=2304, out_features=9216, bias=False)\n",
       "          (up_proj): Linear(in_features=2304, out_features=9216, bias=False)\n",
       "          (down_proj): Linear(in_features=9216, out_features=2304, bias=False)\n",
       "          (act_fn): PytorchGELUTanh()\n",
       "        )\n",
       "        (input_layernorm): Gemma2RMSNorm((2304,), eps=1e-06)\n",
       "        (post_attention_layernorm): Gemma2RMSNorm((2304,), eps=1e-06)\n",
       "        (pre_feedforward_layernorm): Gemma2RMSNorm((2304,), eps=1e-06)\n",
       "        (post_feedforward_layernorm): Gemma2RMSNorm((2304,), eps=1e-06)\n",
       "      )\n",
       "    )\n",
       "    (norm): Gemma2RMSNorm((2304,), eps=1e-06)\n",
       "    (rotary_emb): Gemma2RotaryEmbedding()\n",
       "  )\n",
       "  (lm_head): Linear(in_features=2304, out_features=256000, bias=False)\n",
       ")"
      ]
     },
     "execution_count": 64,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "llm_model\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 65,
   "id": "3acc1f0d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "2614341888"
      ]
     },
     "execution_count": 65,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "def get_model_num_params(model:torch.nn.Module):\n",
    "    return sum([param.numel() for param in model.parameters()])\n",
    "\n",
    "get_model_num_params(llm_model)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 66,
   "id": "99b4b914",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'model_mem_bytes': 10457368064, 'model_mem_mb': 9972.92, 'model_mem_gb': 9.74}"
      ]
     },
     "execution_count": 66,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "def get_model_mem_size(model: torch.nn.Module):\n",
    "    mem_params = sum([param.nelement() * param.element_size() for param in model.parameters()])\n",
    "    mem_buffers = sum([buf.nelement() * buf.element_size() for buf in model.buffers()])\n",
    "\n",
    "    model_mem_bytes = mem_params + mem_buffers\n",
    "    model_mem_gb = model_mem_bytes / (1024**3)\n",
    "    model_mem_mb = model_mem_bytes / (1024**2)\n",
    "\n",
    "    return {\"model_mem_bytes\" : model_mem_bytes, \"model_mem_mb\": round(model_mem_mb,2), \"model_mem_gb\": round(model_mem_gb,2)}\n",
    "\n",
    "get_model_mem_size(llm_model)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 67,
   "id": "e851b7c0",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Input Text:\n",
      "What are the effects of hypertension on the human body? Can you provide a brief overview?\n",
      "\n",
      "Prompt:\n",
      " <bos><start_of_turn>user\n",
      "What are the effects of hypertension on the human body? Can you provide a brief overview?<end_of_turn>\n",
      "<start_of_turn>model\n",
      "\n"
     ]
    }
   ],
   "source": [
    "input_text = \"What are the effects of hypertension on the human body? Can you provide a brief overview?\"\n",
    "\n",
    "print(f\"Input Text:\\n{input_text}\")\n",
    "\n",
    "#Creating a prompt template\n",
    "\n",
    "dialogue_template = [\n",
    "    {\"role\":\"user\",\n",
    "     \"content\": input_text}\n",
    "]\n",
    "\n",
    "prompt = tokenizer.apply_chat_template(conversation=dialogue_template, \n",
    "                                       tokenize=False, \n",
    "                                       add_generation_prompt=True)\n",
    "\n",
    "print(f\"\\nPrompt:\\n {prompt}\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 68,
   "id": "a03721e8",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Model output (tokens):\n",
      "tensor([     2,      2,    106,   1645,    108,   1841,    708,    573,   5701,\n",
      "           576,  58292,    611,    573,   3515,   2971, 235336,   2551,    692,\n",
      "          3658,    476,   9091,  23330, 235336,    107,    108,    106,   2516,\n",
      "           108,   1620,    714,  20815,    576, 156246,    611,    573,   9998,\n",
      "         14427, 235292,    586,  20199,  20855,    109,  38954,  37935, 235269,\n",
      "           689,   1536,   5330,   5601, 235269,    603,    476,  19887,  31005,\n",
      "        235265,   1165, 235303, 235256,   3695,   3151,    573,    664,  71188,\n",
      "         31005, 235281,   1861,    665,   3695,    919,    793,  12447, 235269,\n",
      "          3547,    665,   5988,    577,  21422,   3274,   6449,   7042,    919,\n",
      "          3303,  12414, 235265, 235248,    109,   4858, 235303, 235256,    476,\n",
      "          9091,  23330,    576,    573,   5701,    576,  58292,    611,    573,\n",
      "          3515,   2971, 235292,    109,    688,  14298, 235290,   7617,   5701,\n",
      "         66058,    109, 235287,   5231,   8285,   8781,  66058,    139, 235280,\n",
      "          3818,  55415, 235269,   3695,   6547,    685,    476, 194610,    689,\n",
      "        118254,  37548, 235265,    108, 235287,   5231, 235299,  78260,  66058,\n",
      "           139,  82729,   2611,  40721,    689, 181684, 235265,    108, 235287,\n",
      "          5231, 114324,    660,   4325,  66058,    139, 173143,    689,   8090,\n",
      "         16482,    660,   4325, 235265,    108, 235287,   5231,  14298,   1746,\n",
      "           576,  10690,  66058,    139,  63359,  24590, 235269,   5199,   2290,\n",
      "        114341, 235265,    108, 235287,   5231,  76639,   4380,  66058,    139,\n",
      "        235280,   7965,    576, 151611,    689,   5601,    575,    573,  15704,\n",
      "        235265,    108, 235287,   5231,  38296,   4552,  66058,    139,  49820,\n",
      "           854,   9678, 235269,   4199,   9678, 235269,    689,   9601,  18881,\n",
      "        235265,    109,    688,   6604, 235290,   7617,   5701,  66058,    109,\n",
      "        235287,   5231,  30280,   7197,  66058,    139,  38954,  37935,  20089,\n",
      "          3437,  18324,    611,    573,   3760, 235269,   8185,    573,   5685,\n",
      "           576,   3760,   6279, 235269,  21339, 235269,    578,   3760,   9633,\n",
      "        235265,    108, 235287,   5231, 177798,   7197,  66058,    139,   7978,\n",
      "          5330,   5601,  23918,   5330,  21254,    575,    573,  77817, 235269,\n",
      "          8133,    577,  34132,   9633, 235265,    108, 235287,   5231,  43386,\n",
      "         66058,    139,  38954,  37935,    603,    476,   3885,   5685,   7435,\n",
      "           604,  21339, 235269,    948,    798])\n",
      "\n",
      "CPU times: total: 4min 10s\n",
      "Wall time: 2min 11s\n"
     ]
    }
   ],
   "source": [
    "%%time\n",
    "\n",
    "#Tokenize the input text\n",
    "\n",
    "input_ids = tokenizer(prompt, return_tensors='pt').to(\"cpu\")\n",
    "\n",
    "\n",
    "outputs = llm_model.generate(**input_ids, max_new_tokens = 256)\n",
    "print(f\"Model output (tokens):\\n{outputs[0]}\\n\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 69,
   "id": "e5384d85",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Model Output(decoded):\n",
      "<bos><bos><start_of_turn>user\n",
      "What are the effects of hypertension on the human body? Can you provide a brief overview?<end_of_turn>\n",
      "<start_of_turn>model\n",
      "## The Effects of Hypertension on the Human Body: A Brief Overview\n",
      "\n",
      "Hypertension, or high blood pressure, is a silent killer. It's often called the \"silent killer\" because it often has no symptoms, making it difficult to detect until serious damage has already occurred. \n",
      "\n",
      "Here's a brief overview of the effects of hypertension on the human body:\n",
      "\n",
      "**Short-term effects:**\n",
      "\n",
      "* **Headaches:**  A common symptom, often described as a throbbing or pounding sensation.\n",
      "* **Dizziness:**  Feeling lightheaded or unsteady.\n",
      "* **Nosebleeds:**  Frequent or heavy nosebleeds.\n",
      "* **Shortness of breath:**  Difficulty breathing, especially during exertion.\n",
      "* **Chest pain:**  A feeling of tightness or pressure in the chest.\n",
      "* **Vision problems:**  Blurred vision, double vision, or seeing spots.\n",
      "\n",
      "**Long-term effects:**\n",
      "\n",
      "* **Heart disease:**  Hypertension puts extra strain on the heart, increasing the risk of heart attack, stroke, and heart failure.\n",
      "* **Kidney disease:**  High blood pressure damages blood vessels in the kidneys, leading to kidney failure.\n",
      "* **Stroke:**  Hypertension is a major risk factor for stroke, which can\n",
      "\n"
     ]
    }
   ],
   "source": [
    "#Decode the output\n",
    "\n",
    "outputs_decoded = tokenizer.decode(outputs[0])\n",
    "print(f\"Model Output(decoded):\\n{outputs_decoded}\\n\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 70,
   "id": "59e7487f",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['What is hypertension and how is it clinically diagnosed?',\n",
       " 'What are the primary and secondary causes of hypertension?',\n",
       " 'How does high blood pressure affect the heart, brain, kidneys, and eyes?',\n",
       " 'What lifestyle changes are recommended to manage or prevent hypertension?',\n",
       " 'Explain the role of sodium and potassium in regulating blood pressure.',\n",
       " 'What are the common classes of antihypertensive medications and how do they work?',\n",
       " 'How is blood pressure measured, and what do systolic and diastolic values indicate?',\n",
       " 'What are the long-term health risks associated with uncontrolled hypertension?',\n",
       " 'How do stress and mental health impact blood pressure levels?',\n",
       " 'Describe the DASH diet and its effectiveness in managing hypertension.',\n",
       " 'What is hypertension?',\n",
       " 'How is blood pressure measured?',\n",
       " 'What causes high blood pressure?',\n",
       " 'What are symptoms of hypertension?',\n",
       " 'What foods increase blood pressure?']"
      ]
     },
     "execution_count": 70,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "gpt4_questions = [\n",
    "    \"What is hypertension and how is it clinically diagnosed?\",\n",
    "    \"What are the primary and secondary causes of hypertension?\",\n",
    "    \"How does high blood pressure affect the heart, brain, kidneys, and eyes?\",\n",
    "    \"What lifestyle changes are recommended to manage or prevent hypertension?\",\n",
    "    \"Explain the role of sodium and potassium in regulating blood pressure.\",\n",
    "    \"What are the common classes of antihypertensive medications and how do they work?\",\n",
    "    \"How is blood pressure measured, and what do systolic and diastolic values indicate?\",\n",
    "    \"What are the long-term health risks associated with uncontrolled hypertension?\",\n",
    "    \"How do stress and mental health impact blood pressure levels?\",\n",
    "    \"Describe the DASH diet and its effectiveness in managing hypertension.\",\n",
    "]\n",
    "manual_questions = [\n",
    "     \"What is hypertension?\",\n",
    "    \"How is blood pressure measured?\",\n",
    "    \"What causes high blood pressure?\",\n",
    "    \"What are symptoms of hypertension?\",\n",
    "    \"What foods increase blood pressure?\"\n",
    "]\n",
    "\n",
    "query_list = gpt4_questions + manual_questions\n",
    "query_list\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 71,
   "id": "41b62d73",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Query: What causes high blood pressure?\n",
      "[INFO] Time taken to get scores on (144) embeddings: 0.00091seconds\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "(tensor([0.5706, 0.4918, 0.4725, 0.4568, 0.4520]),\n",
       " tensor([13, 92, 16, 14,  7]))"
      ]
     },
     "execution_count": 71,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import random\n",
    "\n",
    "query = random.choice(query_list)\n",
    "print(f\"Query: {query}\")\n",
    "\n",
    "scores,indices = retrieve_relavent_resources(query=query, embeddings=embeddings)\n",
    "scores, indices\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 72,
   "id": "29258074",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Query: What lifestyle changes are recommended to manage or prevent hypertension?\n",
      "[INFO] Time taken to get scores on (144) embeddings: 0.00010seconds\n",
      "<bos><start_of_turn>user\n",
      "Based on the following context items, please answer the query.\n",
      "        Give yourself room to think by extracting relevant passages from the context before answering the query.\n",
      "        Don't return the thinking, only return the answer.\n",
      "        Make sure your answers are as explanatory as possible.\n",
      "        Use the following examples as reference for the ideal answer style.\n",
      "        Clearly identifies a specific real-world challenge faced by women in \n",
      "the financial ecosystem. Proposes an AI based innovation that \n",
      "supports economic empowerment, personalized financial literacy, or \n",
      "inclusive access to credit. \n",
      "● Prioritizes ethical use of AI (e.g., bias mitigation, privacy, fairness) \n",
      "and accessibility for all women, including those with low tech or \n",
      "literacy levels.\n",
      "        \n",
      "Now use the following context items to answer the user query:\n",
      "        - GUIDELINE FOR THE PHARMACOLOGICAL TREATMENT OF HYPERTENSION IN ADULTS This guideline will replace the guidance in the modules Evidence-based protocols and Risk-based CVD  management of the HEARTS technical package, as well as the guidance in the WHO PEN package  regarding the threshold for initiation of treatment, and for the preferred pharmacological treatment for  hypertension. The guideline does not address measurement of blood pressure or diagnosis of hypertension. It  addresses pharmacotherapy in individuals with a “confirmed” diagnosis of hypertension, such as  hypertension diagnosed when blood pressure is found to be elevated on two different days. Although this guideline does not address modifiable risk factors for hypertension such as unhealthy  diet, physical inactivity, consumption of tobacco and alcohol, and being overweight or obese, a  comprehensive treatment plan for hypertension must include addressing these risk factors through life- style modifications and other interventions (2). Nonpharmacological approaches to treatment or prevention of hypertension include:   [ reducing salt intake (to less than 5g daily)   [ eating more fruit and vegetables   [ being physically active on a regular basis   [ avoiding use of tobacco   [ reducing alcohol consumption   [ limiting the intake of foods high in saturated fats   [ eliminating/reducing trans fats in diet (2). The guideline does not address hypertensive crisis as it is focused on chronic blood pressure  management in regular care settings. The objectives of the hypertension guideline are to:   [ provide a blood pressure threshold for the initiation of treatment for hypertension;   [ determine if laboratory tests or cardiovascular risk assessment are required prior to initiation of  treatment for hypertension;   [ determine the pharmacological agents with which to initiate treatment;    [ determine the need to initiate treatment with monotherapy, dual therapy, or single-pill  combinations;    [ provide targets for blood pressure control in hypertension;   [ provide intervals for follow up for patients with hypertension; and   [ determine how nonphysician health care workers can participate in the management of  hypertension. Target audience Primary audience Clinicians/health care providers at all levels of health care. Secondary audience  National NCD/CVD programme managers, health care academics, policy-makers setting practice  recommendations, students, and hypertension medicine manufacturers. 2\n",
      " - 1 Introduction More people die each year from cardiovascular diseases than from any other cause. Over three quarters  of heart disease and stroke-related deaths occur in low-income and middle-income countries (1). Blood  pressure is the force exerted by circulating blood against the walls of the body’s arteries, the major blood  vessels in the body. Blood pressure is written as two numbers. The first number (systolic) represents the  pressure in blood vessels when the heart contracts or beats. The second number (diastolic) represents  the pressure in the vessels when the heart rests between beats. Hypertension – or elevated blood  pressure – is a serious medical condition that significantly increases the risk of diseases of the heart,  brain, kidneys and other organs (2). Hypertension can be defined using specific systolic and diastolic  blood pressure levels or reported use of antihypertensive medications. An estimated 1.4 billion people  worldwide have high blood pressure, but just 14% have it under control (2). However, cost-effective  treatment options do exist.\n",
      " - WHO would like to recognize the voices of persons with lived experiences with hypertension whom we  heard from through consultation during development of this guideline. ACKNOWLEDGEMENTS v\n",
      " - Executive summary More people die each year from cardiovascular diseases than from any other cause. Over three  quarters of heart disease and stroke-related deaths occur in low-income and middle-income countries. Hypertension – or elevated blood pressure – is a serious medical condition that significantly increases the  risk of heart, brain, kidney and other diseases. Hypertension can be defined using specific systolic and  diastolic blood pressure levels or reported use of antihypertensive medications. An estimated 1.4 billion  people worldwide have high blood pressure, but just 14% have it under control. However, cost-effective  treatment options do exist. In this guideline, the World Health Organization (WHO) provides the most current and relevant  evidence-based global public health guidance on the initiation of treatment with pharmacological  agents for hypertension in adults. The recommendations target adult, non-pregnant patients who were  appropriately diagnosed with hypertension and counselled about life-style modifications. The guideline provides new recommendations on the threshold for the initiation of pharmacological  treatment for hypertension, as well as recommendations on intervals for follow up, target blood  pressure to be achieved for control, and the cadre of health care workers who may initiate treatment. The guideline provides the basis for deciding whether to initiate treatment with monotherapy, dual  therapy or single-pill combinations, as well as guidance for countries selecting medicines and algorithms  for hypertension control for their national guidelines for hypertension management.\n",
      " - GUIDELINE FOR THE PHARMACOLOGICAL TREATMENT OF HYPERTENSION IN ADULTS Figures Fig.1  Analytic framework for antihypertensive medication treatment  3 Fig.2  Framework for analysis  9 Fig.3  An approach for starting treatment with a single-pill combination   26 Fig.4  An approach for starting treatment not using a single-pill combination   (i.e. with monotherapy or free combination therapy)  27 Fig.5  Algorithm 1  28 Fig.6  Algorithm 2  29 Fig. A3.1 Rating of outcomes  43 iv\n",
      "        \n",
      "Relevant passages: <extract relevant passages from the context here>\n",
      "        User query: What lifestyle changes are recommended to manage or prevent hypertension?\n",
      "        Answer:<end_of_turn>\n",
      "<start_of_turn>model\n",
      "\n"
     ]
    }
   ],
   "source": [
    "def prompt_formatter(query: str,\n",
    "                     context_items: list[dict]) -> str:\n",
    "    context = \"- \" + \"\\n - \".join([item[\"sentence_chunk\"] for item in context_items])\n",
    "\n",
    "    base_prompt = \"\"\"Based on the following context items, please answer the query.\n",
    "        Give yourself room to think by extracting relevant passages from the context before answering the query.\n",
    "        Don't return the thinking, only return the answer.\n",
    "        Make sure your answers are as explanatory as possible.\n",
    "        Use the following examples as reference for the ideal answer style.\n",
    "        Clearly identifies a specific real-world challenge faced by women in \n",
    "the financial ecosystem. Proposes an AI based innovation that \n",
    "supports economic empowerment, personalized financial literacy, or \n",
    "inclusive access to credit. \n",
    "● Prioritizes ethical use of AI (e.g., bias mitigation, privacy, fairness) \n",
    "and accessibility for all women, including those with low tech or \n",
    "literacy levels.\n",
    "        \\nNow use the following context items to answer the user query:\n",
    "        {context}\n",
    "        \\nRelevant passages: <extract relevant passages from the context here>\n",
    "        User query: {query}\n",
    "        Answer:\"\"\"\n",
    "\n",
    "    base_prompt = base_prompt.format(context=context, query=query)\n",
    "\n",
    "    dialogue_template = [\n",
    "    {\"role\":\"user\",\n",
    "     \"content\": base_prompt}\n",
    "        ]\n",
    "\n",
    "    prompt = tokenizer.apply_chat_template(conversation=dialogue_template, \n",
    "                                       tokenize=False, \n",
    "                                       add_generation_prompt=True)\n",
    "\n",
    "    return prompt\n",
    "\n",
    "query = random.choice(query_list)\n",
    "print(f\"Query: {query}\")\n",
    "\n",
    "scores, indices = retrieve_relavent_resources(query=query, \n",
    "                                              embeddings=embeddings)\n",
    "\n",
    "context_items = [pages_and_chunks[i] for i in indices]\n",
    "\n",
    "prompt = prompt_formatter(query=query,context_items=context_items )\n",
    "print(prompt)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 73,
   "id": "bbea098b",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Query: What lifestyle changes are recommended to manage or prevent hypertension?\n",
      "RAG Answer:\n",
      " <bos>The text states that non-pharmacological approaches for managing hypertension include:\n",
      "\n",
      "* **Reducing salt intake** to less than 5g daily.\n",
      "* **Eating more fruit and vegetables** \n",
      "* **Being physically active on a regular basis**\n",
      "* **Avoiding the use of tobacco**\n",
      "* **Reducing alcohol consumption**\n",
      "* **Limiting the intake of foods high in saturated fats**\n",
      "* **Eliminating/reducing trans fats in the diet** \n",
      "<end_of_turn>\n",
      "CPU times: total: 2min 56s\n",
      "Wall time: 1min 35s\n"
     ]
    }
   ],
   "source": [
    "%%time\n",
    "\n",
    "input_ids = tokenizer(prompt, return_tensors=\"pt\").to(\"cpu\")\n",
    "\n",
    "outputs = llm_model.generate(**input_ids, \n",
    "                            temperature=0.7, \n",
    "                            do_sample = True, \n",
    "                            max_new_tokens = 256)\n",
    "\n",
    "output_text = tokenizer.decode(outputs[0])\n",
    "print(f\"Query: {query}\")\n",
    "print(f\"RAG Answer:\\n {output_text.replace(prompt,'')}\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 77,
   "id": "e3aa0b83",
   "metadata": {},
   "outputs": [],
   "source": [
    "def ask(query: str, \n",
    "        temperature: float = 0.7, \n",
    "        max_new_tokens: int=256,\n",
    "        format_answer_text=True, \n",
    "        return_answer_only=True):\n",
    "    \n",
    "    \"\"\"\n",
    "    Takes a query, find relevant resouces/context and generates an answer.\n",
    "    \"\"\"\n",
    "\n",
    "    scores,indices = retrieve_relavent_resources(query=query, \n",
    "                                                  embeddings=embeddings)\n",
    "    \n",
    "    context_items = [pages_and_chunks[i] for i in indices]\n",
    "\n",
    "    for i, item in enumerate(context_items):\n",
    "        item[\"score\"] = scores[i].cpu()\n",
    "\n",
    "    \n",
    "    prompt = prompt_formatter(query=query, \n",
    "                              context_items=context_items)\n",
    "    \n",
    "    input_ids = tokenizer(prompt, return_tensors=\"pt\").to(\"cpu\")\n",
    "\n",
    "    outputs = llm_model.generate(**input_ids, \n",
    "                                 temperature=temperature, \n",
    "                                 do_sample = True,\n",
    "                                 max_new_tokens=max_new_tokens)\n",
    "    \n",
    "    output_text = tokenizer.decode(outputs[0])\n",
    "    if format_answer_text:\n",
    "        output_text = output_text.replace(prompt,\"\").replace(\"<bos>\", \"\").replace(\"<eos>\", \"\").replace(\"<end_of_turn\", \"\")\n",
    "    \n",
    "    if return_answer_only:\n",
    "        return output_text\n",
    "    \n",
    "    return output_text, context_items\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 78,
   "id": "9c1fa516",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Query: What is hypertension?\n",
      "[INFO] Time taken to get scores on (144) embeddings: 0.00014seconds\n",
      "CPU times: total: 4min 16s\n",
      "Wall time: 33.9 s\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "'Hypertension, also known as high blood pressure, is a serious medical condition where the force of blood against the walls of arteries is elevated.  It can be defined using specific systolic and diastolic blood pressure levels or by reporting the use of antihypertensive medications. High blood pressure significantly increases the risk for heart, brain, kidney, and other organ diseases. \\n>'"
      ]
     },
     "execution_count": 78,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "%%time\n",
    "\n",
    "query = random.choice(query_list)\n",
    "print(f\"Query: {query}\")\n",
    "ask(query=query)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "de3eb76c",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": ".venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.9"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
